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ABSTRACT
Cytochrome P450 (CYP) enzymes typically perform hydroxylation chemistry on small
molecule substrates using atmospheric oxygen and electrons from redox partner proteins.
This reactivity is dependent on a thiolate-ligated heme cofactor that also allows for
spectroscopic detection of ligation, oxidation, and environmental changes to the iron metal.
The onset of the genomics era has resulted in the discovery of CYPs that deviate from this
paradigm in terms of reaction performed, cosubstrate requirements, and substrate-scope.
This work focuses on two of these unusual P450s – OleT and NikQ. OleT performs an
unconventional H2O2-dependent decarboxylation reaction on a standard small molecule
fatty acid substrate to yield 1-olefins and CO2. A desire to maximize the biosynthetic
potential of this enzyme while addressing limitations imposed by the peroxide requirement
has resulted in numerous reports that OleT may have the capacity to utilize biological redox
donors and O2 in a canonical P450 reaction mechanism. Chapter 2 centers on transient
kinetics, cryoradiolysis, and turnover studies used to investigate the precise origins of OleT
alkene production using surrogate redox systems and dioxygen. While results show that
this enzyme is ultimately incapable of performing true O2-driven catalysis, conclusions do
illuminate several strategies for improving OleT for downstream biocatalytic applications.
Chapters 3 and 4 focus on NikQ, which carries out classical P450 β-hydroxylation
chemistry using O2 and reducing equivalents from redox donors on a ʟ-histidine substrate
requisitely appended to NikP1, a ~75 kDa nonribosomal peptide synthetase protein. The
first half of the CYP catalytic cycle is typically regulated at multiple steps by the binding
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of substrate; however, this mechanistic gating in P450s acting on protein-tethered
substrates is not well-elucidated. We use various spectroscopic techniques, transient
kinetics, and spectroelectrochemical studies to investigate the influence of this complex
substrate on early NikQ catalysis. Results indicate that NikP1-binding does not
substantially regulate NikQ, which is highly atypical of P450s. Possible molecular
determinants and functional significance of this mechanistic peculiarity will also be
discussed.
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CHAPTER 1
Atypical Reactions and Unusual Substrates of Cytochrome P450 Enzymes in
Bacterial Biosynthetic Pathways

1.1 INTRODUCTION TO CYTOCHROME P450
The cytochrome P450 (CYP) enzyme superfamily is one of the largest and most
diverse, carrying out critical metabolic reactions in organisms from all domains of life.1, 2
As of 2017, an excess of 300,000 P450s have been sequenced, with that number expected
to rise to at least 1,000,000 by 2020 due to global sequencing initiatives.1 Of these, ~62,000
are from bacteria, with >3,000 having been assigned CYP nomenclature and divided into
602 prokaryotic CYP families.1 The ubiquitous nature of these enzymes in bacterial species
warrants in-depth study and characterization due to crucial involvement in natural product
biosynthetic pathways, which could be exploited for a myriad of industrial and
pharmaceutical applications.
All cytochrome P450s possess a heme-iron cofactor with a proximal, cysteinederived thiolate ligand, as shown in Figure 1.1 A. This imparts a red chromophore to the
protein that allows for convenient spectroscopic monitoring of changes in ligation and
oxidation state during catalysis.3-5 This spectroscopic sensitivity, with relatively large
extinction coefficients for the wavelength of maximal absorbance (termed the Soret band),
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is particularly useful for detailed mechanistic investigations.6 The cofactor cycles between
pentacoordinate and hexacoordinate ligation geometries through ligand-switching at the
distal position, with the iron bound to a water molecule at this sixth site in the ferric resting
state.7 The phenomenon for which the name “P450” was bestowed derives from a specific
instance of oxidation and ligation state alterations - upon reduction to the ferrous oxidation
state and immediate ligation of supplemented gaseous carbon monoxide, a pigment with
absorbance maximum at 450 nm is detected, as shown in Figure 1.1 B.8 Though not part
of the P450 catalytic cycle, the formation of this CO-adduct and confirmation of
absorbance at ~450 nm can be used to confirm the integrity of the proximal thiolate ligand
that sets cytochrome P450s apart from other histidine or methionine-ligated hemoproteins
like myoglobin, hemoglobin, and cytochrome c.6

Figure 1.1. Cytochrome P450 enzymes possess a thiolate-ligated heme
cofactor (A) which imparts to the protein a unique absorbance
spectrum (B) when reduced in the presence of carbon monoxide with
maxima at 450 nm, from which the enzyme superfamily derives its
name. A also shows the camphor substrate in the CYP101 (PDB 1DZ4)
active site,9 along with two residues distal to the heme, D251 and T252, that
have been shown to be critical for catalysis in O2-dependent P450s. The
wavelength of maximal absorbance in CYPs is termed the Soret peak, at
~450 nm in B, and is sensitive to changes in oxidation and ligation state,
allowing for sensitive spectroscopic analysis of P450 catalytic
intermediates.
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Classically, CYP enzymes are thought of as monooxygenases, performing
hydroxylation chemistry on small molecule substrates, as shown in the scheme of Figure
1.2.2 This reactivity results from a catalytic cycle dependent upon binding of atmospheric
oxygen, two proton transfers, and two reduction events from an electron source, typically
a distinct iron-sulfur containing protein.2 The most well-characterized of these is P450Cam
(also referred to as “CYP101”), a camphor hydroxylase from Pseudomonas putida that first
appears in the literature in 1968.10-15 CYP101 is still under active investigation today, and
is often thought of as a model for bacteria P450 reactivity. As such, this system in
particular, will often be used as a point of reference throughout this chapter.

Figure 1.2. The overall hydroxylation
reaction catalyzed by cytochrome P450
enzymes.
CYP
monoxygenation
of
unactivated C-H bonds is usually dependent
on the transfer of two electrons from
physiological redox partner proteins, binding
of atmospheric oxygen, and two sequential
protonation events.

CYP hydroxylation chemistry is initiated by the substrate-binding, which displaces
a distal water ligand from the iron, decreasing the energy gap between the non-degenerate
d-orbitals of the iron and promoting two previously paired electrons from the lower energy
orbitals to the higher ones as the ligand geometry changes from hexacoordinate (species 1,
in black, of Figure 1.3 below) to pentacoordinate (2, green, in Figure 1.3).2 This shift from
low-spin (S = 1/2) to high-spin (S = 5/2) is characterized by a change in Soret absorbance
from the resting state at ~418 nm to ~395 nm. As this optical change is dependent upon
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substrate concentration, it can be used for calculation of a binding constant for the
substrate. Additionally, the spin shift is accompanied by a positive change in heme
reduction potential, allowing for single electron transfer from a redox partner protein, 2Fe2S-containing putidaredoxin (Pd) in the case of P450Cam.2, 13
The alteration in enzyme reduction potential serves as a thermodynamic gate, with
the protein that acts as the electron donor to the cytochrome typically possessing a potential
poised between that of the substrate-free and substrate-bound P450, ensuring that only
reduction of the substrate-bound enzyme is thermodynamically favorable.13,

14

This

prevents uncoupling through consumption of NAD(P)H by an enzyme that lacks substrate,
and thus protects against generation of the reactive oxygen species (ROS) that result from
unproductive consumption of the pyridine nucleotide. This redox partner acts as the
electron donor for two distinct, non-consecutive one-electron reduction steps while also
fulfilling secondary functions in effector roles, which are important for efficient catalysis
through specific electrostatic interaction with the P450 surface proximal to the heme.11 The
first electron transfer yields the ferrous cytochrome, shown as intermediate 3, in blue, of
Figure 1.3.
Dioxygen binding to the ferrous iron follows the first electron transfer,2, 10 yielding
an oxy-complex (4, violet, in Figure 1.3) which is then reduced by a second electron in the
rate-limiting step of P450 catalysis to form a ferric-peroxo intermediate (species 5, red, in
Figure 1.3).16 Instability of the oxy-complex can lead to uncoupling through the release of
superoxide and autoxidation of the substrate-bound enzyme back to the ferric high-spin
state. This unproductive and energetically expensive ROS-generating pathway is
minimized by stabilization of the oxy-complex in the presence of substrate due to both
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steric and electronic effects from the substrate, as well as conformational changes that are
induced by interactions with the redox partner proteins.2, 11, 17 The next two catalytic steps
rely on a critical pair of amino acids – termed the acid-alcohol pair and shown in Figure
1.1 A as Aspartate-251 and Threonine-252 for CYP101 - situated distal to the heme
cofactor on the long I-helix that spans the length of the P450.18-26 Mutation of the acid,
which may be a glutamate or an aspartate, results in overall impairment of turnover through
the perturbation of multiple catalytic steps. Second electron transfer is significantly
hindered by several orders of magnitude in studies of the D251N mutant of CYP101.18, 19,
23

Alteration of this acidic residue seemingly results in a separation of the proton-coupled

electron-transfer steps normally linking the second reduction and and first protonation
events of the cycle.19 Correspondingly, the typically elusive ferric-peroxoanion
intermediate is stabilized at low temperatures following reduction of the dioxygen adduct
by ɣ-irradiation in CYP101-D251N, and can be detected using electron paramagnetic
resonance (EPR) spectroscopy at liquid nitrogen temperatures. In contrast, only the ensuing
hydroperoxo-intermediate is observable at 77 K in the wild-type (WT) enzyme.19 This
demonstrates a dependence upon this amino acid for efficient protonation of the ferricperoxo species to yield the ferric-hydroperoxo intermediate (species 6, orange, in Figure
1.3), as well as an influence upon the catalytic steps immediate preceeding and following
the first proton transfer.19, 23 Mutation of the alcohol residue has been shown to result in
severe uncoupling to H2O2, with no detectable turnover in some instances.19-22, 25 Further,
the T252A mutant of CYP101 showed enhanced stability of the ferric-hydroperoxo species
via EPR and thermal annealing experiments, implying that uncoupling occurs from this
state as the second protonation event is acutely impeded.19
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Figure 1.3. The P450 catalytic cycle. The aquo ligand is displaced from
the low-spin ferric enzyme (1, in black) upon substrate-binding to yield the
pentacoordinate high-spin state (2, in green). A corresponding increase in
heme reduction potential allows for the first electron transfer to give the
ferrous P450 (3, in blue), which subsequently ligates atmospheric oxygen
to form the oxy-complex (4, in violet). The rate-limiting second reduction
step to yield the ferric-peroxo intermediate (5, in red) competes kinetically
with the autoxidation shunt (grey dotted pathway), an uncoupling of the
ferric-superoxide intermediate back to the high-spin form via superoxide
release. The initial proton transfer to the peroxo-P450 results in the
hydroperoxo-ferric state (6, in orange), followed by a second protonation
that instigates O-O bond heterolysis for release of H2O and formation of
reactive intermediate compound-I (7, in gold) – a Fe(IV)-oxo species with
delocalized π-cation radical. Hydrogen atom abstraction from the substrate
gives compound-II (8, in fuchsia), an Fe(IV)-hydroxo state, then OHrebound yields the hydroxylated product and water re-binds at the distal
position to re-form the low-spin ferric resting state.

6

The transfer of a second proton to the ferric-hydroperoxo intermediate initiates
heterolysis of the end-on Fe-ligated O-O bond while releasing a water molecule to form
compound-I, a reactive Fe(IV)-oxo intermediate with a delocalized π-cation radical (7,
gold, in Figure 1.3).27 Compound-I abstracts a hydrogen atom from the substrate to yield
compound II, a Fe(IV)-hydroxo species (8, fuchsia, in Figure 1.3), which performs oxygenrebound chemistry resulting in the hydroxylated product and a return to the ferric-aquo
resting state upon the re-ligation of water to the heme-iron.28

1.2 OLETJE: UNCONVENTIONAL DECARBOXYLATION CHEMISTRY USING AN
ATYPICAL CO-SUBSTRATE
Cytochrome P450 peroxygenases comprise a sub-group of the CYP superfamily
that is capable of utilizing a H2O2 co-substrate through the aptly termed “peroxide shunt”,
in which peroxide binding to the high-spin protein yields compound-I, without the need for
electron transfer from redox partners, O2-binding, or proton transfer steps.29 Members of
the CYP152 family utilize peroxide in this manner for the chemical transformation of Cn
fatty acids to Cn α- or β-hydroxy fatty acids or Cn-1-length terminal olefins and carbon
dioxide.30 These enzymes share similar structural characteristics that not only enable
efficient utilization of a peroxide oxidant, but may also disfavor the forementioned O2dependent mechanism of product formation.31, 32 Specifically, these P450s lack the acidalcohol residues, instead possessing conserved distal arginine and proline amino acids on
the I-helix. In CYP152 enzymes, this arginine establishes electrostatic contacts critical for
substrate-positioning with the fatty acid during substrate-binding.30, 33-35 Around position
85, CYP152 P450s also feature either a glutamine or a histidine residue that has been
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hypothesized, by analogy to heme-dependent peroxidase enzymes, to play a role in
peroxide activation.36-39

Figure 1.4. Peroxide-dependent decarboxylation of long-chain fatty acids to terminal
alkenes and CO2 by OleTJE. Please note that the numbering of intermediates from Figure
1.3 was retained for consistency, despite the lack of species 3 through 6 in the above
mechanism. Low-spin OleT (1, in black), with Soret at 418 nm, goes appreciably high-spin
(species 2, in green, with Soret at 395 nm) upon binding of eicosanoic acid, for which this
P450 has a high affinity with a dissociation constant of ~300 nM.40 H2O2-binding to the
substrate-bound enzyme occurs rapidly to yield compound-I (7, in gold) with Soret
maximum at ~370 nm and a second order rate constant with respect to peroxide of 7 × 105
M-1s-1.41 The isotopically sensitive decay of compound-I gives rise to compound-II (species
8, in fuchsia, with Soret at 426 nm) as a hydrogen atom is abstracted from the substrate
leaving a substrate-centered radical.41 Proton-coupled electron-transfer results in the
production of 1-nonadecene and carbon dioxide and re-binding of a water molecule
restores the ferric low-spin resting state.40, 41
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One notable member of the CYP152 family, OleTJE, was isolated from
Jeotgalicoccus sp. found in Jeotgal Korean fish sauce and reported to catalyze the
decarboxylation of long-chain fatty acids into carbon dioxide and terminal alkenes.42 This
reactivity inspired a flurry of research, with the hopes of utilizing this enzyme for the
industrial scale production of biofuels.31, 33, 43 Despite acting on a canonical small molecule
substrate, the unusual decarboxylase activity and use of H2O2 co-substrate have presented
an intriguing opportunity for mechanistic inquiry not previously described in cytochrome
P450s. Through transient kinetic studies, our laboratory has mapped much of the reaction
coordinate of OleT with peroxide, as summarized in Figure 1.4.40, 41
The goal of exploiting the reactivity of OleT as an alternative fuel source has led to
investigations into the viability of biofuel production in vivo by this enzyme. However, the
peroxide requirement presents significant complications within an organism due to the
deleterious effects of ROS, as well as the efficient disproportionation of H2O2 by other
intracellular enzymes like catalase. As a solution, recent work has sought to achieve OleTJE
turnover using O2 and reducing equivalents from redox partner proteins.44-46 This method
has demonstrated some success in vitro, which has been attributed to an ability of this
enzyme to utilize the canonical O2-driven P450 reactivity.44-46 In light of the previously
discussed distal architecture of OleT, particularly the lack of acid-alcohol pair, this raises
multiple puzzling mechanistic questions.30,

47

Additionally, as OleTJE lacks the redox

partner binding site for several of the redox donor proteins (including Pd) reported to result
in high alkene titers with this P450, efficient reduction of the cytochrome seems unlikely.4446

Chapter 2 of this thesis is focused on the investigation into the mechanistic origin of

OleTJE reactivity with O2 and electrons using rapid-mix kinetics experiments, single and
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multiple turnover studies, and cryoradiolysis electron paramagnetic resonance
methodologies.48 Our findings indicate that multiple reaction pathways are occurring
simultaneously, with H2O2-production being the commonality between the different routes
to product formation.48

1.3 NIKQ: HYDROXYLATION OF A PROTEIN-TETHERED SUBSTRATE
Nonribosomal peptide synthetases (NRPSs) are protein scaffolds that act as natural
product assembly lines in many bacterial biosynthetic pathways.49 Resulting amino acid
(AA) polymers have amide bond linkages in common with ribosomally-produced
counterparts, but also generally feature functional groups and bonding motifs not observed
in peptides resulting from translational machinery.49 These unique chemical moieties,
typically installed on the maturing peptide by dedicated tailoring enzymes, often impart
medically-relevant activities to the nonribosomal peptide (NRP) product, allowing for
applications as anticancer therapeutics, immunosuppressants, and antimicrobial agents,
examples of which are shown in Figure 1.5.50-57 Tailoring enzymes have been reported to
perform halogenation, hydroxylation, and oxidative crosslinking chemistries, among
others.53,

58-62

Of particular interest are tailoring enzymes that requisitely function on

NRPS-tethered substrates, achieving the highly sought-after synthetic goal of mid-stage
functionalization in vivo.53, 58, 59 An in-depth understanding of the mechanisms underlying
interactions between tailoring enzymes and cognate NRPS substrates could allow for the
generation of libraries of novel potential pharmaceuticals, adding to the antimicrobial
arsenal so rapidly dwindling due to increasing resistance in microorganisms. Despite this
tremendous potential for natural product diversification and targeted synthesis, the
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interplay between tailoring enzymes and NRPS proteins remains poorly elucidated, largely
owing to numerous complexities inherent to the NRPS substrate.50, 59

Figure 1.5. Examples of clinically significant nonribosomal peptides.
Bleomycin is an antitumor therapeutic isolated from a polyketide synthase (PKS)NRPS hybrid pathway out of Streptomyces verticillus.54 Glycopeptide antibiotic
A40926 is produced from a NRPS system out of Nonomuraea sp.55 Light red boxes
correspond to elements deriving from PKS-modules and yellow boxes represent
sugar additions to the peptide along with non-NRPS modifications to the sugar;
remaining unlabeled structures are incorporated using NRPS machinery.

An NRPS may consist of a single ~10 kDa thiolation (T-) domain, but are more
frequently organized into larger modules comprised of catalytic domains alongside one or
more T-domains, including adenylation (A-) domains, condensation (C-) domains, and
thioesterase (TE-) domains, among others.49, 50, 58, 59 Each T-domain can exist in an apo,
unmodified form, or in up to three different possible post-translationally modified states.49,
50

The holo T-domain features a phosphopantetheine (ppant) cofactor appended to a

conserved serine residue.63 In the amino-acyl (or loaded) form, the AA that will ultimately
be incorporated into peptide chain is enzymatically attached to the end of the ppant arm of
the holo T-domain by an upstream or freestanding A-domain.49, 50, 63 Apo, holo, and loaded
T-domains are shown in Figure 1.6 for clarity. Though not extensively discussed in the
studies undertaken within this work, loaded T-domains that serve as substrates for tailoring
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enzymes can formally exist in a product-bound, tailored state as well. Following loading
or tailoring, C-domains instigate peptide bond formation between the cargo tethered to
upstream and downstream T-domains, with TE-domains often carrying out chain
termination for an NRPS module.49, 50, 63 Multi-domain NRPS modules can extend into the
megadalton range, presenting significant challenges in obtaining high yields of stable,
soluble protein.49,

50, 58, 64

Further, the presence of multiple T-domains within a given

module complicates recognition studies of tailoring enzymes with NRPS substrates.50 This
is especially problematic in instances where a single tailoring enzyme acts on multiple Tdomains within a module,65 or where multiple T-domains within the NRPS target the same
AA.66 As an answer to these obstacles, a single T-domain is often excised from the native
module, though this sometimes requires the use of specialized expression tags or refolding
to obtain soluble protein, and excludes the possibility that adjacent domain surface sites
may have a role in NRPS-tailoring enzyme interactions.50, 59
A high degree of catalytic specificity has been demonstrated to vary among
tailoring enzymes acting on NRPS substrates, with regio- and stereospecific product
formation, as well as turnover efficiency, often being dependent upon the identity of the
aminoacyl-NRPS.53, 66-69 The catalytic triggering of aliphatic halogenase SyrB2 has been
shown to be significantly diminished when the target NRPS, SyrB1, is loaded with the
incorrect amino acid, or when the correct amino acid is appended to a similar but nonnative NRPS.66 While some tailoring enzymes will only interact with a single AA-NRPS
pairing, others have demonstrated the ability to catalyze reactions on different T-domain
and amino acid combinations. One example of the latter is P450Sky, a β-hydroxylase in the
skyllamycin biosynthetic pathway, which natively hydroxylates three different T-domains
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that each specifically tether three distinct AAs - phenylalanine, tyrosine, and leucine.65, 70
Interestingly, P450Sky fails to hydroxylate another leucine-tethered T-domain within this
pathway, implicating what is likely a substrate recognition mechanism dependent upon
interactions of the tailoring enzyme with the T-domain surface.65 Whether or not the
surface sequence of adjacent domains have a role in this process is yet to be elucidated for
this system. By contrast, halogenase tailoring enzyme CytC3 displays a strong preference
for one NRPS, but can metabolize several different tethered amino acids.71 Taken together,
this information paints a complex and poorly understood image of the molecular
determinants underlying tailoring enzyme-NRPS recognition.

A

B

C

Figure 1.6. T-domain post-translational modification states. The
apo-NRPS (A) is unmodified. In B, the holo-NRPS has a
phosphopantetheine (ppant) group appended to a conserved serine on
the T-domain. An amino-acyl NRPS is presented in C, with target amino
acid bound via thioester linkage to the end of the ppant arm. (T-domain
is from the P450Sky•PCP7 crystallized co-complex;67 PDB 4PWV)
Within the nikkomycin biosynthetic pathway of Streptomyces tendae Tü901,
didomain NRPS NikP1 and hydroxylase NikQ72 present an attractive potential model
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system for gaining empirical insight into the molecular determinants underlying the
recognition of NRPS-tethered substrates by tailoring enzymes. In this system, the NikP1
A-domain activates an ʟ-histidine residue, covalently linking it to the ppant cofactor of the
adjacent C-terminal T-domain, yielding ʟ-His-NikP1.72 As shown in Figure 1.7,
cytochrome P450 NikQ β-hydroxylates the NikP1-bound AA to give the tailored product,
β-OH-His-NikP1.72 The β-hydroxyhistidine is released from the NRPS by freestanding TEdomain NikP2, and processed further to an imidazolone moiety that is ultimately
incorporated into nikkomycin X, a clinically employed NRP antifungal.72

Figure 1.7. NikQ β-hydroxylates ʟ-his-NikP1 in the biosynthesis of nikkomycin X
antibiotics. Cytochrome P450 NikQ performs a β-hydroxylation reaction on an ʟ-histidine
residue that is requisitely tethered to 75 kDa NRPS didomain NikP1. The βhydroxyhistidine is further processed to an imidazolone after NikQ tailoring and release
from NikP1 by NikP2, and is then incorporated into nikkomycin X antibiotics in
Streptomyces tendae.

NikQ and NikP1 proteins are both soluble, stable, and express in high yeilds
yields.72 For NikP1, this is likely due in part to the presence of an N-terminal MbtH-like
region on the NikP1 A-domain, which is thought to promote proper folding and solubility
of NRPS modules. The relatively simple NikP1 A-T-didomain is the fully intact NRPS
module instead of a truncated form of the protein,72 circumventing issues that arise when
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part of the NRPS is excised and isolated from the full scaffold.50 Further, the heme-iron
cofactor of NikQ also allows for detailed analyses of ligand and oxidation changes via
various spectroscopies that may be more difficult or not possible at all in non-heme
tailoring enzymes.6 Decades of literature describing CYP spectroscopy and the impact of
small molecule substrates on P450 catalysis provide a scaffold for experimental design and
data interpretation of NikQ with its protein-tethered substrate. P450 NikQ therefore enables
a more thorough investigation of the impact of substrate upon tailoring enzyme catalysis
than would be available in many other NRP-producing systems, especially when coupled
to the comparatively uncomplicated nature of NikP1 versus other NRPS proteins.
Our work presented in chapter 3 of this thesis demonstrates stable complex
formation between NikQ and ʟ-His-NikP1 with a KD of 22 µM, along with detailed
mechanistic studies demonstrating an atypical mode of catalytic regulation in this P450 by
the NRPS substrate.73 To date, this is the only binding quantification of an NRPSmodifying tailoring enzyme with native intact substrate, as well as the first analysis into
the impact of an NRPS substrate on the early steps of P450 tailoring enzyme catalysis
beyond substrate binding.73 The fourth chapter will examine the catalytic consequences of
mutating two atypically bulky isoleucine residues to glycines at sites proximal to the NikQ
heme-iron. Data presented in both chapters will illuminate the molecular determinants of
NRPS interactions with P450 tailoring enzymes, and seek to better understand how
proximal site sterics impact P450s reactivity and inhibition.
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CHAPTER 2
Dioxygen Activation by the Biofuel-Generating Cytochrome P450 OleT1

1
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2.1 ABSTRACT
OleT, a recently discovered member of the CYP152 family of cytochrome P450s, catalyzes
a unique decarboxylation reaction, converting free fatty acids into 1-olefins and carbon
dioxide using H2O2 as an oxidant. The C-C reaction proceeds through hydrogen atom
abstraction by an iron(IV)-oxo intermediate known as Compound I. The capacity of the
enzyme for generating important commodity chemicals and liquid biofuels has inspired a
flurry of investigations seeking to maximize its biosynthetic potential. One common
approach has sought to address the limitations imposed by the H2O2 co-substrate,
particularly for in vivo applications. Numerous reports have shown relatively efficient
decarboxylation activity with various combinations of the enzyme with pyridine
nucleotides, biological redox donors, and dioxygen, implicating a mechanism whereby
OleT can generate Compound I via a canonical P450 O2 dependent reaction scheme. Here,
we have applied transient kinetics, cryoradiolysis, and steady state turnover studies to
probe the precise origins of OleT turnover from surrogate redox systems. Electron transfer
from several redox donors is prohibitively sluggish and the enzyme is unable to form the
hydroperoxo-ferric adduct that serves as a critical precursor to Compound I. Despite the
ability for OleT to readily bind O2 once it is reduced, autoxidation of the enzyme and redox
partners leads to the generation of H2O2, which is ultimately responsible for the vast
majority of turnover. These results illuminate several strategies for improving OleT for
downstream biocatalytic applications.
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2.2 INTRODUCTION
The biocatalytic conversion of metabolites from the phylogenetically ubiquitous
fatty acid synthesis (FAS) pathway to hydrocarbons provides a renewable resource for the
supplementation or replacement of petroleum-derived transportation fuels. Collective
efforts from the past decade have resulted in the elucidation of several biochemical routes
for hydrocarbon biosynthesis. A great deal of these pathways are comprised of enzymes
that utilize a myriad of iron-containing cofactors (reviewed in 1) that activate O2 or H2O2
for the transformation of Cn chain length fatty aldehyde or fatty acids to Cn-1 alkanes 2, 3 or
alkenes 4-6 respectively. A common feature of these enzymes is the utilization of catalytic
sites for carbon-carbon cleaving reactions that resemble or duplicate those typically
associated with monoxygenation chemistry. In addition to discerning the precise molecular
basis for this enzymatic reprogramming, a global challenge is to now leverage these
catalysts in a suitable recombinant host with the hope of providing an economically viable
route for advanced biofuel production.
To date, the vast majority of attempts at recombineering genetically-tractable
organisms such as E. coli

3, 7, 8

or S. cerevisiae

9, 10

for the production of FAS-derived

biofuels have utilized the introduction of a two-step pathway from cyanobacteria (Figure
2.1A, lower pathway).3 This route makes use of an acyl-ACP reductase (AAR) to reduce
an acyl carrier protein (ACP) linked hydrocarbon from the FAS pathway to generate a free
Cn aldehyde. In the subsequent step, a non-heme diiron enzyme known as aldehyde
deformylating oxygenase (ADO) forms the Cn-1 alkane. This pathway has been successfully
introduced into several heterologous hosts for the production of gaseous and liquid fuels.
3, 8, 10

Despite providing an excellent template for the transplantation of a pathway to enable
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advanced biofuel production, the resulting titers that result from these bioengineering
efforts are often too low to be economically viable. This is attributed to the sluggish rate
of ADO catalysis that originates from rate-limiting electron transfer steps, 11-13 inhibitory
side-products that can be generated both by ADO

14

and AAR,

15

and the relative

inefficiency of the AAR step for producing the necessary substrate aldehydes.
A potentially attractive alternative route for biocatalytic fuel generation may be
provided by a recently discovered group of cytochrome P450s (CYPs) from the CYP152
family named OleT

4

that have the ability to generate terminal olefins from fatty acid

substrates in a single step (Figure 2.1A, upper pathway).

16, 17

In addition to serving as

valuable fuel components, the alkenes produced by OleT can also be utilized as important
synthetic precursors for a wide array of commercially valuable commodity chemicals.
Importantly, the synthetic biology tools necessary for generating large amounts (as high as
grams per liter) of free fatty acids with carbon chain lengths that can be finely-tuned for
different types of transportation fuels have been developed for several species.10, 18, 19 OleT,
in turn, has been demonstrated to metabolize a broad range of fatty acid substrates in vitro
with catalytic rates 20-23 that far exceed those of ADO.
A limitation for leveraging OleT catalysis, particularly for in vivo bioengineering
platforms, is its requirement for H2O2 as a cosubstrate for the oxidation of the heme-iron
to generate the high-valent intermediate known as Compound I (intermediate 7 in Figure
2.1B). Transient kinetic studies from our laboratory have shown that fatty acid
decarboxylation is initiated by C-H bond cleavage by this ferryl intermediate.

16, 17, 22, 24

The efficient utilization of H2O2 by OleT and its orthologs differs from the vast majority
of CYPs that instead generate Compound I through the binding and activation of
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atmospheric dioxygen using reducing equivalents that are ultimately derived from pyridine
dinucleotide and delivered through an auxiliary redox chain. In contrast, the activation of
H2O2 to initiate OleT decarboxylation is a process that is highly inefficient for most O2
dependent CYPs, even though it has long served as a highly desirable attribute for
leveraging key industrial transformations.25, 26 This inexpensive oxidant (at least 10,000
fold cheaper than reduced nicotinamide on a molar basis) is easily scalable and eliminates
the need for auxiliary redox proteins.
OleT has been leveraged with biological 27 and photochemical (e.g. dye-mediator)
28, 29

approaches that generate H2O2 in a controlled manner in situ and can thus support high

levels of alkene production in vitro by preventing unwanted catalyst inactivation that
occurs upon exposure to excess oxidant.30 The efficient production of olefins in vivo has
remained more elusive as reactive oxygen species (ROS) are ill tolerated by most species
and highly efficient cellular detoxification mechanisms have evolved to prevent their
accumulation in a cellular milieu. Thus a major goal for developing in vivo platform for
alkene generation has been to redirect OleT to utilize O2 with a suitably poised biological
redox chain. To address this, a number of recent reports have shown that a combination of
pyridine nucleotide (NAD(P)H) and surrogate redox partners can support alkene formation
by OleT

20, 21, 23, 31-33

and orthologous CYP152 decarboxylases

34

and hydroxylases

35

in

vitro. Redox chains have included genetic fusions of OleT with RhFred,36 a donor that can
be fused to and serve as a surrogate redox donor to several CYPs,37 the reductase domain
of cytochrome P450 BM3,33 as well as multi-component systems such as the putidaredoxin
(Pd)/putidaredoxin reductase (PdR) system 20, 21, 23, 34 that is native to the CYP camphor 5hydroxylase CYP101 (P450CAM).38 Although these have shown to promote FA
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decarboxylation in studies using purified enzymes or cell-free extracts, in some cases
resulting in total turnover numbers (TTON > 100), attempts to leverage catalysis in vivo
has been met with much more limited success.4, 32, 39 Nonetheless, the realization of 1-olefin
production using OleT and surrogate redox donors has led some to speculate that CYP152s
may natively use O2 and electrons, rather than H2O2.20 However, a recent study has cast
some doubt as the inclusion of catalase in reactions of an OleT ortholog eliminates some
catalytic activity. 34
If dioxygen dependent catalysis is indeed supported by OleT, the catalytic cycle
would most likely need to be comprised of the same set of steps and intermediates that are
common to the vast majority of dioxygen-dependent CYPs and have been resolved over
the course of several decades. These are designated by the purple arrows in Figure 2.1B
and we refer to individual intermediates by their corresponding number throughout the
manuscript. Briefly, oxygen activation by OleT would need to involve reduction of the
substrate-bound enzyme, the subsequent binding of O2, and finally, the proton-linked
processes that enable heterolysis of the O-O bond to form Compound I. The efficiency of
these steps have yet to be clarified for OleT or for any other CYP152. Here, we utilize
transient kinetics to probe the rate of electron transfer from several biological redox donors
to OleT, examine the reactivity of the ferrous enzyme with dioxygen, and use
cryoradiolytic methods to address whether OleT can catalyze O-O bond cleavage. Together
with turnover studies that reveal the origins for the observed turnover by OleT from
pyridine nucleotide in the aforementioned studies, these results highlight several features
that hamper dioxygen activation by OleT. Furthermore, they serve to distinguish the clear
boundaries between oxygenase and peroxygenase catalysis. Ultimately this work may
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provide an important roadmap for enabling future bioengineering efforts to develop new
platforms for sustainable biofuel synthesis.

Figure 2.1. Biofuel production via fatty acid synthesis (A) and the P450 catalytic cycle
(B). (A) Hijacking of the fatty acid synthesis (FAS) pathway for advanced biofuel
synthesis. In the lower cyanobacterial pathway, the acyl carrier protein (ACP) linked acyl
group is reduced by an acyl-ACP reductase (AAR) and further metabolized by the
dinuclear iron enzyme aldehyde deformylating oxygenase (ADO) to an Cn-1 alkane. In the
upper pathway, a Cn-1 olefin is formed from the generation of a free fatty acid by the
thioesterase TesA and subsequent decarboxylation by the cytochrome P450 OleT. (B) The
H2O2 shunt mechanism (red) for the formation of the reactive Compound I oxidant in OleT
versus a canonical dioxygen dependent mechanism of cytochrome P450 involving hemeiron reduction, O2 binding, and O-O bond heterolysis to form Compound I (purple).
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2.3 RESULTS AND DISCUSSION
2.3.1 Sluggish electron transfer to OleT from biological redox donors
The previously measured redox properties for eicosanoic acid bound OleT suggest
that the high-spin (HS) enzyme (2) exhibits an unusually high redox potential (Em ~ -100
mV versus NHE)

40

that could provide a favorable thermodynamic driving force for

electron transfer from a redox partner such as Pd (Em ~ -240 mV) to occur. 41 The binding
of Pd to CYP101 involves a transient association of the two proteins using a
complementary electrostatic interface.42 Several basic residues (e.g. Arg109 and Arg112)
43, 44

on CYP101 are critical for mediating this interaction. A comparison of the surface

electrostatics of CYP101 and OleT shows that the latter enzyme lacks this potential binding
interface, but has another positively charged surface that could possibly serve as a
favorable docking site (Figure 2.2).

Figure 2.2. Molecular surfaces of (A) CYP101 and (B) OleT showing the charge
distribution of both proteins. This was generated by the Adaptive Poisson-Boltzmann
Server plugin of Pymol. Acidic and basic functional groups are shown in red and blue
respectively. The docking interface for putidaredoxin on CYP101, determined by the
Poulos laboratory,42 is circled for reference.

The efficiency of the Pd/PdR/NADH redox chain with OleT was directly examined
using transient kinetic methods. A solution containing eicosanoic acid (EA) bound OleT,
Pd and PdR was rapidly mixed with excess NADH in an anoxic atmosphere containing
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carbon monoxide and catalase to ensure that any H2O2 that could result from uncoupling
reactions was quenched. Successful electron transfer to OleT from pyridine nucleotide
would result in the formation of the ferrous carbonmonoxy-bound (Fe2+-CO) enzyme with
a Soret maximum at 446 nm. The photodiode array (PDA) traces that resulted from the
rapid mixing of OleT:Pd:PdR in a 1:10:10 ratio with a excess NADH are shown in Figure
2.3A. The HS substrate-bound enzyme, with a Soret maximum at 395 nm, very slowly
converts to the Fe2+-CO state. Even over the course of 1,000 seconds, only a fraction of the
enzyme (~ 50 %) was reduced. The time course for reduction at 450 nm is shown in the
inset of Figure 2.3A. Fitting of the time course to a single exponential process revealed an
𝑜𝑏𝑠
observed electron transfer rate 𝑘𝐸𝑇
= 0.0011 ± 0.0004 s-1. Notably, this reduction rate is

over four orders of magnitude slower than that of Pd to HS camphor bound CYP101 (kET
~ 20 s-1)45 and primary electron transfer rates for other native P450:redox pairs (e.g. 46-48).
This process is also more sluggish than the reported turnover frequency of OleT using the
Pd/PdR/NADPH couple (~0.01 s-1 at room temperature).20, 21
In attempts to explore the origin for the slow kinetics for first electron transfer and
possibly improve upon the efficiency of this process for in vivo studies, we turned our
attention to an an alternative flavin-containing redox partner that is native to E. coli termed
NAD(P)H:flavin oxidoreductase (Fre).49 Fre is thought to have a labile flavin cofactor 50,
51

and its use could eliminate the need for forming a preorganized binding interface with

OleT. Although Fre is known to serve as a redox partner to several classes of enzymes as
well as cytosolic Fe3+, it is not known to interact directly with CYPs. Nonetheless, Fre was
able to readily convert HS camphor-bound CYP101 to the ferrous state but failed to support
camphor 5-hydroxylation (Figure 2.4 [S2]). This stems from the well-known inability for

34

redox donors other than Pd to provide the second electron required for O2 activation in
CYP101, where binding of the redox partner also serves an indispensable effector role.52 It
is also consistent with the inability of a solitary flavin cofactor to synchronize the
sequential and timed delivery of two reducing equivalents to a CYP. Nonetheless, we tested
if this system could be more efficient than Pd for primary electron transfer to OleT. Rapid
mixing of solution containing a 1:10:10 ratio of HS OleT:FAD:Fre with excess NADH
resulted in almost complete conversion of HS OleT to the ferrous-CO form (Figure 2.5B).
Moreover, the observed electron transfer rate, shown in the inset of Figure 2.5B, indicated
𝑜𝑏𝑠
that the process is an order of magnitude faster (𝑘𝐸𝑇
= 0.0105 ± 0.0004 s-1) than the

Pd/PdR/NADH system.

Figure 2.3. Primary electron transfer to eicosanoic acid bound OleT. Eicosanoic acid
bound high-spin OleT was rapidly mixed with a solution containing (A) putidaredoxin
(Pd), putidaredoxin reductase (PdR), and NADH or (B) flavin reductase (Fre), flaving
adenine dinucleotide (FAD), and NADH, at 4 oC in the presence of catalase and carbon
monoxide. Concentrations after mixing were 5 μM OleT and 125 μM NADH and either 50
μM Pd, 50 μM PdR or 50 μM Fre, 50 μM FAD respectively. The insets shows single
exponential fitting of the timecourse for reduced carbonmonoxy bound OleT formation
followed at 450 nm with observed electron transfer rates (kET) indicated.
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Figure 2.4. Reduction and attempted turnover of CYP101 with Fre and FAD. Analysis
of the potential for E. coli NAD(P)H flavin reductase (Fre) to support primary electron
transfer (A) and turnover (B) with the camphor 5-hydroxylase CYP101. UV/visible spectra
in (A) show the reaction of camphor-bound CYP101 (10 μM), FAD (10 μM), and Fre (10
μM) before (red) or shortly following (blue) the addition of 100 μM NADH in a carbon
monoxide (CO) atmosphere. The inset shows the Fe2+-CO minus Fe3+ difference spectrum,
indicating that electron transfer has occurred. The gas chromatograms in (B) show a
comparison of the reactions of CYP101 with the Fre/FAD/NADH (black) or
Pd/PdR/NADH turnover systems (red). Reactions included 1 μM CYP101, 1 mM camphor,
50 μM catalase, and 2 mM NADH, and either 10 μM FAD and 10 μM FAD Fre (black) or
2.2 μM PdR and 10 μM Pd. Following incubation for 1 hour at 25oC, reactions were
quenched and extracted with chloroform and 200 nmol 3-bromocamphor as an internal
standard. Products were separated by a DB-5 GC column using the following oven
temperature gradients (170°C, 3 min; 2°C min-1 to 200 °C) and were identified by
comparison to the flame ionization detector (FID) chromatograms of authentic compounds.

2.3.2 Favorable Binding of Dioxygen to Ferrous OleT
Following electron transfer, O2-driven catalysis by OleT would necessitate the
binding of dioxygen to the ferrous-iron (3) to form a ferric-superoxide species (4). To our
knowledge, this process has yet to be examined for any CYP152. Ferrous OleT:EA,
prepared via reduction with dithionite, was rapidly mixed with a solution containing
saturating O2 (~2 mM) at 4 oC (Figure 2.5A). Figure 2.5A shows the photodiode traces
corresponding to the first 200 ms of the reaction. The ferrous enzyme, with a max ~ 412
nm, rapidly decays to form a species with a Soret maximum at 426 nm and a predominant
Q band at 550 nm with a small shoulder at 580 nm. The Soret maximum is red-shifted
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relative to many53,

54

but not all55 O2-bound CYPs and is well within the large range

observed for comparable species in thiolate heme proteins such as chloroperoxidase (CPO)
56

and nitric oxide synthase (NOS).57, 58 The difference in absorbance features of oxyOleT

versus those of many other CYPs may arise from differences at the proximal “cys-pocket”
or from interactions with bound dioxygen at the distal pocket, both of which are
significantly different in CYP152s. A particularly salient example of the perturbation of
the oxyferrous spectrum by the distal pocket is found in oxyNOS, where interactions with
the bound L-arginine substrate induce a similar spectral shift, rendering the ligand more
superoxide-like in character.59 The binding of dioxygen to the ferrous enzyme was
followed by monitoring the time course for absorbance changes at 440 nm, yielding an
observed rate of formation kobs ~ 50 s-1 (Figure 2.5A, inset). The binding process was
further characterized by monitoring the formation of oxy-OleT with varying concentrations
of dioxygen (Figure 2.5B). The on-rate, determined from the slope of the plot, yields a
bimolecular rate constant (kon = 5.7 ± 0.5 × 104 M-1 s-1). This value is quite similar to those
measured for O2-dependent CYPs, revealing that O2 binding characteristics are largely
preserved. 1, 53, 60, 61
2.3.3 OxyOleT Decays Slowly to the Low-Spin Enzyme and Forms Product
For coupled O2 driven catalysis to occur, the Fe3+-O2- complex (4) must be
sufficiently stable to allow for second electron transfer and ensuing O-O heterolysis,
thereby preventing the unwanted production of superoxide. The PDA traces corresponding
to the decomposition of oxyOleT from 200 ms to 500 s and the full kinetics of the process
are shown in Figures 2.6A and 2.6B respectively. The spectra reveal a very slow and
relatively complex process whereby the OleT oxy-complex appears to directly decay to the
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low-spin enzyme (λmax ~ 418 nm) over the course of 10 minutes at 4 oC. No
spectroscopically distinct intermediate accumulates during decomposition as revealed by
several isosbestic points for the transtion. The timecourse for oxyOleT decay required a
two summed exponential function for adequate fitting. The predominant phase, accounting
for ~90 % of the spectral amplitude exhibits a rate of ~ 0.004 s -1 while the smaller phase
(~10 % amplitude) has a decay rate of ~ 1 s-1. This kinetic behavior could in principle result
from a decay process involving multiple steps or more likely from multiple configurations
of the oxy-complex which decay at different rates. One plausible source of this
heterogeneity could arise from a small fraction of low-spin, substrate free enzyme present
at 4 oC, typically 10 – 15%, under the limiting EA used to prepare enzyme:substrate
complexes for the single-turnover studies described in the following section. To test this,
the autoxidation properties of substrate-free OleT were examined, revealing a much higher
rate of decomposition (~ 10 s-1) than the substrate-bound enzyme (Figure 2.7).

Figure 2.5. Dioxygen binding to ferrous substrate-acid bound OleT. (A) The dithionite
reduced eicosanoic acid bound enzyme (10 µM, blue spectrum) was rapidly mixed with 2
mM O2 at 4 oC. The inset shows the time course for oxyOleT (red spectrum) formation at
440 nm. Single exponential fitting reveals a rate of formation ~ 50 s-1. (B) O2 concentration
dependence oxyOleT formation. The slope of the plot reveals the bimolecular rate for
dioxygen binding, kon = 5.7 x 104 M-1s-1.
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Figure 2.6. Autoxidation of oxyOleT at 4 oC monitored by stopped flow spectroscopy.
(A) The oxy-complex (red spectrum) decays over the course of 500 s to the low-spin ferric
enzyme (violet spectrum). (B) The time course for oxyOleT formation and decay at 440
nm. Fitting required a three summed exponential with the two reciprocal relaxation times
corresponding to decay processes (in s-1) shown and their relative spectral amplitudes in
parentheses. Protein and O2 concentrations were identical to those described in Figure
2.3A.

Figure 2.7. Autoxidation properties of
substrate free oxy-OleT. The substrate-free
enzyme (5 µM) was rapidly mixed with 2
mM O2 at 4oC. Oxy-OleT (red spectrum)
rapidly decays to the ferric low-spin enzyme
(blue spectrum). The inset shows the time
course for decay at 440 nm. Single
exponential fitting reveals a rate of decay ~ 9
s-1.
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Overall, the kinetics and thermodynamics (Figure 2.8) for oxyOleT decomposition
reveal an intermediate that in the presence of substrate is amongst the most stable of any
CYP reported to date and very similar to the bacterial archetype CYP101.52 At first glance,
the substrate-mediated stabilization of oxyOleT (by ~3 orders of magnitude) by the fatty
acid substrate would appear to be a highly advantageous trait to ensure that the
consumption of pyridine nucleotide can be coupled to product formation. Despite its
stability, however, the rate for oxyOleT decay is still comparable to primary electron
transfer from Pd or Fre/FAD to OleT, and for many CYPs, delivery of the second electron
required to reduce the oxy-intermediate to the peroxo-level can be significantly slower.62, 63
The most intriguing aspect of the decay process, however, is that the HS EA-bound form
of the enzyme fails to regenerate at the end of the reaction. Single turnover transient
kinetics studies have shown that, upon reaction with excess H2O2, HS OleT converts to the
LS form
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with intervening Compound I (7)

16, 22

and Compound II (8) intermediates.17

The decay of the latter intermediate, accompanied by a rate-limiting product release step,
24

results in formation of the 1-alkene. Although failure to restore the HS state from

oxyOleT could signal the metabolism of the substrate it could also stem from alteration of
the substrate-binding mode, or release of the substrate from the enzyme altogether, upon
reduction and oxygenation. This prompted us to more closely examine the autoxidation
properties of oxyOleT in the presence of catalase in the reaction mixture. The PDA spectra
that correspond to oxyOleT decay (from 200 ms to 1000s) are shown in Figure 2.9A. Due
to the overlapping background absorption of catalase, the difference spectra generated by
substracting the spectrum of oxyOleT (4) from those corresponding to later timepoints are
more revealing. Difference spectra are compared for reactions that included or omitted
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catalase in Figure 2.9B. The features with positive absorption (pointing upward) are
associated with the developing species while those pointing downward correspond to
oxyOleT. The negative absorbance features are quite similar in both sets of difference
spectra, as expected, but the positive features reveal significant differences in the identity
of the oxyOleT decay product. The difference spectra obtained from reactions where
catalase was omitted reveal a dominant positive feature at 418 nm and a much smaller
shoulder at 396 nm, suggesting that oxyOleT largely (> 80 %) decays to the LS form. On
the other hand, the addition of catalase resulted in the regeneration of the HS enzymesubstrate complex with a maximal positive absorption feature at 396 nm.

Figure 2.8. Arrhenius plot of the rate
constant for eicosanoic-acid bound oxyOleT decay. The ferrous enzyme was reacted
with
O2-saturated
buffer
and
the
autoxidation, with maximal absorbance
change at 440 nm, was monitored by stopped
flow. The rate constant was derived at each
temperature by the slowest phase of a
summed-three exponential fit.
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The possibility of a product-forming pathway involving H2O2 as a consequence of
autoxidation was further probed by following the formation of the Cn-1 alkene product. A
solution of ferrous EA:OleT was oxygenated and aged several minutes prior to extraction
with chloroform and analysis by gas chromatography. Paired reactions included catalase
in the reaction mixture as well as the O2-saturated buffer to ensure efficient H2O2scavenging. Catalase-supplemented reactions resulted in the production of only 0.13 ± 0.02
equivalents of 1-nonadecene per HS-OleT, versus nearly stoichiometric production of the
olefin (0.98 ± 0.05 per HS OleT) in catalase-free reaction (Figure 2.10A). This strongly
implicates a mechanism involving peroxide, rather than direct reduction of bound O2, as
the pathway utilized by OleT for turnover from dithionite. In order to verify that the H2O2
derives from autoxidation of OleT, a set of single turnover reactions were prepared at 4 °C
and quenched at various timepoints. The equivalents of 1-nonadecene formed per HS-OleT
were plotted as a function of time, and the resulting data was fit to a single exponential
function, shown in Figure 2.10B. The fit resulted in a y-intercept of ~0.4 equivalents
nonadecene, suggesting a small level of background turnover occurring from a mechanism
distinct from autoxidation. This most likely arises from small amounts of H2O2 that are
formed during preparation of dithionite. Accordingly, this value agrees well with a control
reaction containing ferrous-OleT that was directly quenched without the addition of
dioxygen, which resulted in 0.37 equivalents of product per HS-OleT. Interestingly, the
formation rate of nonadecene formation (0.002 s-1) closely parallels the autoxidation rate
of ~0.004 s-1. Together with the substantial quenching that occurs upon the addition of
catalase, this strongly implicates a mechanism involving superoxide generation from oxyOleT followed by more rapid disproportionation to H2O2 (k ~ 105 M-1s-1 at neutral pH).64
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Figure 2.9. OleT autoxidizes to the high-spin form in the
presence of catalase. (A) Autoxidation of 10 μM oxyOleT
in the presence of 2.5 μM catalase (active sites) at 4 oC
monitored by stopped flow spectroscopy. The oxy-complex
(red spectrum) decays over the course of 500 s to form the
high-spin ferric enzyme (blue spectrum). (B) Comparison of
the difference spectra corresponding to oxyOleT
decomposition. The spectrum of oxy-OleT (formed at 200
ms) was used as a baseline and subtracted from spectra at
later timepoints.

2.3.4 Activation of Molecular Oxygen – Proton Delivery in OleT
Presupposing that a redox donor can be identified to efficiently reduce oxyOleT to
the ferric-peroxoanion intermediate (5), generation of the Compound I oxidant would still
entail the orchestrated delivery of protons to the distal oxygen atom for O-O heterolysis.
In many ways the most surprising aspect of the successful multiple turnover of OleT from
pyridine nucleotide is that CYP152s lack the conserved active site acid-alcohol pair shared
by most O2-dependent CYPs. A vast panoply of work has probed the critical role of these
residues for proton delivery to generate Compound I in O2-dependent CYPs, and we refer
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the interested reader to comprehensive reviews on the topic.

65, 66

Briefly summarized,

structural, spectroscopic, and turnover studies have revealed that mutation of the acid
residue typically results in a slow but coupled enzyme where primary proton delivery to
form the hydroperoxo adduct (5) is impaired. In contrast, preservation of the active site
alcohol is necessary for delivery of the second proton required for O-O heterolysis to form
Compound I and suppress uncoupling to H2O2. As the relevant peroxo-intermediates (5
and 6) are highly transient, Hoffman, Davydov and colleagues have found that a very useful
method to probe the integrity of proton-donation pathways is to generate them via
cryoreduction of the oxy- precursor. 67 In CYPs that utilize Compound I as a direct oxidant,
proton transfer is highly efficient and cryoradiolysis of the oxy-complex results in
formation of the ferric-hydroperoxo adduct as the primary reduced species at 77 K. 68-70

Figure 2.10. Single-turnover experiments of oxyOleT. (A) The eicosanoic acid
bound OleT-oxy complex (25 µM) was formed and allowed to decay for 35 minutes
at 25 oC prior to chloroform extraction and analysis for nonadecene formation.
Control reactions included 8 mg/mL catalase. (B) Time dependence of nonadecene
formation from oxyOleT. OxyOleT was formed at 4 oC and quenched at the
indicated time points with HCl and analyzed by gas chromatography to determine
the rate for nonadecene formation. The y-intercept (~0.4 equivalents of 1nonadecene/OleT) is similar to a control reaction where O2 was omitted.
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An EPR spectrum of EA-bound oxy-OleT that was cryoreduced at 77 K and stored
for ~ 6 months at liquid N2 temperature is shown in Figure 2.11. The spectrum shows a
major species with g-values at 2.24, 2.15, and 1.90 and a minor contaminant that derives
from the ferric low-spin aquo- heme. The low g-anisotropy of the peroxo-adduct is
consistent with an assignment as the unprotonated peroxo-anion species (5). For example,
very similar EPR spectra are observed in CYPs where the proton delivery network is
interrupted through mutagenesis of the conserved acid (e.g. the Asp251Asn mutant of
CYP101) or alteration of the immediate hydrogen-bonding environment mediated by
active site solvent. 69, 71 Although these coupled but slow CYP101 mutants ultimately form
hydroperoxo species at temperatures approaching the glass transition temperature (> 180
K) and ultimately form product, the behavior of cryoreduced oxyOleT differs substantially.
As revealed through progressive thermal annealing, the signal corresponding to (5)
progressively decays from 180 K to 220 K and does not directly form any species that can
be detected. This suggests that the peroxo adduct decays to an intermediate that is either
diamagnetic or that has an EPR spectrum that is within the spectral window (g ~ 2) masked
by free radicals produced from irradiation. Given the absence of any detectable ferrichydroperoxo species throughout the annealing process, it is highly unlikely that such a
species would represent Compound I. Rather, with analogy to optical annealing
experiments of CYP11972 and horseradish peroxidase (HRP),73 this more likely reflects a
process that involves uncoupling at the peroxo- branchpoint. In these enzymes, the ferric
enzyme produced from ligand dissociation is reduced and subsequently binds CO that is
formed from the radiolysis of glycerol. Consistent with this, the ferric-LS resting state of
OleT was only observed after the sample was fully thawed at 270 K for a prolonged time
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and allowed to exchange with oxygen. Taken together, the annealing profile of cryoreduced
oxyOleT reflects a combination of the chemical phenotypes associated with absence of
both the conserved acid and alcohol in CYP152s, and interruption of both proton transfer
steps.

Figure 2.11. Thermal annealing and
EPR of the cryo-irradiated OleT oxycomnplex. X-band EPR spectra of oxyOleT irradiated by 4 Mrad at 77 K and
thermally annealed at the indicated
temperatures. The 77 K spectrum was
acquired after storage under N2,(l) for 6
months.
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Figure 2.12. Steady state turnover reactions of OleT. Reactions were
initiated by the addition of 500 µM H2O2 or 500 µM NAD(P)H with the
redox chain indicated, and incubated for one hour at room temperature prior
to analysis by GC. Solutions contained 1 µM OleT, 500 µM eicosanoic acid
and 10 µM of the redox components (Pd, PdR, Fre, and FAD) in the
combinations indicated. Reactions with catalase were performed in the
presence of 2 µM tetramer. All combinations were tested in triplicate with
the mean total turnover number (TTON) and 1 standard deviation of the
mean indicated by the error bars.

2.3.5 OleT multiple turnover with NAD(P)H results from H2O2 production
Multiple turnover studies were utilized to assess the decarboxylation ability of OleT
with the Pd/PdR and Fre/FAD redox systems. The results from steady-state turnover
experiments performed in triplicate are shown in Figure 2.12. For experiments using the
Pd/PdR couple, reactions that used either NADH or NADPH were analyzed, as the
NADPH/Pd/PdR system was previously demonstrated to result in higher alkene yields than
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those using NADH.20 This is surprising given the highly preferential nature of PdR for
NADH. Work by Peterson and colleagues has shown that the reduction of PdR by NADPH
is 3 orders of magnitude slower than NADH.74 This suggests that the previously observed
OleT activity may have originated from processes independent from electron transfer.
Reactions were performed in triplicate in the absence and presence of catalase (≥ 1000
U/mL) over the course of one hour before extraction and analysis by GC. A large amount
of catalase was used due to the relatively high-affinity of OleT and the CYP152
H O

hydroxylase BSβ for H2O2 (KD2 2 ~ 50 μM).17, 22, 24, 75 Likewise, relatively short (1 hour)
reaction times were employed in order to prevent the unwanted inactivation of OleT and
catalase. The catalase concentrations and reaction conditions used here were able to fully
eliminate the activity of OleT when 500 nmol of H2O2, equivalent to the amount of pyridine
nucleotide used in the turnover studies described below,was slowly added to the enzyme
over the course of an hour. In the absence of catalase, the Pd/PdR/NADH system produced
303 ± 6 nmol of alkene product with NADH, and despite the relative inability for PdR to
utilize NADPH, 173 ± 4 nmol of nonadecene was still observed when the less preferred
pyridine nucleotide was used. The omission of Pd from the presumptive redox chain
resulted in a large retention (> 93 %) of activity and reactions that only included NAD(P)H
still showed a good degree of decarboxylation (12 – 15 % ). Despite the inability of Fre to
serve as a CYP effector and unlikelihood that it can deliver the second electron required
for O-O bond cleavage, the Fre/FAD/NADH redox system still showed relatively high
activity (> 50 %) when compared to the Pd/PdR/NADH couple. The absence of any clear
correlation of activity to redox donor properties or components clearly invokes a
mechanism distinct from the canonical O2/e- cycle for CYPs. Instead, the elimination of ≥
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90% of the decarboxylation product by catalase clearly points to H2O2, produced as a result
of redox cofactor autoxidation, as the major source for OleT activity from pyridine
nucleotide.

2.4 CONCLUSIONS
Biological redox chains have proven to be effective for OleT turnover and studies
using these systems have elaborated on the catalytic versatility of this enzyme class for
decarboxylating a suite of fatty acid substrates. Despite the success of such bioengineering
efforts for elucidating and expanding upon the substrate scope of OleT, the results
presented in this manuscript serve as a cautionary guide when searching for new redox
donors to enhance OleT activity or to adapt this enzyme for in vivo biofuel synthesis. The
sluggishness of electron transfer and inability for OleT to mediate the proton-dependent
cleavage of dioxygen leaves little doubt that the turnover observed in these systems stems
from the adventitious production of H2O2. This can occur through autoxidation from the
oxy-ferrous complex, the redox donor, or the pyridine nucleotide itself75 (Figure 2.13). As
a result, the coupling value (product formed per NADH), commonly used as a metric to
gauge the efficiency of the process, is a poor guide as all of these processes could yield
stoichiometric product per pyridine nucleotide consumed. In addition to rewiring electron
and proton donor pathways, the ability for OleT to efficiently scavenge H2O2 could be
harnessed for generating biofuels in hosts that are oxidatively challenged through chemical
or genetic approaches. The autoxidation shunt pathway revealed in these studies provide
an equally intriguing alternative. If the oxy-complex can be sufficiently destabilized, it may
be possible to produce H2O2 in a manner that is sequestered from ROS scavengers.
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Figure 2.13. Scheme for the generation of H2O2 from pyridine
nucleotide and OleT. Operant pathways involve the autoxidation of
the redox donor (a flavin group is designated) or the OleT-oxy
complex to form superoxide, and ultimately H2O2.

2.5 MATERIALS AND METHODS
2.5.1 Chemicals and Reagents
All microbiology reagents and media, reduced β-nicotinamide adenine dinucleotide
(NADH) and reduced β-nicotinamide adenine dinucleotide phosphate (NADPH) were
purchased from Research Products International. Glycerol, buffers, and chloramphenicol
(CAM) were from VWR International. Bovine liver catalase (2,000-5,000 units∙mg-1),
tetracycline, methyl viologen, 30% hydrogen peroxide, and sodium hydrosulfite
(dithionite)

were

from

Sigma

Aldrich.

Antibiotics

and

isopropyl-β-ᴅ-

thiogalactopyranoside (IPTG) were from Gold Biotechnology. Hemin was purchased from
Carbosynth. Flavin adenine dinucleotide (FAD), 1-hexadecene, and 1-nonadecene gas
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chromatography standards were from Tokyo Chemical Industry (TCI) Company. The
pChuA plasmid was a gift from Alan Jasanoff (Addgene plasmid # 42539). 76 The pG-Tf2
chaperone plasmid was from Takara Bio Inc. Protiated (C20H40O2) and perdeuterated
(C20D40O2) eicosanoic acid were from Supelco Analytical and CDN Isotopes respectively.
2.5.2 Protein Expression and Purification
Heterologous expression and purification of OleT is described in earlier work.

24

The fre gene was cloned from genomic DNA prepared from E. coli DH5α cells using a
Promega Wizard SV Genomic DNA Purification kit. The fre gene, which encodes E. coli
NAD(P)H:flavin oxidoreductase, was amplified and subsequently cloned into a pet21b
vector following PCR amplification using the following primers with restriction sites
underlined: FreFwd (NdeI) 5’-GGATGGCATATGACAACCTTAAGCTGTA-3’ and
FreRvs (XhoI) 5’-GGATGGCTCGAGGATAAATGCAAACGCA-3’. The resulting
construct was transformed into E. coli BL21(DE3) cells and grown in 2 L flasks containing
1 L of Luria broth (LB) supplemented with 100 mg/L ampicillin and inoculated with 10
mL of an overnight starter culture at 37 °C and 180 rpm. At OD600 = 0.7, expression was
induced via addition of 250 µM IPTG and the temperature was decreased to 18 °C for 24
hours. Cells were harvested via centrifugation and stored at -70 °C. Fre-containing cells
were resuspended in pH 8.0 lysis buffer containing 50 mM NaH2PO4, 300 mM NaCl, 10
mM imidazole, and 0.1 % (v/v) Triton-X100. Following sonication and centrifugation, the
clarified lysate was loaded onto a Ni-NTA column pre-equilibrated in lysis buffer, then
washed in the same buffer containing 20 mM imidazole. Bound protein was eluted with 50
mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, and 0.1 % (v/v) Triton X-100 pH 8.0.
Fractions containing protein were pooled, and dialyzed overnight against 50 mM NaH2PO4
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and 300 mM NaCl pH 8.0, then concentrated and stored at -70 °C. Pentahistidine-tagged
putidaredoxin reductase and hexahistidine-tagged puridaredoxin were expressed and
purified using published procedures.77, 78
2.5.3 Ultraviolet-Visible (UV-vis) Spectroscopy
Optical spectra were recorded using an HP 8453 spectrophotometer. The
concentration and high-spin content of OleT was determined using ε395 = 53 mM-1cm-1 and
ε418 = 110 mM-1cm-1 for the low-spin enzyme, ε395 = 96 mM-1cm-1 and ε418 = 52 mM-1cm1

for the high-spin form, and ε406 = 81 mM-1cm-1 for the isosbestic point between the two

species. High-spin, substrate-bound enzyme was prepared by adding 2 molar equivalents
of eicosanoic acid (dissolved at a concentration of 10 mM in 10 % Triton X-100: 90 %
ethanol (v:v), incubating on ice, and centrifuging to eliminate the unsolubilized fatty acid
and aggregated protein. This preparation yielded P450 with a high spin content of
approximately 85 – 90 %. When low-spin OleT was required, the as-purified enzyme was
treated with 4 equivalents of H2O2, incubated for 1 hour, and subsequently desalted on a
PD-10 column.
Dithionite solutions were prepared in septa-sealed vials with anaerobic buffer, and
concentrations were determined by optical spectroscopy in a sealed anaerobic cuvette prior
to use with ε315 = 8 mM-1 cm-1.79 NADH and NADPH were quantified aerobically using
ε340 = 6.2 mM-1 cm-1.80 The concentrations of Pd and PdR were determined using ε412 = 11
mM-1cm-1 and ε454 = 10 mM-1 cm-1respectively.77 The percent of FAD bound to Fre was
found to vary between preparations, so in order to accurately quantify Fre (ε 280 = 27 mM1

cm-1 for the apoprotein) it was necessary to subtract the contribution of FAD at 280 nm

ε280, FAD = 20 mM-1cm-1 determined using the unique absorption of the cofactor (ε450, FAD =
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11 mM-1cm-1 ). 81

Catalase stocks were prepared fresh daily by dissolving 8 - 20 mg of

the lyophilized protein in 1 mL of 50 mM KH2PO4 pH 7.5. Solutions were centrifuged and
dissolved catalase was quantified based on the heme content for the tetrameric protein
using ε405 = 324 mM-1cm-1. 82
2.5.4 Transient Kinetics Studies
Stopped flow spectroscopy was performed on an Applied Photophysics SX20
stopped flow with a 1 msec dead-time using a photodiode array (PDA) detector. For
anaerobic studies, the instrument was equipped with an anaerobic accessory and scrubbed
of oxygen using a 2-5 mM dithionite solution, then rinsed thoroughly with an anaerobic
buffer prepared by sparging with N2 gas. Electron transfer studies were conducted by
preparing a carbon monoxide (CO) saturated solution of 10 µM high-spin OleT, 5 µM
excess eicosanoic acid, 2.6 µM catalase, and either 100 µM Fre/FAD or 100 µM Pd/PdR.
This solution was rapidly mixed with 250 µM NADH, supplemented with 0.8 µM catalase
tetramer, which was degassed in the same manner as the protein samples. Spectra were
collected and traces at 446 nm were fit to a single exponential equation using Pro-Data SX
Software to determine the electron transfer rate.
Oxy-complex formation and decay was performed in a 250 mM KH2PO4 pH 7.5,
250 mM NaCl buffer. Buffer was purged with oxygen gas on ice for 2 hours to achieve O2saturation (~2 mM O2 at 4 oC). Protein samples contained either 10 µM of a stoichiometric
OleT:eicosanoic acid complex or the substrate free enzyme. The protein was sparged with
N2 gas on ice and complete reduction of P450 was acheived by the addition of
approximately 50 µM dithionite in the presence of 1 µM methyl viologen. Ferrous P450
was transferred anaerobically to the stopped flow using a gastight syringe, and rapidly
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mixed with either an O2-saturated buffer or a mixture of O2 and N2 saturated buffers for
the O2 concentration dependence studies. Formation of the oxy-complex is kinetically well
resolved from autoxidation phases, which are much slower. The O2 on rate was determined
through fitting the increase in absorbance at 440 nm over short time (< 1 s) time scales
where no appreciable decay occurs to a single exponential expression to determine an
observed rate (kobs) for oxyOleT formation. The O2 on rate is determined by the slope of
the kobs versus O2 concentration plots under pseudo-first order conditions in O2.
Autoxidation rates were determined by fitting the 440 nm time courses to the following
three summed exponential equation which is appropriate for a series of first order or pseudo
first order reactions. At,obs is the observed absorbance, 1/t is the reciprocal relaxation time
(RRT) of a particular phase (in inverse seconds), a is the amplitude of that phase, t is the
time (seconds), and A∞ is the final absorbance:
𝐴𝑡,𝑜𝑏𝑠 = 𝐴∞ + 𝑎1 𝑒 −𝑡/𝑡1 +𝑎2 𝑒 −𝑡/𝑡2 + 𝑎3 𝑒 −𝑡/𝑡3
The observed reciprocal relaxation times were kinetically well separated where the fastest
phase with a negative amplitude (positive absorbance) represents the observed rate for
oxyferrous formation. The two slower phases with positive amplitudes represent the rates
of autoxidation which are O2 independent and hence irreversible in nature. In experiments
that probed autoxidation in the presence of catalase, a solution of 20 µM of OleT:eicosanoic
acid, 2 µM methyl viologen and 5 µM catalase (active sites) was made anaerobic and
reduced as described above. The solution was mixed at 4 oC with a KH2PO4 solution
containing 2 mM O2.
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2.5.5 Product Formation Studies
Single Turnover - Single turnover experiments were performed at 4 °C on ice in 10
mL anaerobic, septum-sealed vials. Initial reaction mixtures (2 mL) contained 25 µM highspin OleT:C20D40O2 complex and 2.5 µM methyl viologen in 150 mM KH2PO4 pH 7.5,
and 150 mM NaCl. The protein was sparged with N2 gas and subsequently reduced via the
addition of 5 equivalents of dithionite. Following a 2-3 minute incubation to allow
complete reduction, 2 mL of O2-saturated buffer was added. Reactions were quenched at
1, 2.5, 5, 10, 20, or 35 minutes after O2 addition via the addition of HCl to a final
concentration of ~ 2 M. N2-saturated buffer was added to the anaerobic control. For
reactions where catalase was included, the O2 solution contained 8 mg∙mL-1 catalase in
both the initial reaction mixture and the O2-saturated buffer. As an internal standard, 50
nmol of 1-hexadecene was added and samples were analyzed by gas chromatography using
methods we have reported previously. 24, 30
Multiple Turnover - Multiple turnover reactions were performed in 75 mM KH2PO4
and 75 mM NaCl pH 7.5 at room temperature over a 60 minute time course. Each 1 mL
reaction contained 1 µM Ole, 0.5 mM eicosanoic acid, 10 µM redox partner(s), and either
0.5 mM NADH or NADPH. Peroxide control reactions were carried out by slow perfusion
of 0.5 mM H2O2 via syringe pump over the same time period. All reactions were performed
in triplicate and paired with reactions containing 2 µM catalase tetramer, also in triplicate.
Due to the photoreactivity of FAD, reactions containing this component were set-up and
carried out in the dark. Reactions were quenched and analyzed as described above.
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2.5.6 Cryoreduction Studies
A 0.75 mL solution of 200 µM OleT bound to deuterated eicosanoic acid (~80%
high-spin content) and 20 µM methyl viologen in 200 mM KH2PO4 pH 7.5, 200 mM NaCl,
and 20% glycerol was sparged with N2 on ice in a septum-sealed anaerobic vial. Dithionite
from a 40 mM stock was added to achieve a final concentration of 1 mM, and the protein
mix was stirred on ice for ~3 minutes to ensure complete reduction. The sample was
subsequently transferred to 3 septum-sealed EPR tubes. Samples were chilled in a -15 °C
dry ice/ethanol cryobath, and O2 was gently bubbled into the protein solution for 10 - 20
seconds while quickly lowering and raising the EPR tube in and out of the cryobath to
generate the oxy-ferrous intermediate. Septa were removed and the tubes were frozen in
liquid nitrogen within 1 minute of oxygen exposure. The OleT oxy complexes were γirradiated at 77 K to a total absorbed dose of ~4 Mrad with a 60Co source at the Notre Dame
Radiation Laboratory and kept at liquid nitrogen temperatures prior to analysis. Samples
were thermally annealed in one minute increments using a liquid nitrogen-cooled ethanol
cryobath initially set at ~160 K. Temperatures were increased by 10-20 K increments via
titration of cyclohexane into the cryobath, were subsequently annealed at 270 K for 5-10
minutes. For each annealing temperature, EPR spectra were collected using a Bruker Xband EMXplus equipped with an Oxford Instruments ESR continuous flow liquid helium
cryostat at 20 K using a microwave power of 2 mW and a modulation amplitude of 10
gauss. Samples were maintained at 77 K between annealing and transfer to the EPR cavity.
Following annealing, samples were thawed, extracted in chloroform, then analyzed for 1nonadecene formation by GC.

56

2.6 ACKNOWLEDGMENTS
This work was supported by National Science Foundation CAREER Grant 1555066 and
grants from the University of South Carolina Vice President of Research to T.M.M.
through the ASPIRE I and II programs. We thank Prof. James Kincaid and Yilin Liu
(Marquette University) and Dr. Jay A. LaVerne at Notre Dame Radiation Laboratory
(Notre Dame University, IN), a facility of the US Department of Energy, Office of Basic
Energy Science, for their assistance in cryoreduction experiments.

57

2.7 REFERENCES
1. Wise, C. E.; Grant, J. L.; Amaya, J. A.; Ratigan, S. C.; Hsieh, C. H.; Manley, O. M.;
Makris, T. M., Divergent mechanisms of iron-containing enzymes for hydrocarbon
biosynthesis. J Biol Inorg Chem 2017, 22 (2-3), 221-235.
2. Qiu, Y.; Tittiger, C.; Wicker-Thomas, C.; Le Goff, G.; Young, S.; Wajnberg, E.;
Fricaux, T.; Taquet, N.; Blomquist, G. J.; Feyereisen, R., An insect-specific P450
oxidative decarbonylase for cuticular hydrocarbon biosynthesis. Proc Natl Acad Sci
USA 2012, 109 (37), 14858-14863.
3. Schirmer, A.; Rude, M. A.; Li, X.; Popova, E.; del Cardayre, S. B., Microbial
biosynthesis of alkanes. Science 2010, 329 (5991), 559-62.
4. Rude, M. A.; Baron, T. S.; Brubaker, S.; Alibhai, M.; Del Cardayre, S. B.; Schirmer,
A., Terminal Olefin (1-Alkene) Biosynthesis by a Novel P450 Fatty Acid
Decarboxylase from Jeotgalicoccus Species. Appl Environ Microb 2011, 77 (5), 17181727.
5. Rui, Z.; Harris, N. C.; Zhu, X. J.; Huang, W.; Zhang, W. J., Discovery of a Family of
Desaturase-Like Enzymes for 1-Alkene Biosynthesis. ACS Catal 2015, 5 (12), 70917094.
6. Rui, Z.; Li, X.; Zhu, X. J.; Liu, J.; Domigan, B.; Barr, I.; Cate, J. H. D.; Zhang, W. J.,
Microbial biosynthesis of medium-chain 1-alkenes by a nonheme iron oxidase. Proc
Natl Acad Sci USA 2014, 111 (51), 18237-18242.
7. Choi, Y. J.; Lee, S. Y., Microbial production of short-chain alkanes. Nature 2013, 502
(7472), 571-4.

58

8. Kallio, P.; Pasztor, A.; Thiel, K.; Akhtar, M. K.; Jones, P. R., An engineered pathway
for the biosynthesis of renewable propane. Nat Commun 2014, 5, 4731.
9. Buijs, N. A.; Zhou, Y. J.; Siewers, V.; Nielsen, J., Long-chain alkane production by the
yeast Saccharomyces cerevisiae. Biotechnol Bioeng 2015, 112 (6), 1275-9.
10. Zhou, Y. J.; Buijs, N. A.; Zhu, Z.; Qin, J.; Siewers, V.; Nielsen, J., Production of fatty
acid-derived oleochemicals and biofuels by synthetic yeast cell factories. Nat Commun
2016, 7, 11709.
11. Rajakovich, L. J.; Norgaard, H.; Warui, D. M.; Chang, W. C.; Li, N.; Booker, S. J.;
Krebs, C.; Bollinger, J. M.; Pandelia, M. E., Rapid Reduction of the DiferricPeroxyhemiacetal Intermediate in Aldehyde-Deformylating Oxygenase by a
Cyanobacterial Ferredoxin: Evidence for a Free-Radical Mechanism. J Am Chem Soc
2015, 137 (36), 11695-11709.
12. Warui, D. M.; Li, N.; Norgaard, H.; Krebs, C.; Bollinger, J. M.; Booker, S. J., Detection
of Formate, Rather than Carbon Monoxide, As the Stoichiometric Coproduct in
Conversion of Fatty Aldehydes to Alkanes by a Cyanobacterial Aldehyde
Decarbonylase. J Am Chem Soc 2011, 133 (10), 3316-3319.
13. Zhang, J. J.; Lu, X. F.; Li, J. J., Conversion of fatty aldehydes into alk (a/e)nes by in
vitro reconstituted cyanobacterial aldehyde-deformylating oxygenase with the cognate
electron transfer system. Biotechnol Biofuels 2013, 6.
14. Aukema, K. G.; Makris, T. M.; Stoian, S. A.; Richman, J. E.; Munck, E.; Lipscomb, J.
D.; Wackett, L. P., Cyanobacterial aldehyde deformylase oxygenation of aldehydes
yields n-1 aldehydes and alcohols in addition to alkanes. ACS Catal 2013, 3 (10), 22282238.

59

15. Patrikainen, P.; Carbonell, V.; Thiel, K.; Aro, E. M.; Kallio, P., Comparison of
orthologous cyanobacterial aldehyde deformylating oxygenases in the production of
volatile C3-C7 alkanes in engineered E. coli. Metab Eng Commun 2017, 5, 9-18.
16. Grant, J. L.; Hsieh, C. H.; Makris, T. M., Decarboxylation of fatty acids to terminal
alkenes by cytochrome P450 compound I. J Am Chem Soc 2015, 137 (15), 4940-3.
17. Grant, J. L.; Mitchell, M. E.; Makris, T. M., Catalytic strategy for carbon-carbon bond
scission by the cytochrome P450 OleT. Proc Natl Acad Sci USA 2016, 113 (36), 1004910054.
18. Lu, X.; Vora, H.; Khosla, C., Overproduction of free fatty acids in E. coli: implications
for biodiesel production. Metab Eng 2008, 10 (6), 333-9.
19. Xu, P.; Gu, Q.; Wang, W.; Wong, L.; Bower, A. G.; Collins, C. H.; Koffas, M. A.,
Modular optimization of multi-gene pathways for fatty acids production in E. coli. Nat
Commun 2013, 4, 1409.
20. Dennig, A.; Kuhn, M.; Tassoti, S.; Thiessenhusen, A.; Gilch, S.; Bulter, T.; Haas, T.;
Hall, M.; Faber, K., Oxidative Decarboxylation of Short-Chain Fatty Acids to 1Alkenes. Angew Chem Int Ed Engl 2015, 54 (30), 8819-8822.
21. Dennig, A.; Kurakin, S.; Kuhn, M.; Dordic, A.; Hall, M.; Faber, K., Enzymatic
Oxidative Tandem Decarboxylation of Dioic Acids to Terminal Dienes. Eur J Org
Chem 2016, (21), 3473-3477.
22. Hsieh, C. H.; Huang, X.; Amaya, J. A.; Rutland, C. D.; Keys, C. L.; Groves, J. T.;
Austin, R. N.; Makris, T. M., The Enigmatic P450 Decarboxylase OleT Is Capable of,
but Evolved To Frustrate, Oxygen Rebound Chemistry. Biochemistry 2017, 56 (26),
3347-3357.

60

23. Wang, J. B.; Lonsdale, R.; Reetz, M. T., Exploring substrate scope and stereoselectivity
of P450 peroxygenase OleTJE in olefin-forming oxidative decarboxylation. Chem
Commun (Camb) 2016, 52 (52), 8131-3.
24. Amaya, J. A.; Rutland, C. D.; Leschinsky, N.; Makris, T. M., A Distal Loop Controls
Product Release and Chemo- and Regioselectivity in Cytochrome P450
Decarboxylases. Biochemistry 2018, 57 (3), 344-353.
25. Joo, H.; Lin, Z.; Arnold, F. H., Laboratory evolution of peroxide-mediated cytochrome
P450 hydroxylation. Nature 1999, 399 (6737), 670-3.
26. Kumar, S.; Liu, H.; Halpert, J. R., Engineering of cytochrome P450 3A4 for enhanced
peroxide-mediated substrate oxidation using directed evolution and site-directed
mutagenesis. Drug Metab Dispos 2006, 34 (12), 1958-65.
27. Matthews, S.; Tee, K. L.; Rattray, N. J.; McLean, K. J.; Leys, D.; Parker, D. A.;
Blankley, R. T.; Munro, A. W., Production of alkenes and novel secondary products by
P450 OleT(JE) using novel H2O2-generating fusion protein systems. FEBS Lett 2017,
591 (5), 737-750.
28. Zachos, I.; Gassmeyer, S. K.; Bauer, D.; Sieber, V.; Hollmann, F.; Kourist, R.,
Photobiocatalytic decarboxylation for olefin synthesis. Chem Commun (Camb) 2015,
51 (10), 1918-21.
29. Bojarra, S.; Reichert, D.; Grote, M.; Baraibar, A. G.; Dennig, A.; Nidetzky, B.; Mugge,
C.; Kourist, R., Bio-based ,-Functionalized Hydrocarbons from Multi-step Reaction
Sequences with Bio- and Metallo-catalysts Based on the Fatty Acid Decarboxylase
OleT(JE). ChemCatChem 2018, 10 (5), 1192-1201.

61

30. Amaya, J. A.; Rutland, C. D.; Makris, T. M., Mixed regiospecificity compromises
alkene synthesis by a cytochrome P450 peroxygenase from Methylobacterium populi.
J Inorg Biochem 2016, 158, 11-16.
31. Fang, B.; Xu, H. F.; Liu, Y.; Qi, F. X.; Zhang, W.; Chen, H.; Wang, C.; Wang, Y. L.;
Yang, W. X.; Li, S. Y., Mutagenesis and redox partners analysis of the P450 fatty acid
decarboxylase OleT(JE). Sci Rep 2017, 7.
32. Liu, Y.; Wang, C.; Yan, J. Y.; Zhang, W.; Guan, W. N.; Lu, X. F.; Li, S. Y., Hydrogen
peroxide-independent production of alpha-alkenes by OleT(JE) P450 fatty acid
decarboxylase. Biotechnol Biofuels 2014, 7.
33. Lu, C.; Shen, F.; Wang, S.; Wang, Y.; Liu, J.; Bai, W.-J.; Wang, X., An Engineered
Self-Sufficient Biocatalyst Enables Scalable Production of Linear α-Olefins from
Carboxylic Acids. ACS Catal 2018, 5794-5798.
34. Xu, H.; Ning, L.; Yang, W.; Fang, B.; Wang, C.; Wang, Y.; Xu, J.; Collin, S.; Laeuffer,
F.; Fourage, L.; Li, S., In vitro oxidative decarboxylation of free fatty acids to terminal
alkenes by two new P450 peroxygenases. Biotechnol Biofuels 2017, 10, 208.
35. Girhard, M.; Schuster, S.; Dietrich, M.; Durre, P.; Urlacher, V. B., Cytochrome P450
monooxygenase from Clostridium acetobutylicum: a new alpha-fatty acid hydroxylase.
Biochem Biophys Res Commun 2007, 362 (1), 114-9.
36. Liu, Y.; Wang, C.; Yan, J.; Zhang, W.; Guan, W.; Lu, X.; Li, S., Hydrogen peroxideindependent production of alpha-alkenes by OleTJE P450 fatty acid decarboxylase.
Biotechnol Biofuels 2014, 7 (1), 28.

62

37. Li, S.; Podust, L. M.; Sherman, D. H., Engineering and analysis of a self-sufficient
biosynthetic cytochrome P450 PikC fused to the RhFRED reductase domain. J Am
Chem Soc 2007, 129 (43), 12940-1.
38. Katagiri, M.; Ganguli, B. N.; Gunsalus, I. C., A Soluble Cytochrome P-450 Functional
in Methylene Hydroxylation. J Biol Chem 1968, 243 (12), 3543-&.
39. Chen, B.; Lee, D. Y.; Chang, M. W., Combinatorial metabolic engineering of
Saccharomyces cerevisiae for terminal alkene production. Metab Eng 2015, 31, 53-61.
40. Belcher, J.; McLean, K. J.; Matthews, S.; Woodward, L. S.; Fisher, K.; Rigby, S. E. J.;
Nelson, D. R.; Potts, D.; Baynham, M. T.; Parker, D. A.; Leys, D.; Munro, A. W.,
Structure and Biochemical Properties of the Alkene Producing Cytochrome P450
OleTJE (CYP152L1) from the Jeotgalicoccus sp 8456 Bacterium. J Biol Chem 2014,
289 (10), 6535-6550.
41. Wilson, G. S.; Tsibris, J. C.; Gunsalus, I. C., Electrochemical studies of putidaredoxin
and its selenium analog. J Biol Chem 1973, 248 (17), 6059-61.
42. Tripathi, S.; Li, H. Y.; Poulos, T. L., Structural Basis for Effector Control and Redox
Partner Recognition in Cytochrome P450. Science 2013, 340 (6137), 1227-1230.
43. Shimada, H.; Nagano, S.; Hori, H.; Ishimura, Y., Putidaredoxin-cytochrome P450cam
interaction. J Inorg Biochem 2001, 83 (4), 255-260.
44. Unno, M.; Shimada, H.; Toba, Y.; Makino, R.; Ishimura, Y., Role of Arg112 of
cytochrome p450cam in the electron transfer from reduced putidaredoxin. Analyses
with site-directed mutants. J Biol Chem 1996, 271 (30), 17869-74.

63

45. Davies, M. D.; Sligar, S. G., Genetic variants in the putidaredoxin-cytochrome P450cam electron-transfer complex: identification of the residue responsible for redoxstate-dependent conformers. Biochemistry 1992, 31 (46), 11383-9.
46. Guengerich, F. P.; Johnson, W. W., Kinetics of ferric cytochrome P450 reduction by
NADPH-cytochrome P450 reductase: rapid reduction in the absence of substrate and
variations among cytochrome P450 systems. Biochemistry 1997, 36 (48), 14741-50.
47. Ost, T. W.; Clark, J.; Mowat, C. G.; Miles, C. S.; Walkinshaw, M. D.; Reid, G. A.;
Chapman, S. K.; Daff, S., Oxygen activation and electron transfer in flavocytochrome
P450 BM3. J Am Chem Soc 2003, 125 (49), 15010-20.
48. Uhlmann, H.; Bernhardt, R., The role of threonine 54 in adrenodoxin for the properties
of its iron-sulfur cluster and its electron transfer function. J Biol Chem 1995, 270 (50),
29959-66.
49. Fontecave, M.; Eliasson, R.; Reichard, P., NAD(P)H:flavin oxidoreductase of
Escherichia coli. A ferric iron reductase participating in the generation of the free
radical of ribonucleotide reductase. J Biol Chem 1987, 262 (25), 12325-31.
50. Gray, K. A.; Pogrebinsky, O. S.; Mrachko, G. T.; Xi, L.; Monticello, D. J.; Squires, C.
H., Molecular mechanisms of biocatalytic desulfurization of fossil fuels. Nat
Biotechnol 1996, 14 (13), 1705-9.
51. Niviere, V.; Vanoni, M. A.; Zanetti, G.; Fontecave, M., Reaction of the
NAD(P)H:flavin oxidoreductase from Escherichia coli with NADPH and riboflavin:
identification of intermediates. Biochemistry 1998, 37 (34), 11879-87.

64

52. Lipscomb, J. D.; Sligar, S. G.; Namtvedt, M. J.; Gunsalus, I. C., Autooxidation and
Hydroxylation Reactions of Oxygenated Cytochrome P-450cam. J Biol Chem 1976,
251 (4), 1116-1124.
53. Denisov, I. G.; Grinkova, Y. V.; Baas, B. J.; Sligar, S. G., The ferrous-dioxygen
intermediate in human cytochrome P450 3A4 - Substrate dependence of formation and
decay kinetics. J Biol Chem 2006, 281 (33), 23313-23318.
54. Peterson, J. A.; Ishimura, Y.; Griffin, B. W., Pseudomonas putida cytochrome P-450:
characterization of an oxygenated form of the hemoprotein. Arch Biochem Biophys
1972, 149 (1), 197-208.
55. Wise, C. E.; Makris, T. M., Recruitment and Regulation of the Non-ribosomal Peptide
Synthetase Modifying Cytochrome P450 Involved in Nikkomycin Biosynthesis. ACS
Chem Biol 2017, 12 (5), 1316-1326.
56. Sono, M.; Eble, K. S.; Dawson, J. H.; Hager, L. P., Preparation and properties of ferrous
chloroperoxidase complexes with dioxygen, nitric oxide, and an alkyl isocyanide.
Spectroscopic dissimilarities between the oxygenated forms of chloroperoxidase and
cytochrome P-450. J Biol Chem 1985, 260 (29), 15530-5.
57. Abu-Soud, H. M.; Gachhui, R.; Raushel, F. M.; Stuehr, D. J., The ferrous-dioxy
complex of neuronal nitric oxide synthase. Divergent effects of L-arginine and
tetrahydrobiopterin on its stability. J Biol Chem 1997, 272 (28), 17349-53.
58. Bec, N.; Gorren, A. C.; Voelker, C.; Mayer, B.; Lange, R., Reaction of neuronal nitricoxide synthase with oxygen at low temperature. Evidence for reductive activation of
the oxy-ferrous complex by tetrahydrobiopterin. J Biol Chem 1998, 273 (22), 13502-8.

65

59. Marchal, S.; Gorren, A. C.; Sorlie, M.; Andersson, K. K.; Mayer, B.; Lange, R.,
Evidence of two distinct oxygen complexes of reduced endothelial nitric oxide
synthase. J Biol Chem 2004, 279 (19), 19824-31.
60. Bui, S. H.; McLean, K. J.; Cheesman, M. R.; Bradley, J. M.; Rigby, S. E.; Levy, C. W.;
Leys, D.; Munro, A. W., Unusual spectroscopic and ligand binding properties of the
cytochrome P450-flavodoxin fusion enzyme XplA. J Biol Chem 2012, 287 (23),
19699-714.
61. Kashem, M. A.; Dunford, H. B., The formation and decay of the oxyferrous complex
of beef adrenocortical cytochrome P-450scc. Rapid-scan and stopped-flow studies.
Biochem Cell Biol 1987, 65 (5), 486-92.
62. Zhang, H.; Gruenke, L.; Arscott, D.; Shen, A.; Kasper, C.; Harris, D. L.; Glavanovich,
M.; Johnson, R.; Waskell, L., Determination of the rate of reduction of oxyferrous
cytochrome P450 2B4 by 5-deazariboflavin adenine dinucleotide T491V cytochrome
P450 reductase. Biochemistry 2003, 42 (40), 11594-603.
63. Brewer, C. B.; Peterson, J. A., Single turnover kinetics of the reaction between
oxycytochrome P-450cam and reduced putidaredoxin. J Biol Chem 1988, 263 (2), 7918.
64. Bielski, B. H. J.; Allen, A. O., Mechanism of Disproportionation of Superoxide
Radicals. J Phys Chem A 1977, 81 (11), 1048-1050.
65. Denisov, I. G.; Makris, T. M.; Sligar, S. G.; Schlichting, I., Structure and chemistry of
cytochrome P450. Chem Rev 2005, 105 (6), 2253-77.
66. Poulos, T. L.; Madrona, Y., Oxygen activation and redox partner binding in
cytochromes P450. Biotechnol Appl Biochem 2013, 60 (1), 128-33.

66

67. Davydov, R.; Hoffman, B. M., Active intermediates in heme monooxygenase reactions
as revealed by cryoreduction/annealing, EPR/ENDOR studies. Arch Biochem Biophys
2011, 507 (1), 36-43.
68. Davydov, R.; Macdonald, I. D. G.; Makris, T. M.; Sligar, S. G.; Hoffman, B. M., EPR
and ENDOR of catalytic intermediates in cryoreduced native and mutant oxycytochromes P450cam: Mutation-induced changes in the proton delivery system. J Am
Chem Soc 1999, 121 (45), 10654-10655.
69. Davydov, R.; Makris, T. M.; Kofman, V.; Werst, D. E.; Sligar, S. G.; Hoffman, B. M.,
Hydroxylation of camphor by reduced oxy-cytochrome P450cam: mechanistic
implications of EPR and ENDOR studies of catalytic intermediates in native and
mutant enzymes. J Am Chem Soc 2001, 123 (7), 1403-15.
70. Denisov, I. G.; Makris, T. M.; Sligar, S. G., Cryotrapped reaction intermediates of
cytochrome p450 studied by radiolytic reduction with phosphorus-32. J Biol Chem
2001, 276 (15), 11648-52.
71. Makris, T. M.; von Koenig, K.; Schlichting, I.; Sligar, S. G., Alteration of P450 distal
pocket solvent leads to impaired proton delivery and changes in heme geometry.
Biochemistry 2007, 46 (49), 14129-40.
72. Denisov, I. G.; Hung, S. C.; Weiss, K. E.; McLean, M. A.; Shiro, Y.; Park, S. Y.;
Champion, P. M.; Sligar, S. G., Characterization of the oxygenated intermediate of the
thermophilic cytochrome P450 CYP119. J Inorg Biochem 2001, 87 (4), 215-26.
73. Denisov, I. G.; Makris, T. M.; Sligar, S. G., Formation and decay of hydroperoxo-ferric
heme complex in horseradish peroxidase studied by cryoradiolysis. J Biol Chem 2002,
277 (45), 42706-10.

67

74. Roome, P. W.; Peterson, J. A., The Reduction of Putidaredoxin Reductase by Reduced
Pyridine-Nucleotides. Arch Biochem Biophys 1988, 266 (1), 32-40.
75. Matsunaga, I.; Yamada, M.; Kusunose, E.; Nishiuchi, Y.; Yano, I.; Ichihara, K., Direct
involvement of hydrogen peroxide in bacterial alpha-hydroxylation of fatty acid. FEBS
Lett 1996, 386 (2-3), 252-4.
76. Lelyveld, V. S.; Brustad, E.; Arnold, F. H.; Jasanoff, A., Metal-Substituted Protein MRI
Contrast Agents Engineered for Enhanced Relaxivity and Ligand Sensitivity. J Am
Chem Soc 2011, 133 (4), 649-651.
77. Sevrioukova, I. F.; Hazzard, J. T.; Tollin, G.; Poulos, T. L., Laser flash induced electron
transfer in P450cam monooxygenase: Putidaredoxin reductase-putidaredoxin
interaction. Biochemistry 2001, 40 (35), 10592-10600.
78. Sevrioukova, I. F.; Garcia, C.; Li, H. Y.; Bhaskar, B.; Poulos, T. L., Crystal structure
of putidaredoxin, the [2Fe-2S] component of the P450cam monooxygenase system
from Pseudomonas putida. J Mol Biol 2003, 333 (2), 377-392.
79. Yousafzai, F. K.; Eady, R. R., Dithionite reduction kinetics of the dissimilatory
coppercontaining nitrite reductase of Alcalegenes xylosoxidans - The SO2 radical
binds to the substrate binding type 2 copper site before the type 2 copper is reduced. J
Biol Chem 2002, 277 (37), 34067-34073.
80. Bergmeyer, H. U., Methods of Enzymatic Enalysis. Verlag Chemie: Weinheim, 1974.
81. Chapman, S. K.; Reid, G. A., Flavoprotein Protocols. Humana Press: Totowa, N.J.,
1999.

68

82. Haber, J.; Maslakiewicz, P.; Rodakiewicznowak, J.; Walde, P., Activity and
Spectroscopic

Properties

of

Bovine

Liver

Catalase

in

Sodium

Bis(2-

Ethylhexyl)Sulfosuccinate Isooctane Reverse Micelles. Eur J Biochem 1993, 217 (2),
567-573.

69

CHAPTER 3
Recruitment and Regulation of the Non-Ribosomal Peptide Synthetase
Modifying Cytochrome P450 Involved in Nikkomycin Biosynthesis1

1

Reprinted with Permission from: Wise, C. E. and Makris, T. M. Recruitment and
Regulation of the Non-ribosomal Peptide Synthetase Modifying Cytochrome P450
Involved in Nikkomycin Biosynthesis. ACS Chemical Biology 2017, 12 (5), 13161326. Copyright 2017 American Chemical Society.
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3.1 ABSTRACT
The beta-hydroxylation of ʟ-histidine is the first step in the biosynthesis of the
imidazolone base of the antifungal drug nikkomycin. The cytochrome P450 (NikQ)
hydroxylates the amino acid while it is appended via a phosphopantetheine linker to the
non-ribosomal peptide synthetase (NRPS) NikP1. The latter enzyme is comprised of an
MbtH, and single adenylation and thiolation domains, a minimal composition that allows
for detailed binding and kinetics studies using an intact and homogeneous NRPS substrate.
Electron paramagnetic resonance studies confirm that a stable complex is formed with
NikQ with NikP1 when the amino acid is tethered. Size exclusion chromatography is used
to further refine the principal components that are required for this interaction. NikQ binds
NikP1 in the fully charged state, but binding also occurs when NikP1 is lacking both the
phosphopantetheine arm and appended amino acid. This demonstrates that the interaction
is mainly guided by presentation of the thiolation domain interface, rather than the attached
amino acid. Electrochemistry and transient kinetics have been used to probe the influence
of ʟ-His-NikP1 binding on catalysis by NikQ. Unlike many P450s, the binding of substrate
fails to induce significant changes on the redox potential and autoxidation properties of
NikQ, and slows down the binding of dioxygen to the ferrous enzyme to initiate catalysis.
Collectively, these studies demonstrate a complex interplay between the NRPS maturation
process and the recruitment and regulation of an auxiliary tailoring enzyme required for
natural product biosynthesis.
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3.2 INTRODUCTION
Nonribosomal peptides (NRPs) often contain amino acids with moieties that are not
found in translationally-synthesized proteins. This expanded chemical diversity can impart
potent and medicinally-important biological activities that include functions as antibiotics,
siderophores, anti-cancer therapeutics, and immunosuppressants, among others.1-3
Construction of these intricate chemical architectures is accomplished by the tandem role
of non-ribosomal peptide synthetases (NRPS) and in some cases, accessory tailoring
enzymes that interact with the NRPS at various stages of peptide assembly. The NRPS
machinery, highly variable in terms of complexity and domain composition, is principally
comprised of repeating modules that include a domain for amino acid adenylation (A), a
thiolation (T) domain (also referred to as a peptidyl carrier protein, or PCP) which serves
as a scaffold for the growing peptide, and a condensation domain (C) which catalyzes
amide bond formation between adjacent modules.2, 4 The thiolation domain can then exist
in three distinct post-translationally modified states during antibiotic assembly: an
unmodified apo form, one in which a conserved serine on the T-domain is
phosphopantetheinylated (termed holo), or an aminoacylated (aa) form in which an amino
acid or peptide is appended to the phosphopantetheine (ppant).2 Non-proteinogenic amino
acids are incorporated into the growing peptide as a result of their biosynthesis and
subsequent activation by the A domain, modifications in cis by specialized NRPS modules,
or in trans by accessory enzymes that are distinct from the NRPS machinery. In this latter
approach, an amino acid is tailored during the chain elongation process while it is appended
to the T-domain via a thioester linkage to a phosphopantetheine arm.5-6
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The principle molecular determinants which govern tailoring enzyme specificity
have yet to be fully clarified despite a central importance in the biosynthesis pathways of
many bacterial virulence factors and clinically deployed pharmaceuticals. Elucidating the
basis for NRPS interactions with trans-acting proteins may prove invaluable for
engineering catalysts to act on non-native substrates and allow for the targeted production
of new natural products with enhanced pharmacological properties or the synthesis of
diverse libraries of compounds. For example, the demonstrated highly selective nature of
some tailoring enzymes, combined with the modular nature of the NRPS assembly process,
enables a specific amino acid, and even a single C-H bond in a very complex polypeptide,
to be selectively modified. Though highly sought-after, this feat is extraordinarily difficult
to achieve through late stage functionalization strategies after the peptide is assembled.
One major limitation for understanding the basis of NRPS:tailoring enzyme
interactions stems from challenges with obtaining these complex substrates in suitably
large quantities and in a homogeneous form. For instance, NRPS-linked substrates can
sometimes consist of a complex polypeptide appended to an extremely large synthetase
composed of several modules. A particularly relevant example includes the extensive and
well-ordered P450-catalyzed oxidative cross coupling reactions involved in the maturation
of glycopeptide (GPA) antibiotics such as vancomycin.7-9 To circumvent some of the
limitations in working with these complex substrates, one common approach for
interrogating the binding of accessory enzymes with NRPS-linked substrates has been the
excision of a single module, often as the minimal ~10 kDa T-domain. This strategy has
been utilized for the reconstitution of activity of many newly-discovered NRPS-modifying
enzymes,9-13 and in some cases, has permitted more detailed binding and structural
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studies13-15 to gauge the individual contributions of T-domain surface, ppant arm, and
tethered amino acid on molecular recognition. Studies using isolated peptidyl carrier
proteins, as native stand-alone proteins or excised from larger NRPS modules, have
collectively that both the NRPS-tailoring enzyme interface and identity of the tethered
amino acid can guide these interactions and be used to trigger catalysis.13, 15-16
The omission of additional NRPS subunits may undervalue potential contributions
of neighboring domains or linker regions on the molecular recognition of auxiliary
proteins. For the GPA antibiotics, elegant studies by the Cryle laboratory have shown that
a specialized module, known as the X-domain, mediates the correct recruitment and
ensuing catalysis of enzymes involved in peptide crosslinking.17-19 However, this module
is highly-specific to GPAs and is not present in many NRP biosynthetic pathways that
contain tailoring enzymes. An additional layer of complexity arises from the extraordinary
conformational flexibility of the NRPS in different charged states. Structural studies of
individual A and T domains,20-23 complexes obtained from mechanism-based inhibitors,2425

and recent comparative x-ray crystal structures of AT modules,26-27 have illustrated that

the NRPS is highly dynamic and can adopt several different architectures during peptide
assembly. It is not known whether these substantial structural changes influence the
presentation of aminoacyl substrates, or the T domain surface, and gate the binding of
enzymes for efficient tailoring to occur.
In order to examine how the NRPS coordinates the binding of auxiliary proteins,
we sought a relatively simple NRPS and cognate tailoring enzyme pair that would allow
for finite control of the NRPS post-translational state and enable detailed spectroscopic and
kinetic studies. A system meeting these criteria is provided within the nikkomycin
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biosynthetic gene cluster of Streptomyces tendae that produces a first-in-class antifungal
drug that inhibits cell wall synthesis.10 The pathway consists of a relatively simple ~70 kDa
NRPS (NikP1) that is composed of a single AT module flanked by an N-terminal MbtHlike domain thought to be important for efficient adenylation and for ensuring NRPS
folding and solubility in vitro.28-31 Following the activation and tethering of ʟ-histidine, a
cytochrome P450 (NikQ) hydroxylates the T-appended amino acid at the beta-position.10
The regio-specific Cβ-hydroxylation of T-domain-linked amino acids is a common
modification found in many natural product biosynthetic pathways and is catalyzed by
several classes of iron-containing enzymes including several cytochrome P450s, the nonheme carboxylate-bridged dinuclear iron enzyme CmlA involved in chloramphenicol
biosynthesis,32-33 and a number of Fe2+ and α-ketoglutarate-dependent enzymes (e.g. KtzP
from the kutzneride pathway).12, 34-35 In nikkomycin biosynthesis, following hydroxylation
by NikQ, a thioesterase (NikP2) releases β-hydroxyhistidine from the NikP1, shown in
Figure 3.1.10 Downstream processing results in the formation of an imidazolone base that
can have diverse pharmacological properties.
We have examined the interaction of NikQ with NikP1 at different stages of the
NRPS maturation process. Unlike many P450s that undergo a spin-state conversion upon
substrate binding, aminoacylated ʟ-His-NikP1 fails to induce appreciable changes to the
optical absorption spectrum of NikQ. However, changes in the electron paramagnetic
resonance (EPR) spectrum of NikQ upon substrate binding reveal that a stable complex is
formed. Analytical size exclusion chromatography (SEC) studies have been used to further
probe the nature of the protein interface and identify the NRPS elements that are necessary
for efficient binding to occur. Finally, we have examined the influence of the binding of
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the ʟ-His-NikP1 substrate on the dioxygen activation strategy of NikQ using
spectroelectrochemistry and transient kinetics. Aminoacylated-NikP1 exerts little effect on
the low reduction potential of NikQ, but restricts the binding of dioxygen to the heme-iron.
In sum, these results reveal a complex linkage of NRPS structural changes for the
recruitment and regulation of P450 tailoring enzymes.

Figure 3.1. The biosynthesis of nikkomycin by Streptomyces tendae. The
cytochrome P450 NikQ hydroxylates a histidine at the Cβ position while it is
appended to the non-ribosomal peptide synthetase (NRPS) NikP1 as a
phosphopantetheine-linked thioester. NikP1 is composed of an MbtH (not shown),
and single adenylation (A) and thiolation (T) domains. Release by the thioesterase
NikP2, followed by downstream processing, results in production of an
imidazolone base that is integrated into nikkomycin X.
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3.3 RESULTS AND DISCUSSION
3.3.1 Fine Control of the NikP1 Post-Translational Modification State
The ability to precisely control the NRPS post-translational state is imperative for
calibrated binding studies. Nearly quantitative phosphopantheinylation and aminoacylation
reactions were verified by quadrupole time-of-flight mass spectrometry (QTOF-MS) of
NikP1. Figure 3.2 shows the deconvoluted mass spectra of NikP1 obtained for the apo
form, upon co-expression of the NRPS with the phosphopantetheine (ppant) transferase
Sfp and following incubation with ATP and ʟ-histidine to initiate successive adenylation
and thiolation reactions. The spectra of each preparation show two dominant forms that are
separated by m/z = 131 – 134, most likely owing to incomplete excision of the N-terminal
methionine during expression. The MS of heterologously expressed and purified NikP1
(Figure 3.2, trace a) displays a main peak at 74,024 ± 4 Da, in close agreement with the
expected mass of the apo form lacking the methionine (74,028 Da). Upon co-expression
with Sfp (Figure 3.2, trace b), both forms convert to a species with a mass that is 342 Da
higher, with a main peak at 74366 ± 5 Da, consistent with addition of the ppant arm (m/z
= 341 Da) and full conversion to the holo form. Following prolonged incubation with ATP
and ʟ-histidine (trace c), the spectrum shifts by 135 Da to 74,501 ± 4 Da, demonstrating
quantitative attachment of ʟ-histidine to the phosphopantetheine arm as a thioester (m/z =
139 Da). Thus, all of the relevant forms of NikP1 (apo, holo, and ʟ-His-loaded) can be
generated in a highly homogeneous manner.
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Figure 3.2. Deconvoluted quadrupole time of flight mass
spectra of purified NikP1 in different posttranslationally modified states. MS was performed on the
(a) as isolated apo-form, (b) upon co-expression with the
phosphopantetheine transferase Sfp, and (c) after the
addition of ʟ-histidine and ATP to produce ʟ-His-NikP1.

3.3.2 Optical and EPR Characterization of NikQ
NikQ was cloned and heterologously expressed in E. coli as previously reported10
and purified through a two-step chromatographic procedure, outlined in the Methods. The
enzyme was characterized by optical spectroscopy in the ferric, ferrous, and ferrouscarbonmonoxy bound states (Figure 3.3). NikQ exhibits absorption characteristics that are
similar to many other P450 cytochromes. The purified enzyme displays a Soret maximum
at 419 nm and Q-bands at 536 and 567 nm, indicative of a ferric low-spin (LS) water bound
enzyme. Upon reduction with dithionite, the Soret and Q-bands shift to 410 and 536 nm
respectively. Retention of the axial thiolate ligand was demonstrated after exposure of the
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ferrous form to carbon monoxide and produced the characteristic 446 nm Soret maximum
that defines the enzyme class. Only a small fraction (≤ 20 % of total enzyme) was found to
be in the inactive P420 state (λmax~ 422 nm), which progressively forms in the time frame
required to reduce the protein, expose to CO, and collect a spectrum.

Figure 3.3. Optical absorption spectrum of
NikQ in the ferric (purple), ferrous (blue),
and ferrous carbonmonoxy-bound states. The
inset shows the expanded region from 500 to
600 nm.
Many P450s, including some NRPS-modifying enzymes,8-9, 13, 17, 36 undergo some
degree of Type I spectral changes upon substrate binding that results from a displacement
of the axial-bound water. This ligation change can produce a low- to high-spin (HS) state
conversion, and accompanying shift in the Soret maximum from 418 nm to around 392
nm. The addition of a 10 fold molar excess of ʟ-His-NikP1 did not result in any appreciable
alteration in the optical spectrum of NikQ (Figure 3.4). The absence of absorption changes
could be attributed to lack of stable complex formation, a large dissociation constant (KD)
between NikQ and ʟ-His-NikP1, or an optically silent binding event. These possibilities
are addressed below.
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Figure 3.4. NikQ does not undergo an
optical change upon addition of substrate.
Absorption spectrum of ferric NikQ alone
(blue), and in the presence of 10 molar
equivalents of L-His-NikP1 (red).
The binding of NikP1 to NikQ was also probed by electron paramagnetic resonance
(EPR) spectroscopy (Figure 3.5). The spectrum of NikQ is highly homogeneous and
exhibits a single set of g-values at 2.44, 2.25, and 1.91, features that are consistent with a
LS thiolate ligated heme with an axial-bound water and in good agreement with the optical
data (Figure 3.5, trace A). Upon addition of 5 molar equivalents of NikP1 in the holo-form
lacking an appended amino acid, the signal was unchanged (Figure 3.5, trace B). However,
introduction of a similar amount ʟ-His-NikP1 to NikQ resulted in a decrease of the signal
at gz = 2.44 which is accompanied by the appearance of two new features at gz = 2.47 and
2.41 and a new gx signal at 1.92 (Figure 3.5, trace C). These new spectral forms of NikQ
were not observed when free ʟ-histidine was added to NikQ at a similar stoichiometry
(Figure 3.5, trace D), congruent with previous studies that have concluded that the free
amino acid is not a competent substrate.10 This implies that NikP1, the ppant arm, and the
amino acid are all required to bind to NikQ, or in the very least, are necessary to elicit the
observed electronic changes at the heme-iron.
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Figure 3.5. EPR of NikQ in the absence or
presence of substrate, the holo-NRPS, or
ʟ-histidine. 8K X-band EPR of 100 μM
NikQ (A) in the substrate free form, or with
addition of 5 molar equivalents of (B) holoNikP1, (C) ʟ-His-NikP1, or (D) free ʟhistidine. The principle g-values of all major
species are indicated.
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Both new sets of g-values observed with ʟ-His-NikP1 binding are consistent with
the introduction of a tethered ʟ-histidine substrate into the active site of NikQ and in close
proximity to the heme iron. Based on similarity to EPR of P450s bound to nitrogen donors
(e.g. azole),37-39 we assign the less populated gz = 2.47 state as most likely arising from
direct coordination of the tethered histidine. The origin of the major gz = 2.41 species is
more difficult to interpret, but may signal an alteration in the strength of the axial water
upon introduction of a hydrogen bond acceptor to the pocket. This binding
conFigureuration may not be anticipated to produce significant changes to the absorption
spectrum of NikQ at room temperature.37 The spectral perturbations that occur upon ʟ-HisNikP1 binding were used as a probe to determine the affinity of NikQ to its cognate
aminoacylated NRPS. ʟ-His-NikP1 was added at several different concentrations to 100
µM NikQ and EPR spectra were collected. Following baseline subtraction of the spectra,
the gz signals were fit to a series of Gaussians, and the resulting areas were used to
determine the fraction of NikQ bound to ʟ-His-NikP1. Representative spectra of the
expanded gz region and the fits at several NRPS concentrations are shown in the inset of
Figure 3.6. Both of the EPR species specific to binding grow with increasing concentrations
of ʟ-His-NikP1 and appear to saturate at molar ratios of NRPS:P450 above 3:1 (300 µM ʟHis-NikP1 and 100 µM NikQ). When plotted as a function of ʟ-His-NikP1 and fit to a
Morrison quadratic equation, necessary due to the large concentration of NikQ required for
EPR titrations, a dissociation constant of 22 ± 5 µM was obtained. The dissociation
constant measured for ʟ-His-NikP1 and NikQ by EPR falls within the considerably large
range of values measured for P450 Cβ amino acid hydroxylases obtained from other
methods (Table 3.1).
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Figure 3.6. X-band EPR of NikQ with varying
concentrations of ʟ-His-NikP1. The fraction bound was
calculated by a ratio of the forms corresponding to substratebound NikQ (gz = 2.47, 2.41) over the total area and a
dissociation constant was determined by fitting to the
Morrison equation. Inset: Expanded gz region after baseline
subtraction and Gaussian fits to three individual species with
gz values of 2.47, 2.44, and 2.41 respectively. The resulting
fit is indicated in red. The molar ratios of NikQ to ʟ-HisNikP1 are noted for each titration point and the NikQ
concentration was 100 µM.

Table 3.1 Binding Parameters of NRPS-amino acid Cβ hydroxylases
P450

NRPS
composition

Amino Acid

KD (μM)

NikQ

AT

ʟ-His

22

Method

Reference

EPR

This study

UV/Vis,
Sedimentation
Velocity

13a, 15b

a

a

b

b

P450Sky

T

L-(O-Me)-Tyr

89 - 93

P450Sky

T

L-Phe

187

UV/Vis

13

OxyD

T

L-Tyr

14

UV/Vis

8
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3.3.3 Multiple forms of NikP1 bind to NikQ
The absence of EPR signal changes with holo-NikP1 could be due to a lack of stable
complex formation or from the inability of the bare ppant arm to extend far enough into
the NikQ active-site to induce electronic changes at the heme-iron. In order to correlate the
EPR spectral perturbations to a macromolecular binding event, size exclusion
chromatography (SEC) was employed to identify the minimal requirements necessary for
stable complex formation. Crystallographic studies of an NRPS-modifying P450 βhydroxylase (P450sky) ligated to an excised T-domain containing an unnatural azolecontaining ppant analog have suggested that the interface may be largely dominated by
hydrophobic interactions between the two proteins.14 Each form of NikP1 was added to
NikQ and analyzed by SEC under both low (150 mM) and high (500 mM) ionic strength
conditions to examine the nature of the interaction and assess the importance of
electrostatics for binding (Figures 3.7 and 3.8 respectively). The elution pattern was
monitored for total protein at 280 nm and by SDS-PAGE, and analysis of heme-containing
fractions at 417 nm. In the absence of NikP1, NikQ (46 kDa) elutes off an S200 column
with a retention volume of approximately 24 mL, consistent with an assignment as a
monomer (Figure 3.9). NikP1 similarly elutes as a monomer at ~16 mL (Figure 3.8). The
addition of a ten-fold molar excess of ʟ-His-NikP1 results in nearly complete (>95%)
disappearance of the peak corresponding to unbound NikQ and is replaced by a new peak
with a significantly lower retention volume (~13.5 mL), evident in both the 280 nm and
417 nm traces (Figure 3.8 A, B). SDS-PAGE of individual elution fractions shows that
both NikQ and NikP1 are present in this higher molecular weight form, consistent with
formation of a stable complex (Figure 3.8 C). Under lower ionic strength conditions, the
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peak corresponding to the ternary complex at 13.5 mL still forms, albeit to a lesser (~ 80
%) degree (Figure 3.7). The efficiency and partial enhancement for hetero-oligomer
formation with high salt suggests that hydrophobic interactions are likely to be the most
important for stabilizing the NRPS-P450 interface. A comparison of the absorption spectra
of free NikQ and the enriched NikQ:ʟ-His-NikP1 complex purified by SEC showed only
very small changes in the Soret region (Figure 3.10).

Figure 3.7. SEC reveals stable complex formation between NikQ and
ʟ-His-NikP1. Size exclusion chromatography (SEC) of free NikQ, or NikQ
with the addition of different forms of NikP1 at a stoichiometry of 1:10
(NikQ:NikP1) in 25 mM HEPES pH 7.5, 150 mM NaCl. Chromatograms
are from (A) online monitoring at 280nm or through (B) analysis of heme
containing fractions at 419 nm.

The prerequisites for binding to NikQ were further probed using the holo- and apoforms of NikP1 at the same fixed NRPS:P450 ratio of 10:1. The 419 nm chromatograms
of NikQ incubated with holo-NikP1 were identical to those of free NikQ alone, with one
elution peak at 24 mL, and SDS PAGE on individual fractions verified that no P450 was
apparent in earlier fractions that would correspond to those of a complex. This would seem
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to insinuate that the presence of the appended amino acid is critical for binding to occur.
As a result, chromatograms obtained by mixing apo- form with NikQ were surprising as
they revealed the formation (~ 60 %) of a new higher molecular weight complex that eluted
significantly earlier than free NikQ. This new peak is differentiable in its retention volume
(15.5 mL) from the ʟ-His-NikP1:NikQ complex and free NikQ. As with the aminoacylated
form, the apo-NikP1:NikQ complex still forms, but less efficiently in lower ionic strength.

Figure 3.8: NikQ:ʟ-His-NikP1 complex-formation exhibits an ionic strength
dependence. Size exclusion chromatography (SEC) of free NikQ, or NikQ with the
addition of different forms of NikP1 at a stoichiometry of 1:10 (NikQ:NikP1) in 25 mM
HEPES pH 7.5, 500 mM NaCl. Chromatograms are from (A) online monitoring at a
wavelength of 280 nm or through (B) analysis of heme containing fractions at 419 nm. (C)
SDS PAGE of elution fractions.
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Figure 3.9. Size exclusion chromatography of
NikQ, NikP1, and NikP1:NikQ complexes. The
elution volume (Ve), normalized to the void volume
(Vo) is plotted for NikQ and a series of calibrated
molecular weight standards.
The calculated
molecular weight of the NikQ and NikP1 fall within
the predicted range expected for a monomer. The
apparent and calculated molecular weights follow:
NikQ (43.7 kDa measured, 46.6 kDa calculated),
NikP1 (80.7 kDa measured, 74.2 kDa calculated,
NikQ:L-His-NikP1 (103.1 kDa measured, 121.2 kDa
calculated), NikQ:apoNikP1 (87.6 kDa measured,
120.8 kDa calculated).

The SEC studies reveal an unusual pattern for the association of NikP1 and NikQ,
which does not appear to scale with progressive modifications at the T-domain. In
comparison, the broad-specificity Cβ hydroxylase involved in skyllamycin biosynthesis
(P450sky)13 fails to bind to apo- or holo- T-domain forms,15 suggesting that the NRPS cargo
may help to establish interactions in that system. Given that different types of complexes
seem to form with apo- and ʟ-His-NikP1, reflecting slight differences in hydrodynamic
radii, we probed the binding site location of NikQ with apo-NikP1. Provided that NikQ
binds apo-NikP1 with similar contacts near the site of ppant attachment, rather than a distal
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site (e.g. at the A or MbtH domains), the presence of NikQ should occlude
phosphopantetheinyl transfer to NikP1.

Figure 3.10. Absorbance spectra of SEC-eluted
NikQ:ʟ-His-NikP1 complex, versus free NikQ.
Optical absorption spectrum of enriched NikQ:ʟHis-NikP1 (red) and free NikQ (black). Fractions of
the co-complex, partially purified by size exclusion
chromatography, were compared to the free enzyme.
The Soret band is normalizes to facilitate
comparison. A difference spectrum is shown in the
inset, and shows minimal absorption differences.

The efficiency of ppant transfer to apo-NikP1 by the general-utility transferase
(Sfp) was probed at various time points using a Bodipy-CoA analog, allowing for direct
visualization of its addition by fluorescence. The SDS-PAGE gel, stained by coomassie or
imaged at a wavelength near the excitation maximum of Bodipy, is shown in Figure 3.11.
In the absence of NikQ, efficient ppant transfer proceeded rapidly and reached completion
within 10 minutes. In comparison, when a five-fold molar excess of NikQ was included in
the reaction mixture, the extent of ppant transfer progressed much more slowly and was
incomplete by 20 minutes. Taken together with the SEC data, the Bodipy-CoA assay

88

provides evidence that NikQ binds apo- and ʟ-His-NikP1 at very similar sites. Thus, the
surface composition of the protein interface, rather than the appended amino acid, is the
most important element for guiding molecular recognition by NikQ. In this context, the
inability of holo-NikP1 to bind to NikQ would seem to originate from an alternative
conformation of the NRPS that does not successfully expose the T-domain surface that is
used for binding. Using a mechanism-based inhibitor, Gulick and Aldrich have
structurally-characterized an AT didomain24 and full NRPS module26 in states that
approximate those used during thioester formation. If a similar architecture is adopted by
holo-NikP1, the surface of the T-domain required for NikQ binding would be occluded due
to extensive interactions with the A domain, which are also thought to be largely
hydrophobic.

Figure 3.11. Bodipy-CoA binding to apo-NikP1 is impaired in the
presence of NikQ. SDS PAGE of phosphopantetheinylation reactions of 20
µM apo-NikP1 in the absence (-) or presence (+) of 100 µM NikQ using a
Bodipy-coenzyme A analog. Reactions were quenched at the indicated time
points and visualized by (A) Coomassie staining or (B) excitation at 473 nm
to monitor the transfer of the Bodipy to the NRPS.
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3.3.4 Role of the ʟ-His-NikP1 on the Regulation of NikQ Dioxygen Activation
P450s are often finely regulated at several steps of catalysis by effectors that can
be broadly characterized as small molecules (e.g. substrates or inhibitors), or auxiliary
proteins (e.g. redox partners). In some ways, an NRPS-tethered substrate could resemble a
hybrid of both classes. In light of the lack of a spectroscopic change in NikQ upon binding
to ʟ-His-NikP1, we sought to examine whether this substrate exerted any effects on the
early catalytic steps of NikQ. To the best of our knowledge, the influence of NRPS binding
on individual steps of the oxygen activation process has not been probed for any P450 to
date. For many P450s, substrate binding is accompanied by an increase in heme midpoint
potential,40-41 which thermodynamically gates transfer of the first electron required by the
catalytic cycle. The midpoint potential of NikQ was measured in the presence and absence
of ʟ-His-NikP1 using a dye-mediator approach that is described in the Materials and
Methods. The resulting Nernst plots for both conditions are presented in Figure 3.12, and
representative spectra obtained from reductive titrations of substrate-free and -bound NikQ
are shown in the inset of Figure 3.12 and in Figure 3.13 respectively. In the substrate-free
form, NikQ exhibits a midpoint potential of -415 ± 40 mV. This value is lower than many,
but still within the range (-300 to -400 mV) observed for low-spin P450s (Table 3.2). The
Nernst plot of the substrate-bound form is superimposable with substrate-free NikQ, and
linear fitting results in an identical value within the experimental error (-414 ± 20 mV).
These results imply that the perturbations that are observed by EPR upon ʟ-His-NikP1
binding do not exert any appreciable changes on heme electronics. In the absence of any
additional changes that may occur upon redox partner binding, electron transfer appears to
be completely decoupled from substrate binding. Although the native redox partner for
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NikQ has yet to be identified, the redox potential values measured here are consistent with
previous turnover studies by Chen et al that utilized the low-potential spinach ferredoxin
(-420 mV)42 as a competent, albeit sluggish, surrogate redox donor.10

Figure
3.12.
Reduction
potential
measurements of NikQ. Nernst plots for the
reduction of free NikQ (open circles) and
NikQ bound to ʟ-His-NikP1 (open squares).
Inset: Reductive titration of free NikQ.

Figure 3.13. Representative spectra from
reduction potential measurement with
methyl viologen indicator dye. These were
obtained during reductive titration of the
NikQ:NikP1 co-complex.
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Table 3.2 Redox Potential, O2-binding (kon), and autoxidation rates (kautox) of NikQ
in comparison to other cytochromes P450
P450

Substrate

E° (mV)

kon
(M-1s-1)

kautox
(s-1)

References

NikQ

ʟ-His-NikP1

-415
-415

2.2 × 106
4.6 × 104

2.8
2.5

This study
This study

CYP3A4

bromocriptine

a

-

c

camphor

e

-

g

arachidonate

g

h

cholesterol

i

j

CYP101
CYP102
CYP11A1
CYP8A1

b

5 × 105
b
3.5 × 104

-220
a
-137

b

d

-303
7.7 × 105

g

44

h

0.032
†

5.8 × 105

5.9 × 105

12

41, d56
57, f58

0.11*

0.004
j
0.0003 †

k

-

e

g

-289

-412
i
-278

0.0001

3.0 × 106 *

g

-427

c

f

54
55

b

0.002

f

-170

a

20
b
0.12

i

59

60, j61
k
62
63

6

XplA
-268
6.6 × 10 *
2.25*
64
Unless otherwise noted, O2 on rates (kon) and autoxidation rates (kautox) were determined
at temperatures of 2 oC – 10 oC. *measured at 15 – 25 oC; †measured at -17 oC

Dioxygen binding in P450s, and the stability of the resulting oxy-complex, is also
finely tuned by the binding of either small molecule or protein effectors. NRPS-substrates
have been previously shown to trigger O2-activation in other types of tailoring enzymes,
such as the Fe2+ and α-ketoglutarate-dependent halogenase SyrB216 and the dinuclear iron
Cβ-hydroxylase CmlA.33,

43

To probe for these influences in NikQ, we measured the

oxygen binding and autoxidation rates by rapidly mixing the ferrous form of the enzyme
with O2 at 4 °C in stopped flow studies. Photodiode array (PDA) traces for the reactions of
substrate-free and bound NikQ with 200 μM O2 are shown in Figure 3.14 A and B. The
PDA spectra are essentially identical and reveal rapid formation of the NikQ-oxy complex
with a Soret maximum at 426 nm and Q-band at 556 nm. This is followed by the decay of
the oxy-complex over the course of 1 second to the low-spin ferric enzyme at 418 nm.
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Figure 3.14. Transient kinetic studies of the reaction of
ferrous (A) NikQ, and the (B) ferrous NikQ:ʟ-His-NikP1
complex with O2 at 4°C. Concentrations were ~2.5 μM
NikQ and 200 μM O2 after mixing. Photodiode array spectra
show the initial ferrous heme (black), formation of the oxyferrous intermediate (red), and decay to the ferric-aquo state
(blue). Inset: Timecourse for oxyferrous formation (k1) and
decay (k2) monitored at 443 nm, fit to a two summed
exponential expression with observed rates shown.
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The time courses for oxy- formation and decay at 443 nm, shown in the insets, are
more revealing. Fitting to a two-exponential expression revealed a relatively fast rate of
autoxidation (2.8 s-1) of NikQ compared to many P450s (Table 3.2). The rate constants for
autoxidation of the ʟ-His-NikP1:NikQ complex are largely unchanged (2.5 s-1),
demonstrating that the origin of fast decay in both cases most likely stems from the low
reduction potential44 of NikQ. However, the formation of the oxyferrous intermediate is
considerably altered upon ʟ-His-NikP1 binding. A plot of the observed rates versus O2
concentration yield linear plots (Figure 3.15). The bimolecular rate constants for formation
of the oxygenated complex, obtained from the slopes, are 2.2 x 106 M-1 s-1 and 4.6 x 104
M-1 s-1 for substrate-free and ʟ-His-NikP1 bound NikQ.

Figure 3.15. O2-dependence of NikQ oxyintermediate formation. Oxygen concentration
dependence of the observed rates for oxyferrous
NikQ formation in the absence (closed circles)
and presence (open circles) of ʟ-His-NikP1. The
slope of the plot yields the bimolecular rate
constant for O2 binding.
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3.4 CONCLUSIONS
The results described here indicate that the regulation of NikQ is gated by the NikP1
assembly process at several steps, revealed by use of an intact trimodular NRPS. Figure
3.16 summarizes our current understanding of the remarkable interplay between NikP1
post-translational modifications and tailoring by NikQ. NikQ binds to apo-NikP1 with an
estimated dissociation constant of ~ 50 µM based on the fraction bound that is observed
from SEC studies. Although slightly weaker than the interactions with the cognate ʟ-HisNikP1 substrate measured by EPR, this data suggests that correct exposure of the carrier
protein surface, rather than the appended amino acid, serves as the most important binding
determinant. Once the ppant arm is installed by an associated transferase, the NRPS may
adopt a new conformation which is directed towards the A domain for subsequent loading
of ʟ-histidine onto the T-domain. As a result, binding to NikQ cannot occur. Following
thiolation, the T-domain surface necessary for binding is again exposed, allowing for the
recruitment of NikQ. It is possible that other modules of the NRPS may also facilitate the
binding process. Intriguingly, the lyngbyatoxin biosynthetic gene cluster contains an
unusual P450 that contains an N-terminal MbtH domain, but can oxidize free dipeptides
and exhibits a more relaxed substrate specificity than NikQ.45-46 For nikkomycin, the
coupling of macromolecular recognition to NRPS maturation may serve to reinforce
directionality in the biosynthetic process. Tailoring enzyme binding is largely thwarted
until the NRPS is primed with an amino acid.
The regulation of NikQ by NikP1 is highly atypical for P450s and much different
than other classes of tailoring enzymes such as CmlA and SyrB2. The redox potential and
autoxidation rate of NikQ are largely unregulated, and even dysregulated in the case of
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dioxygen binding, from a substrate binding event. At first glance, this would appear to
uncouple an important biosynthetic process and possibly lead to the production of reactive
oxygen species. The most straightforward explanation is that the low redox potential of
NikQ ensures that first electron transfer is thermodynamically unfavorable and ratelimiting with respect to O2 binding and subsequent catalytic steps. It is possible that free
NikQ is limited by the rapid adenylation of ʟ-histidine by NikP1, or possibly, through a
regulation of steps after installation of the OH at the Cβ position. A slow release of the
product from NikQ, coupled to sluggish hydrolysis by the thioesterase NikP210 could
possibly serve this role.

Figure 3.16. Proposed summary of the interplay of NikP1 maturation, the
recruitment of NikQ, and the regulation of early catalytic steps by ʟ-His-NikP1. The
MbtH domain of NikP1 is omitted for clarity. The KD value describing the interaction
between NikQ and apo-NikP1 was approximated from the level of complex formation
observed during SEC experiments. The KD value for ʟ-His-NikP1 was determined by EPR.
Redox potentials and O2 binding and autoxidation rates were determined by
spectroelectrochemistry and rapid mixing stopped flow studies respectively.
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3.5 MATERIALS AND METHODS
3.5.1 Reagents and Chemicals
The p283 plasmid was obtained from the DNASU plasmid repository. All
microbiology reagents, and adenosine 5’-triphosphate (ATP), chloramphenicol,
dithiothreitol (DTT), and kanamycin were purchased from Research Products
International. Ampicillin and lysozyme were purchased from bioWorld. δ-aminolevulinic
acid was from Carbosynth. ʟ-histidine, Neutral Red, Safranin T, sodium hydrosulfite, Tris(2-carboxyethyl)-phosphine hydrochloride (TCEP) were from Sigma Aldrich. Isopropylβ-ᴅ-Thiogalactopyranoside (IPTG) was from Gold Biotechnology. Vectors for
overproduction of the general utility phosphopantetheine transferase from Bacillus subtilis
(Sfp)47 and co-expression were provided by Prof. Courtney Aldrich.
3.5.2 Cloning, Heterologous Expression, and Purification
Genomic DNA was isolated from Streptomyces tendae Tü901 (ATCC) using a
Promega Wizard SV Genomic DNA Purification kit with the following modifications. The
cell pellet was resuspended in a mixture of 480 µL 50 mM EDTA and 120 µL 10 mg/mL
chicken lysozyme, incubated at 37 °C for 1 hour, then centrifuged and the supernatant
discarded. Polymerase chain reactions (PCR) were performed to amplify the nikQ and
nikP1 genes using the following primers with restriction sites underlined.
NikQF (NdeI) 5’-CCCAAACATATGAGAGTTGACCTGTTCGACCCGCTC-3’
NikQR (XhoI) 5’-CCCTATCTCGAGTCAGGCCCTCGGGACGAATTT-3’
NikP1F (NdeI) 5’-CCCGGGCATATGGTGAACCCGATTCATGACGACAAC-3’
NikP1R (XhoI) 5’-GGAATACTCGAGGCTCCGTCCGGCGCG-3’
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The nikQ insert was cloned into pET28b and the nikP1 insert into pET21b. In order to
ensure that the C-terminal hexahistidine tag on the NRPS had no influence on P450 binding
parameters, the nikP1 gene was also cloned into a p283 vector to introduce a tobacco etch
virus (TEV) protease cleavable histidine tag, using the same forward primer and the
following reverse primer.
NikP1R2 (EcoRI) 5’-GAGATAGAATTCGCTCCGTCCGGCGCG-3’
No significant changes were noted in size exclusion chromatography studies. NikQ was
expressed using BL21(DE3) cells in 1 liter cultures of Luria Broth (LB) from Research
Products International (RPI), and supplemented with 50 µg/mL kanamycin (RPI), 25 µM
FeCl3, and 25 µM δ-aminolevulinic acid. Following inoculation with 10 mL of an overnight
starter culture, the cultures were grown to OD600 = 0.8 at 37 °C and 200 rpm, then incubated
for 74 hours at 15 °C and 150 rpm. Cells were harvested via centrifugation, then
resuspended in Ni-NTA equilibration buffer (50 mM potassium phosphate monobasic, 10
mM imidazole, 300 mM NaCl, pH 7.5), lysed by sonication and centrifuged at 16,000
RPM. The clarified lysate was loaded onto an Ni-NTA column equilibrated in the same
buffer. The column was washed with 10 column volumes of Ni-NTA wash buffer (50 mM
potassium phosphate monobasic, 25 mM imidazole, 300 mM NaCl, pH 7.5), and eluted in
the same buffer containing 200 mM imidazole. Red fractions were dialyzed overnight at 4
°C against 50 mM HEPES pH 7.5 with 5% glycerol. The dialyzed fractions were loaded
onto a DEAE column equilibrated with 50 mM HEPES pH 6.5, and eluted with a 500 mL
gradient of 50 mM HEPES pH 6.5 from 0 to 500 mM NaCl. The resulting protein was
~95% pure, based on SDS-PAGE analysis and by optical spectroscopy, with an R z
(A417/A280) = 1.70.
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NikP1 was expressed in BL21 (DE3) cells to yield the apo form, and co-expressed
with Sfp to produce the holo form. Similar expression conditions were used for the
heterologous expression of both constructs in LB media, with the exception of the
antibiotic used (100 µg/mL ampicillin for pET21b, and 50 µg/mL kanamycin for p283).
When co-expressed with Sfp, 30 µg/mL chloramphenicol was also included. Following
inoculation, cultures were grown at 37 °C to an OD600 = 0.9 - 1.2, 60 µM of IPTG was
added, and the temperature was decreased to 15 °C. Cells were harvested 16 hours after
induction via centrifugation and purified by Ni-NTA chromatography as described above
for NikQ. Following elution, protein-containing fractions were dialyzed against 75 mM
Tris, 10% glycerol, 1 mM dithiothreitol, pH 7.5. The resulting protein was >95% pure, as
determined by SDS-PAGE. The extinction coefficient of NikQ at 419 nm was determined
using the pyridine hemochromagen method (Ɛ419 nm = 110 mM-1 cm-1).48 An extinction
coefficient for NikP1 at 280 nm was estimated using a calculated extinction coefficient
from ExPASy ProtParam (Ɛ280 nm = 84 mM-1 cm-1).49
3.5.3 Aminoacylation of NikP1
Aminoacylation reactions of NikP1 were carried out at the following final
concentrations:

30

µM

Holo-NikP1,

3

mM

Tris-(2-Carboxyethyl)-Phosphine

Hydrochloride (TCEP), 750 µM ʟ-histidine, 3 mM Adenosine 5’-Triphosphate Disodium
Salt Hydrate, 10 mM MgCl2, and 75 mM Tris pH 7.5. Reactions were incubated at 4 °C
for 12-16 hours and desalted into 50 mM HEPES pH 7.5 buffer using PD-10 desalting
columns from GE Healthcare Life Sciences. Samples were then concentrated at 4 °C using
Amicon Ultra-15 30,000 kDa filters. Samples that were not used immediately were frozen
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in liquid nitrogen and stored at -70 °C. MS analysis showed no influence of desalting,
concentrating, or freeze-thawing on the post-translational state of the NikP1.
3.5.4 Mass Spectrometry
Apo-, holo-, and ʟ-histidine-loaded NikP1 samples were desalted into water using
a PD-10 desalting column, concentrated to 120 µM, flash frozen in liquid nitrogen, and
stored at -20 °C prior to mass spectrometric (MS) analysis. Prior to injection, samples were
thawed on ice, and diluted to 7.5 µM by adding 10 µL of the 120 µM protein to 150 µM
1:1 MeOH/H2O with 1% acetic acid. MS was performed at the Mass Spectrometry Center
at the University of South Carolina. ESI (+) spectra were obtained using a Waters
Quadrupole Time-of-Flight (QTOF) Micromass instrument and deconvoluted using
MaxEnt software.
3.5.5 Absorbance Spectrophotometry
An Agilent 8453 UV-vis instrument was used for all optical spectrophotometric
studies. Sodium hydrosulfite (dithionite) was prepared in a septum-sealed bottle at a
concentration of 10 mM by degassing the solid, followed by the addition of N2-purged 50
mM HEPES pH 7.5 using a gas-tight Hamilton syringe. The solution was subsequently
degassed for an additional 40 minutes to ensure complete anaerobicity. In a sealed cuvette,
1 mL of 6 µM NikQ in 50 mM HEPES pH 7.5 was purged on ice with CO gas for 20
minutes, and a low spin/oxidized spectrum was recorded. The protein was reduced via the
addition of dithionite solution, and a Fe2+-CO spectrum was collected. The experiment was
repeated using the same protein stock and preparation method, but purging the cuvette and
protein with N2 gas instead of CO, to obtain the ferrous P450 spectrum. In order to
investigate whether NikQ undergoes any spectral changes upon substrate binding, 10 µM
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NikQ was titrated with ʟ-His-NikP1 to concentrations of 100 µM, and the spectrum of free
NikQ compared to that of the enzyme in the presence of excess ʟ-His-NikP1. These spectra
were comparable, both in terms of Soret and Q-band maxima, to those obtained from
fractions containing the NikQ:ʟ-His-NikP1 complex in size exclusion chromatography
(SEC) studies.
3.5.6 Electron Paramagnetic Resonance (EPR)
ʟ-His-NikP1 was prepared as described above, and concentrations ranging from 0
to 500 µM were incubated with 100 µM NikQ in a total volume of 225 µL for 1 hour at 4
°C before transferring into EPR tubes and flash freezing in liquid nitrogen. Data was
collected at 8-9 K using a Bruker X-band EMXplus EPR with an Oxford Instruments
ESR900 X-band continuous flow liquid helium cryostat with 10 G modulation amplitude
and a microwave power of 2 mW. Data was baseline corrected using SpinCount and Origin
software using a spline function. The gz peak (2600 to 2900 Gauss) was fit to a single
Gaussian function for samples containing NikQ, NikQ + ʟ-histidine, and NikQ + holoNikP1, or the sum of three Gaussians for spectra of NikQ + ʟ-His-NikP1. For EPR data
from samples containing ʟ-His-NikP1 and NikQ, the sum of areas corresponding to spectral
signatures of the bound complex (gz = 2.47 and 2.41), were divided by the sum of the total
area (gz = 2.47, 2.44, and 2.41), and the fraction of NikQ perturbed was calculated for each
NikQ:ʟ-His:NikP1 ratio. The bound fraction was calculated and plotted as a function of ʟHis-NikP1 concentration. The dissociation constant (KD) was calculated from a Morrison
fit50 using the following equation, where fpert is the fraction perturbed, fpert,max is the spectral
perturbation at saturation, [ES] is the concentration of NikQ:ʟ-His-NikP1 complex, [Etot]
is total NikQ concentration, [Stot] is the total ʟ-His-NikP1 concentration, and the fraction
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bound is given by the ratio of [ES] to [Etot]. Non-linear fitting procedures indicated that fpert,Max
~ 0.52.
fpert
fpert,max

=

[ES]
( KD + [Etot ] + [Stot ]) - √(KD + [Etot ] + [Stot ]) 2 - (4 [Etot ] [Stot ])
=
[Etot ]
2 [Etot ]

3.5.7 Size Exclusion Chromatography (SEC)
SEC experiments were carried out using a HiPrep 16/60 Sephacryl S200 HR
column from GE Healthcare using an ÄKTA FPLC with a P-920 pump, Frac900 fraction
collector, and UPC900 monitor equipped with a 280 nm UV filter. A 25 mM HEPES pH
7.5 buffer containing either 500 or 150 mM NaCl was used to equilibrate the column. A
1.3 mL mixture of 10 µM NikQ, alone or in the presence of 100 µM apo-, holo-, or ʟ-HisNikP1, was incubated on ice for 1 hour, and loaded onto the column with a flow rate of 0.3
mL/minute over a 5 mL block column injection equipped with a 1.1 mL injection loop at
8 °C. The elution was carried out over a 120 mL at a flow rate of 0.4 mL/minute, and 0.5
mL fractions were collected and analyzed for absorbance at 419 nm on to determine the
quantity of NikQ in each fraction. The absorbance at 419 nm was plotted against the
retention volume corresponding to each fraction.
3.5.8 Reduction Potential Measurements
The

reduction

potential

of

free

and

bound

NikQ

was

determined

spectrophotometrically using a dye/mediator approach described previously.41 Methyl
viologen (E°= -446 mV) was chosen as a redox indicator dye following unsuccessful
attempts using safranin T (E°= -289 mV) or neutral red (E°= -325 mV) that suggested that
NikQ has a reduction potential significantly lower than these indicators. A 1 mL mixture
of 10 µM NikQ and 10 µM methyl viologen in 50 mM HEPES pH 7.5 was purged in N2
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gas in a septum-sealed cuvette on ice for 20 minutes. After taking an initial spectrum of
the starting degassed mixture, dithionite was titrated into the cuvette in 1 µL aliquots from
an anaerobic 5 mM stock solution. After each addition of dithionite, multiple spectra were
taken to ensure equilibrium was reached. This procedure was repeated until both the dye
and P450 were fully reduced. The absorbance increase at 395 nm upon reduction of methyl
viologen (Ɛ395nm = 42.1 mM-1cm-1)51 and decrease at 419 nm upon reduction of P450 (Ɛ419nm
= 110 mM-1cm-1) were used to monitor the reduction of dye and P450 respectively. Data
processing was analyzed using the Nernst equation in the manner previously described by
Wilson et al.52 The reduction potential of NikQ in the presence of 100 µM ʟ-His-NikP1
was measured in an identical fashion.
3.5.9 Stopped Flow Spectroscopy
An Applied Photophysics SX20 stopped flow equipped with an anaerobic
accessory was used for all rapid kinetics experiments. Degassed 50 mM HEPES pH 7.5
buffer and 10 mM sodium dithionite were prepared as described above. Stopped flow
syringes were rinsed with dithionite followed by anaerobic buffer to scrub the system of
O2. NikQ (5 µM) was degassed under N2 gas in a sealed bottle on ice stirring for 20 minutes.
The protein solution was reduced using a limited amount of sodium dithionite and
transferred to the stopped flow with a gas-tight Hamilton syringe. In the experiments
containing NRPS, samples were prepared as described for NikQ, but with 50 µM ʟ-HisNikP1 added. Oxygen-saturated buffers were prepared by bubbling 50 mM HEPES with
O2 gas on ice for at least 20 minutes. Desired O2 concentrations were prepared by mixing
O2-saturated buffer with N2-degassed buffer using a Hamilton syringe. Measurements were
collected at 4 °C using photodiode array (PDA) detection. Single wavelength time traces
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at 443 nm were extracted from the data, as this wavelength displayed the maximum
difference in absorption between ferrous (Fe2+), oxygen bound (Fe2+-O2) and autoxidized
ferric (Fe3+) low-spin forms. The 443 nm traces were fit to a two-summed exponential
expression using Applied Photophysics Pro-Data SX software according to Equation 1
below, where k1,obs is the observed formation rate of the oxy-intermediate, and k2 is the
autoxidation rate. Both are in units of s-1 under pseudo-first order conditions.
k1,obs

Fe2+ + O2 →

k2

Fe2+ -O2 → Fe3+ + O⋅2-

The bimolecular rate constant for O2 binding was determined by repeating the experiment
at several O2 concentrations under pseudo-first order conditions and plotting k1,obs (s-1) as
a function of O2. The slope yields the bimolecular rate constant (M-1 s-1) for dioxygen
binding, and the y-intercept (equal to zero) indicates that the formation of the oxy-ferrous
complex is essentially irreversible. When the autoxidation rate constant (k2), was plotted
as a function of O2, no appreciable dependence was observed, as expected due to the
irreversibility of this step.
3.5.10 Phosphopantetheinylation Assay
The boron-dipyrromethene (Bodipy) coenzyme A derivative was synthesized using
published procedures53 and stored at -20 °C until further use. Concentrations were
determined

using

an

extinction

coefficient

of

Ɛ504

nm

=

68

mM-1 cm-1.

Phosphopantetheinylation reactions (500 µL total volume) consisted of 40 µM BodipyCoA and 20 µM apo-NikP1 in a buffer containing 50 mM HEPES pH 8.1, 500 mM NaCl,
and 10 mM MgCl2. For reactions containing NikQ, the P450 was added to a final
concentration of 100 µM. Reactions were initiated by the addition of Sfp (100 nM) and 20
µL aliquots were quenched with 10 µL SDS-loading buffer at various time points and
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incubated at 85 °C for 5 minutes. Samples were run on a 12.5% SDS-PAGE gel and imaged
using a Typhoon FLA 7000 imager using an excitation wavelength of 473 nm, a 520 nm
filter, and a PMT detection of 650 V.

3.6 ACKNOWLEDGEMENTS
We thank M. Walla and W. Cotham at the USC Mass Spectrometry center for their
assistance in analyzing NRPS samples. We thank Prof. C. Aldrich for providing the
plasmids for Sfp co- and over-expression, and Prof. J. Sodetz for his assistance in the
analytical SEC measurements. This work was supported by National Science Foundation
CAREER grant 1555066 and an ASPIRE grant from the USC Vice President of Research
to T.M.M..

105

3.7 REFERENCES
1. Cane, D. E.; Walsh, C. T.; Khosla, C., Biochemistry - Harnessing the biosynthetic code:
Combinations, permutations, and mutations. Science 1998, 282 (5386), 63-68.
2. Fischbach, M. A.; Walsh, C. T., Assembly-line enzymology for polyketide and
nonribosomal peptide antibiotics: Logic, machinery, and mechanisms. Chem. Rev.
2006, 106 (8), 3468-3496.
3. Marahiel, M. A.; Stachelhaus, T.; Mootz, H. D., Modular Peptide Synthetases Involved
in Nonribosomal Peptide Synthesis. Chem. Rev. 1997, 97 (7), 2651-2674.
4. Finking, R.; Marahiel, M. A., Biosynthesis of nonribosomal peptides. Annu. Rev.
Microbiol. 2004, 58, 453-488.
5. Lin, S.; Huang, T.; Shen, B., Tailoring enzymes acting on carrier protein-tethered
substrates in natural product biosynthesis. Methods Enzymol. 2012, 516, 321-43.
6. Walsh, C. T.; Chen, H. W.; Keating, T. A.; Hubbard, B. K.; Losey, H. C.; Luo, L. S.;
Marshall, C. G.; Miller, D. A.; Patel, H. M., Tailoring enzymes that modify
nonribosomal peptides during and after chain elongation on NRPS assembly lines.
Curr. Opin. Chem. Biol. 2001, 5 (5), 525-534.
7. Bischoff, D.; Pelzer, S.; Bister, B.; Nicholson, G. J.; Stockert, S.; Schirle, M.;
Wohlleben, W.; Jung, G.; Sussmuth, R. D., The biosynthesis of vancomycin-type
glycopeptide antibiotics - The order of the cyclization steps. Angew. Chem. 2001, 40
(24), 4688-4691.
8. Cryle, M. J.; Meinhart, A.; Schlichting, I., Structural Characterization of OxyD, a
Cytochrome P450 Involved in beta-Hydroxytyrosine Formation in Vancomycin
Biosynthesis. J Biol Chem 2010, 285 (32), 24562-24574.

106

9. Woithe, K.; Geib, N.; Zerbe, K.; Li, D. B.; Heck, M.; Fournier-Rousset, S.; Meyer, O.;
Vitali, F.; Matoba, N.; Abou-Hadeed, K.; Robinson, J. A., Oxidative phenol coupling
reactions catalyzed by OxyB: A cytochrome p450 from the vancomycin producing
organism. Implications for vancomycin biosynthesis. J Am Chem Soc 2007, 129 (21),
6887-6895.
10. Chen, H.; Hubbard, B. K.; O'Connor, S. E.; Walsh, C. T., Formation of beta-hydroxy
histidine in the biosynthesis of nikkomycin antibiotics. Chemistry & biology 2002, 9
(1), 103-12.
11. Rivera, H.; Dhar, S.; La Clair, J. J.; Tsai, S. C.; Burkart, M. D., An unusual
intramolecular trans-amidation. Tetrahedron 2016, 72 (25), 3605-3608.
12. Singh, G. M.; Fortin, P. D.; Koglin, A.; Walsh, C. T., beta-Hydroxylation of the
Aspartyl Residue in the Phytotoxin Syringomycin E: Characterization of Two
Candidate Hydroxylases AspH and SyrP in Pseudomonas syringae. Biochemistry-Us
2008, 47 (43), 11310-11320.
13. Uhlmann, S.; Sussmuth, R. D.; Cryle, M. J., Cytochrome p450sky interacts directly
with the nonribosomal peptide synthetase to generate three amino acid precursors in
skyllamycin biosynthesis. ACS chemical biology 2013, 8 (11), 2586-96.
14. Haslinger, K.; Brieke, C.; Uhlmann, S.; Sieverling, L.; Sussmuth, R. D.; Cryle, M. J.,
The structure of a transient complex of a nonribosomal peptide synthetase and a
cytochrome P450 monooxygenase. Angewandte Chemie 2014, 53 (32), 8518-22.

107

15. Kokona, B.; Winesett, E. S.; von Krusenstiern, A. N.; Cryle, M. J.; Fairman, R.;
Charkoudian, L. K., Probing the selectivity of beta-hydroxylation reactions in nonribosomal peptide synthesis using analytical ultracentrifugation. Anal Biochem 2016,
495, 42-51.
16. Matthews, M. L.; Krest, C. M.; Barr, E. W.; Vaillancourt, F. H.; Walsh, C. T.; Green,
M. T.; Krebs, C.; Bollinger, J. M., Substrate-triggered formation and remarkable
stability of the C-H bond-cleaving chloroferryl intermediate in the aliphatic
halogenase, SyrB2. Biochemistry 2009, 48 (20), 4331-43.
17. Brieke, C.; Peschke, M.; Haslinger, K.; Cryle, M. J., Sequential In Vitro Cyclization
by Cytochrome P450 Enzymes of Glycopeptide Antibiotic Precursors Bearing the XDomain from Nonribosomal Peptide Biosynthesis. Angew. Chem. Int. Ed. Engl. 2015,
54 (52), 15715-15719.
18. Haslinger, K.; Peschke, M.; Brieke, C.; Maximowitsch, E.; Cryle, M. J., X-domain of
peptide synthetases recruits oxygenases crucial for glycopeptide biosynthesis. Nature
2015, 521 (7550), 105-U271.
19. Peschke, M.; Haslinger, K.; Brieke, C.; Reinstein, J.; Cryle, M. J., Regulation of the
P450 Oxygenation Cascade Involved in Glycopeptide Antibiotic Biosynthesis. J Am
Chem Soc 2016, 138 (21), 6746-6753.
20. Koglin, A.; Mofid, M. R.; Lohr, F.; Schafer, B.; Rogov, V. V.; Blum, M. M.; Mittag,
T.; Marahiel, M. A.; Bernhard, F.; Dotsch, V., Conformational switches modulate
protein interactions in peptide antibiotic synthetases. Science 2006, 312 (5771), 273276.

108

21. Reger, A. S.; Carney, J. M.; Gulick, A. M., Biochemical and crystallographic analysis
of substrate binding and conformational changes in Acetyl-CoA synthetase.
Biochemistry 2007, 46 (22), 6536-6546.
22. Reger, A. S.; Wu, R.; Dunaway-Mariano, D.; Gulick, A. M., Structural characterization
of a 140 degrees domain movement in the two-step reaction catalyzed by 4Chlorobenzoate : CoA ligase. Biochemistry 2008, 47 (31), 8016-8025.
23. Weber, T.; Baumgartner, R.; Renner, C.; Marahiel, M. A.; Holak, T. A., Solution
structure of PCP, a prototype for the peptidyl carrier domains of modular peptide
synthetases. Structure 2000, 8 (4), 407-418.
24. Mitchell, C. A.; Shi, C.; Aldrich, C. C.; Gulick, A. M., Structure of PA1221, a
Nonribosomal Peptide Synthetase Containing Adenylation and Peptidyl Carrier Protein
Domains. Biochemistry 2012, 51 (15), 3252-3263.
25. Sundlov, J. A.; Shi, C.; Wilson, D. J.; Aldrich, C. C.; Gulick, A. M., Structural and
Functional Investigation of the Intermolecular Interaction between NRPS Adenylation
and Carrier Protein Domains. Chem. Biol. 2012, 19 (2), 188-198.
26. Drake, E. J.; Miller, B. R.; Shi, C.; Tarrasch, J. T.; Sundlov, J. A.; Allen, C. L.;
Skiniotis, G.; Aldrich, C. C.; Gulick, A. M., Structures of two distinct conformations
of holo-non-ribosomal peptide synthetases. Nature 2016, 529 (7585), 235-238.
27. Tanovic, A.; Samel, S. A.; Essen, L. O.; Marahiel, M. A., Crystal structure of the
termination module of a nonribosomal peptide synthetase. Science 2008, 321 (5889),
659-663.

109

28. Drake, E. J.; Cao, J.; Qu, J.; Shah, M. B.; Straubinger, R. M.; Gulick, A. M., The 1.8 A
crystal structure of PA2412, an MbtH-like protein from the pyoverdine cluster of
Pseudomonas aeruginosa. J. Biol. Chem. 2007, 282 (28), 20425-20434.
29. Felnagle, E. A.; Barkei, J. J.; Park, H.; Podevels, A. M.; McMahon, M. D.; Drott, D.
W.; Thomas, M. G., MbtH-Like Proteins as Integral Components of Bacterial
Nonribosomal Peptide Synthetases. Biochemistry 2010, 49 (41), 8815-8817.
30. Herbst, D. A.; Boll, B.; Zocher, G.; Stehle, T.; Heide, L., Structural Basis of the
Interaction of MbtH-like Proteins, Putative Regulators of Nonribosomal Peptide
Biosynthesis, with Adenylating Enzymes. J. Biol. Chem. 2013, 288 (3), 1991-2003.
31. Zhang, W. J.; Ostash, B.; Walsh, C. T., Identification of the biosynthetic gene cluster
for the pacidamycin group of peptidyl nucleoside antibiotics. Proc. Natl. Acad. Sci.
USA 2010, 107 (39), 16828-16833.
32. Makris, T. M.; Knoot, C. J.; Wilmot, C. M.; Lipscomb, J. D., Structure of a Dinuclear
Iron Cluster-Containing beta-Hydroxylase Active in Antibiotic Biosynthesis.
Biochemistry 2013, 52 (38), 6662-6671.
33. Makris, T. M.; Chakrabarti, M.; Munck, E.; Lipscomb, J. D., A family of diiron
monooxygenases catalyzing amino acid beta-hydroxylation in antibiotic biosynthesis.
Proc. Natl. Acad. Sci. USA 2010, 107 (35), 15391-15396.
34. Neary, J. M.; Powell, A.; Gordon, L.; Milne, C.; Flett, F.; Wilkinson, B.; Smith, C. P.;
Micklefield, J., An asparagine oxygenase (AsnO) and a 3-hydroxyasparaginyl
phosphotransferase (HasP) are involved in the biosynthesis of calcium-dependent
lipopeptide antibiotics. Microbiology-Sgm 2007, 153, 768-776.

110

35. Strieker, M.; Nolan, E. M.; Walsh, C. T.; Marahiel, M. A., Stereospecific Synthesis of
threo- and erythro-beta-Hydroxyglutamic Acid During Kutzneride Biosynthesis. J. Am.
Chem. Soc. 2009, 131 (37), 13523-13530.
36. Cryle, M. J.; Staaden, J.; Schlichting, I., Structural characterization of CYP165D3, a
cytochrome P450 involved in phenolic coupling in teicoplanin biosynthesis. Arch.
Biochem. Biophys. 2011, 507 (1), 163-173.
37. Conner, K. P.; Cruce, A. A.; Krzyaniak, M. D.; Schimpf, A. M.; Frank, D. J.; Ortiz de
Montellano, P.; Atkins, W. M.; Bowman, M. K., Drug modulation of water-heme
interactions in low-spin P450 complexes of CYP2C9d and CYP125A1. Biochemistry
2015, 54 (5), 1198-207.
38. Conner, K. P.; Schimpf, A. M.; Cruce, A. A.; McLean, K. J.; Munro, A. W.; Frank, D.
J.; Krzyaniak, M. D.; de Montellano, P. O.; Bowman, M. K.; Atkins, W. M., Strength
of Axial Water Ligation in Substrate-Free Cytochrome P450s Is Isoform Dependent.
Biochemistry 2014, 53 (9), 1428-1434.
39. Conner, K. P.; Vennam, P.; Woods, C. M.; Krzyaniak, M. D.; Bowman, M. K.; Atkins,
W. M., 1,2,3-Triazole-Heme Interactions in Cytochrome P450: Functionally
Competent Triazole-Water-Heme Complexes. Biochemistry 2012, 51 (32), 6441-6457.
40. Batabyal, D.; Lewis-Ballester, A.; Yeh, S. R.; Poulos, T. L., A Comparative Analysis
of the Effector Role of Redox Partner Binding in Bacterial P450s. Biochemistry 2016,
55 (47), 6517-6523.
41. Sligar, S. G.; Gunsalus, I. C., A thermodynamic model of regulation: modulation of
redox equilibria in camphor monoxygenase. Proc. Natl. Acad. Sci. USA 1976, 73 (4),
1078-82.

111

42. Tagawa, K.; Arnon, D. I., Oxidation-Reduction Potentials and Stoichiometry of
Electron Transfer in Ferredoxins. Biochim. Biophys. Acta 1968, 153 (3), 602-&.
43. Jasniewski, A. J.; Knoot, C. J.; Lipscomb, J. D.; Que, L., A Carboxylate Shift Regulates
Dioxygen Activation by the Diiron Nonheme beta-Hydroxylase CmIA upon Binding
of a Substrate-Loaded Nonribosomal Peptide Synthetase. Biochemistry 2016, 55 (41),
5818-5831.
44. Ost, T. W. B.; Clark, J.; Mowat, C. G.; Miles, C. S.; Walkinshaw, M. D.; Reid, G. A.;
Chapman, S. K.; Daff, S., Oxygen activation and electron transfer in flavocytochrome
P450BM3. J. Am. Chem. Soc. 2003, 125 (49), 15010-15020.
45. Edwards, D. J.; Gerwick, W. H., Lyngbyatoxin biosynthesis: Sequence of biosynthetic
gene cluster and identification of a novel aromatic prenyltransferase. J. Am. Chem. Soc.
2004, 126 (37), 11432-11433.
46. Huynh, M. U.; Elston, M. C.; Hernandez, N. M.; Ball, D. B.; Kajiyama, S.; Irie, K.;
Gerwick, W. H.; Edwards, D. J., Enzymatic Production of (-)-Indolactam V by LtxB,
a Cytochrome P450 Monooxygenase. J. Nat. Prod. 2010, 73 (1), 71-74.
47. Quadri, L. E. N.; Weinreb, P. H.; Lei, M.; Nakano, M. M.; Zuber, P.; Walsh, C. T.,
Characterization of Sfp, a Bacillus subtilis phosphopantetheinyl transferase for peptidyl
carrier protein domains in peptide synthetases. Biochemistry 1998, 37 (6), 1585-1595.
48. Berry, E. A.; Trumpower, B. L., Simultaneous Determination of Hemes-a, Hemes-B,
and Hemes-C from Pyridine Hemochrome Spectra. Anal. Biochem. 1987, 161 (1), 115.
49. Artimo, P.; Jonnalagedda, M.; Arnold, K.; Baratin, D.; Csardi, G.; de Castro, E.;
Duvaud, S.; Flegel, V.; Fortier, A.; Gasteiger, E.; Grosdidier, A.; Hernandez, C.;

112

Ioannidis, V.; Kuznetsov, D.; Liechti, R.; Moretti, S.; Mostaguir, K.; Redaschi, N.;
Rossier, G.; Xenarios, I.; Stockinger, H., ExPASy: SIB bioinformatics resource portal.
Nucleic Acids Res. 2012, 40 (Web Server issue), W597-603.
50. Morrison, J. F., Kinetics of Reversible Inhibition of Enzyme-Catalysed Reactions by
Tight-Binding Inhibitors. Biochim. Biophys. Acta 1969, 185 (2), 269-&.
51. Watanabe, T.; Honda, K., Measurement of the Extinction Coefficient of the Methyl
Viologen Cation Radical and the Efficiency of Its Formation by Semiconductor
Photocatalysis. J. Phys. Chem. 1982, 86 (14), 2617-2619.
52. Wilson, G. S.; Tsibris, J. C. M.; Gunsalus, I. C., Electrochemical Studies of
Putidaredoxin and Its Selenium Analog. J. Biol. Chem. 1973, 248 (17), 6059-6061.
53. La Clair, J. J.; Foley, T. L.; Schegg, T. R.; Regan, C. M.; Burkart, M. D., Manipulation
of carrier proteins in antibiotic biosynthesis. Chem. Biol. 2004, 11 (2), 195-201.
54. Das, A.; Grinkova, Y. V.; Sligar, S. G., Redox potential control by drug binding to
cytochrome p450 3A4. J. Am. Chem. Soc. 2007, 129 (45), 13778-+.
55. Denisov, I. G.; Grinkova, Y. V.; Baas, B. J.; Sligar, S. G., The ferrous-dioxygen
intermediate in human cytochrome P450 3A4 - Substrate dependence of formation and
decay kinetics. J. Biol. Chem. 2006, 281 (33), 23313-23318.
56. Eisenstein, L.; Debey, P.; Douzou, P., P450cam - Oxygenated Complexes Stabilized at
Low-Temperature. Biochem. Biophys. Res. Commun. 1977, 77 (4), 1377-1383.
57. Gunsalus, I. C.; Sligar, S. G., Redox regulation of cytochrome P450cam mixed function
oxidation by putidaredoxin and camphor ligation. Biochimie 1976, 58 (1-2), 143-7.

113

58. Peterson, J. A.; Ishimura, Y.; Griffin, B. W., Pseudomonas-Putida Cytochrome-P-450
- Characterization of an Oxygenated Form of Hemoprotein. Arch. Biochem. Biophys.
1972, 149 (1), 197-&.
59. Sevrioukova, I. F.; Peterson, J. A., Reaction of Carbon-Monoxide and MolecularOxygen with P450terp (Cyp108) and P450bm-3 (Cyp102). Arch. Biochem. Biophys.
1995, 317 (2), 397-404.
60. Lambeth, J. D.; Kriengsiri, S., Cytochrome-P-450scc-Adrenodoxin Interactions - Ionic
Effects on Binding, and Regulation of Cytochrome Reduction by Bound Steroid
Substrates. J. Biol. Chem. 1985, 260 (15), 8810-8816.
61. Tuckey, R. C.; Kamin, H., The Oxyferro Complex of Purified Adrenal Cytochrome P450scc. Federation Proceedings 1982, 41 (4), 1405-1405.
62. Kashem, M. A.; Dunford, H. B., The Formation and Decay of the Oxyferrous Complex
of Beef Adrenocortical Cytochrome P-450scc. Rapid-Scan and Stopped-Flow Studies.
Biochem. Cell Biol. 1987, 65 (5), 486-492.
63. Yeh, H. C.; Hsu, P. Y.; Tsai, A. L.; Wang, L. H., Spectroscopic characterization of the
oxyferrous complex of prostacyclin synthase in solution and in trapped sol-gel matrix.
FEBS J. 2008, 275 (9), 2305-2314.
64. Bui, S. H.; McLean, K. J.; Cheesman, M. R.; Bradley, J. M.; Rigby, S. E. J.; Levy, C.
W.; Leys, D.; Munro, A. W., Unusual Spectroscopic and Ligand Binding Properties of
the Cytochrome P450-Flavodoxin Fusion Enzyme XplA. J. Biol. Chem. 2012, 287
(23), 19699-19714.

114

CHAPTER 4
Sterics Proximal to the Heme of Carrier Protein-Modifying Cytochrome
P450 NikQ Protect Against Inhibitory Substrate Ligation
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4.1 ABSTRACT
Mutations to the atypically bulky residues at the 338 and 345 positions proximal to
the heme-iron cofactor of P450 tailoring enzyme NikQ have yielded variants, I338G and
I338GI345G with altered ligand-binding properties. NikQ performs a β-hydroxylation
reaction on an ʟ-histidine residue requisitely tethered to NikP1 (ʟ-his-NikP1), a
nonribosomal peptide synthetase, for the biosynthesis of Nikkomycin X antibiotics. Both
mutants show ʟ-histidine ligation by the P450 iron in substrate and ligand binding studies
using optical and electron paramagnetic resonance spectroscopies. The double mutant in
particular exhibits a substantial increase in affinity for the small molecule imidazole, which
closely resembles the ʟ-his substrate and a propensity to bind free ʟ-his that is not observed
in the wild-type enzyme or the single mutant. Reduction attempts with ʟ-his-NikP1-bound
I338GI345G have failed to yield the expected pentacoordinate ferrous geometry, instead
resulting in a mixture of nitrogen-ligated hexacoordinate ferrous P450 and seemingly
inactivated enzyme. As such, attempts to form the ferric-superoxide intermediate necessary
for catalysis have proven unsuccessful in this substrate-bound variant, implicating
chemical inhibition through substrate-ligation. These results, alongside those confirming
cyanide-ligand displacement by substrate in the mutants, indicate that these unusual
isoleucines proximal to the NikQ heme may function in a manner that protects the enzyme
against ligation of the protein-tethered substrate ʟ-histidine residue.
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4.2 INTRODUCTION
Cytochrome P450 (CYP) NikQ β-hydroxylates a protein-tethered ʟ-histidine
residue in the biosynthesis of nikkomycin X antibiotics.1 CYP reactivity is dependent on a
thiolate-ligated heme-iron cofactor and requires one equivalent of O2, two protons, and two
electrons to carry out activation of relatively inert C-H bonds.2 A vast majority of the
mechanistic work on P450s has been on enzymes that catalyze hydroxylation reactions on
small molecule substrates.3, 4 In contrast, the ʟ-his-NikP1 substrate of NikQ is a large 75
kDa nonribosomal peptide synthetase (NRPS) protein. This NRPS has been posttranslationally modified at a conserved serine residue by linkage to a phosphopantetheinyl
(ppant) group, which forms a thioester bond with the ʟ-histidine (his) target that NikQ acts
upon.1,

5

Previous work on wild-type (WT) NikQ, summarized in Figure 4.1, has

demonstrated a unique mode of catalytic regulation by its cognate substrate.5 However,
comparable studies regarding the role of the NRPS substrate on P450 mechanism are
extremely limited in the literature.4 This partially owes to complexities intrinsic to NRPS
proteins.6
Typically in P450 catalysis, the presence of substrate induces significant
thermodynamic and kinetic changes that influence the reactivity of several P450 cycle
intermediates.7-9 ʟ-His-NikP1, however, appears to exert virtually no influence on NikQ
catalysis.5 In particular, WT-NikQ does not exhibit the structural changes upon substrate
binding that correspond to a reconfiguration of the heme-iron d-electrons from the 6coordinate, ferric-aquo low-spin form to the 5-coordinate high-spin state.5 This spin shift
gates the next catalytic step, a one-electron transfer from a redox partner protein, often a
ferredoxin, with reduction potential poised between that of the low-spin enzyme and the
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more-positive E° of the high-spin form.9 This thermodynamic regulation serves to prevent
consumption of NAD(P)H by an enzyme that lacks the target substrate, as NAD(P)H is an
expensive commodity in the energetic currency of the cell and uncoupling leads the
generation of deleterious reactive oxygen species (ROS). Indeed, measurements of the
NikQ-WT redox potential in the absence and presence of ʟ-his-NikP1 show no alteration
to the cofactor E°, with the value being unusually low for a CYP at ~ -415 mV.5 This is
problematic not only from the standpoint of catalytic regulation, but also in regards to
reconstitution of a viable turnover system, as most bacterial redox systems do not possess
potentials sufficiently negative for favorable reduction of NikQ.

Figure 4.1. A summary of the influence of the ʟ-his-NikP1 substrate on the
early steps of NikQ catalysis.5 The tailoring enzyme binds the loaded NRPS with
a dissociation constant of 22 µM, yielding a stable protein-protein complex.
Notably, the NikQ reduction potential is atypically low for a CYP, and the
autoxidation rate is quite fast. Further, there is no change in the potential of the
heme-iron in the substrate-free versus -bound P450, nor is the ferric-superoxide
intermediate stabilized by the presence of excess ʟ-his-NikP1.

118

Following the first electron transfer event in CYP catalysis, atmospheric oxygen
ligates the ferrous heme-iron to yield a ferric-superoxide intermediate, colloquially referred
to as the oxy-complex.3 Decay of this species can occur through two different pathways,
signifying a critical branch-point between uncoupling via superoxide release and
productive continuation through the P450 cycle by means of a second reduction, which is
classically the rate-limiting step in CYP turnover.10 Therefore, stability of the dioxygen
adduct is paramount to maintaining a coupled and efficient process, as an impaired rate of
autoxidation allows time for the slow transfer of a second electron from the ferredoxin. In
the presence of substrate, autoxidation is typically at least an order of magnitude slower
than in the substrate-free P450.8, 11-13 This kinetic safeguard against uncoupling, however,
is also lacking in WT-NikQ, as there is no appreciable change in autoxidation rate in the
absence versus the presence of excess ʟ-his-NikP1.5 Further, the autoxidation rate constant
of ~2.5 s-1 is fast even for the superoxide-release of a substrate-free CYP.5

Figure 4.2. The 338 and 345 positions proximal to the NikQ heme. A
model of the region proximal to the NikQ heme was generated in
SwissModel47-49 using the PDB 4PWV structure of P450Sky50 (the most
homologous crystallized CYP to NikQ in the Protein Data Bank) as a
template. NikQ-WT (A) features bulky isoleucine residues at the 338 and
345 positions. Two NikQ variants have been generated, one with a glycine
substituted for I338, and another (B) with both isoleucines mutated to
glycine residues.
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Taken together, the lack of regulation by substrate in cytochrome P450 NikQ raises
mechanistic questions regarding the functional purpose of this absence of catalytic gating,
as well as the molecular determinants that give rise to it. Given the ability of the region
proximal to the heme to modulate enzyme spin equilibria, reactivity, and electronics,14-25
we directed our attentions to analysis of the residues surrounding the NikQ thiolate ligand.
Homology analysis, shown in Table 4.1, of P450s known to act on carrier protein-bound
substrates revealed that residues at positions -6 and +1 relative to the cys-thiolate (set as
position 0 for standardization of amino acid numbering) are typically glycine or leucine
respectively. These positions in NikQ correspond to dual isoleucines at residues 338 and
345, highlighted in a homology model in Figure 4.2. We were only able to find one other
instance of this unusual combination in our analysis, which exists in an ortholog with near100% identity to NikQ that also acts on an NRPS-tethered histidine in another nikkomycin
biosynthetic pathway.8, 26 To determine whether these proximal sterics may contribute to
the absence of mechanistic regulation by substrate in NikQ, we eliminated any side-chain
bulk at these positions by mutating each of these two isoleucine to a glycine. Substrate and
ligand-binding studies of the resulting I338G and I338GI345G NikQ variants were carried
out via electron paramagnetic resonance (EPR) and electronic absorption spectroscopies
alongside rapid-mix kinetics and equilibrium methodologies. Our results indicate that I338
may contribute to the lack of substrate-mediated influence on catalysis in WT-NikQ, as the
I338G variant demonstrates stabilization of the dioxygen intermediate when bound to ʟhis-NikP1. Further, both I338 and I345 appear to play a critical role in preventing inhibitory
ligation of the histidine substrate by the heme-iron, with the single and double mutants
exhibiting some degree of nitrogen ligation when bound to ʟ-his-NikP1. In the case of
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I338GI345G, total ligation is suggested by the optical spectra and the inhibitory nature
implied by an inability to form the 5-coordinate ferrous P450 and related difficulties in
obtaining a dioxygen-bound form of this mutant.

Table 4.1. Sequence alignment of amino acids around the cysteine-derived thiolate
ligand in P450 hydroxylases acting on carrier protein-tethered substrates. Unless
otherwise specified via superscript, CYPs listed below β-hydroxylate the target substrate.
Position Relative to Thiolate-Cys
-7 -6 -5 -4 -3 -2 -1 0 +1

+2

NikP1
SanO
AcmG101
Ecm13
TrsR

F
F
F
F
F

I
I
G
G
G

Q
Q
H
H
H

G
G
G
G
G

N
N
V
P
P

H
H
H
H
H

Y
Y
F
F
F

C
C
C
C
C
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P450

Substrate

Carrier
Protein

NikQ
SanQ
AcmG8a
Ecm12
TrsB

ʟ-his-PCP
ʟ-his-PCP
ʟ-thr-PCP
ʟ-trp-PCP
ʟ-trp-PCP
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Swb13
Qui15
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SimIb
CouId
OxyDBal
P450Sky

CalO2k
orsellinyl-ACP
CalO5
F G A G M R Y C L
G
Chemistries other than β-hydroxylation: aɣ-hydroxylation, ghydroxylation and C-C
h
C28-hydroxylation, iC50-hydroxylation, jC2-hydroxylation, khydroxylation
Alternative protein names: bSimD1, cSimD6, dCumD, eCumC
Substrate abbreviations: fCHA = 3-cyclohex-2’-enylalanine
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4.3 RESULTS AND DISCUSSION
4.3.1 Expression, purification, and verification of thiolate-ligand and substratebinding
Both the I338G single mutant and the I338GI345G double mutant express in high
yields (≥60 mg P450 per liter culture), though this is only achieved in the latter upon coexpression with chaperones to promote proper folding. These variants were deemed ~90%
pure following a two-column purification, with A 419 nm/A 280 nm ≥ 1.60. Multiple attempts
were made to express the I345G single mutant with and without the heme-importer ChuA
and various chaperone suites in conjunction with changes to induction temperatures, IPTG
concentrations, and expression times. However, all resulting yields were extremely low
(≤2 mg protein per liter culture) following Ni-NTA chromatography, and negligible after
a necessary second column.

Figure 4.3. Verification of the proximal thiolate ligand in the
NikQ mutants via CO-binding. Carbonmonoxy-ferrous spectra of
NikQ-I338G (A, pink) and NikQ-I338GI345G (B, gold) confirm
that the cysteine-derived thiolate ligand is intact following addition
of chemical reductant to the anaerobic substrate-free enzyme (single
mutant in light blue and double mutant in teal) in a sealed, COsparged cuvette.
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UV-visible spectroscopy of the as-purified I338G and I338GI345G NikQ mutants
showed spectra characteristic of low-spin, water-ligated, ferric cytochrome P450s. Thiolate
ligation was verified for the I338G and I338GI345G variants of NikQ by optical analysis
of the ferrous-carbonmonoxy adduct. Upon addition of reductant, shift of the Soret maxima
to ~445-450 nm was observed for both mutants (Figure 4.3), signifying intact Cys-Fe
proximal ligation through coordination of the ferrous cytochrome to CO at the distal
position.

Figure 4.4. Electronic absorption spectra of the NikQ variants in the absence and
presence of 10 equivalents of ʟ-his-NikP1 substrate. NikQ-WT (A) exhibits a negligible
change in optical properties upon the addition of substrate (dashed red spectrum) to the aspurified form (dark blue spectrum), with Soret maximum remaining at 418 nm. The I338G
mutant (B) undergoes a slight type-II spectral change from the substrate-free form at 418
nm (light blue spectrum) to 421 nm upon incubation with ʟ-his-NikP1 (dashed pink
spectrum). NikQ-I338GI345G (C) also experiences a bathochromic Soret shift upon
substrate-binding from an initial 420 nm (teal spectrum) to 424 nm (dashed gold spectrum).
Spectra of the bound-P450s have been mathematically corrected for scattering (which
derived from the NRPS protein). Difference spectra are shown in the insets.

The as-purified I338G variant, shown in Figure 4.4 B in light blue, was
spectroscopically indistinguishable from NikQ-WT (dark blue spectrum in Figure 4.4 A),
exhibiting Soret maximum at 419 nm and β and α Q-bands at ~535 and ~580 nm, with the
latter α Q-band being slightly more pronounced than the β band. The Soret of the aspurified double mutant (Figure 4.4 C, teal spectrum) was centered at 420 nm, with Q-bands
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at ~535 and ~580 nm, although the β Q-band of this variant is enhanced relative to the α
band. This may indicate a small percent of the I338GI345G mutant remains imidazoleligated from Ni-NTA column elution even after purification using another
chromatographic method, as the red-shifted Soret and β Q-band enhancement is consistent
with nitrogen-ligation in P450s.51
Upon addition of excess ʟ-his-NikP1 substrate, both mutants exhibit type-II binding
spectra consistent with some degree of nitrogen-ligation, likely to the imidazole moiety of
the substrate histidine, featuring red-shifted Soret, reduced extinction relative to the resting
state, and enhanced β Q-band intensity.51 The single mutant (pink spectrum of Figure 4.4
B) appears to remain partially water-ligated, as with substrate-bound NikQ-WT shown in
the red spectrum of Figure 4.4 A, with only a small fraction of this mutant coordinating the
NikP1-tethered histidine to yield a 421 nm Soret. The double-mutant, however, appears to
fully ligate the ʟ-his R-group, with Soret at 424 nm. These changes should theoretically
allow for determination of a dissociation constant via optical substrate-binding titration.
Attempts at this have proven unsuccessful, however, due to the modest absorbance change
(ie. a ~2 nm shift to a species with a subtle decrease in Soret extinction) in the single mutant
and persistent scattering of the NRPS protein that interferes with the spectrum of both
mutants.
Size exclusion chromatography was used to confirm the ability of the NikQ mutants
to form a stable complex with ʟ-his-NikP1, as has been observed in WT-NikQ (shown in
Figure 4.5 A).5 Figure 4.5 shows retention volumes of ~24-25 mL for each of the substratefree variants (circles), with WT-NikQ (dark blue) in A, I338G (light blue) in B, and
I338GI345G (teal) in C. Incubation with substrate leads to early elution at a retention
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volume of ~13-14 mL, consistent with the formation of a stable NikQ•ʟ-his-NikP1 complex
also observed with the WT-P450.5 The data for ʟ-his-NikP1-bound NikQ-WT, I338G, and
I338GI345G, represented in Figure 4.5 A, B, and C by red, pink, and gold triangles,
respectively, demonstrates that substrate-binding capacity has been retained in the mutants.

Figure 4.5. Size exclusion chromatography shows complex formation between the
NikQ variants and ʟ-his-NikP1. Substrate-free (circles) NikQ-WT (A, dark blue), I338G
(B, light blue), and I338GI345G (C, teal) variants all feature retention times of ~24-25 mL.
Addition of ʟ-his-NikP1 results in earlier retention times of ~13-14 mL (triangles, with WT
in red, I338G in pink, and I338GI345G in gold), indicative of stable binding between the
P450 and its substrate.

4.3.2 The NikQ proximal mutants exhibit altered small molecule ligand affinities
WT-NikQ has been shown to have, at best, a very weak affinity for free ʟ-histidine,
demonstrating no optical change upon incubation with excess free ʟ-his.1, 5 However, since
UV-visible spectra of the mutants imply nitrogen-ligation following substrate addition,
binding of the mutants to free ʟ-his was analyzed using absorbance spectroscopy. Figure
4.6 shows the spectra resulting from the incubation of I338G (A) and I338GI345G (B) with
10 equivalents of this amino acid. The single mutant Soret remains at 419 nm, after the
addition of ʟ-his, however, the double mutant Soret exhibits a 4 nm bathochromic shift and
reduced absorbance, as well as enhancement of the β Q-band. This data confirms that the
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I338GI345G variant possesses an increased affinity for ʟ-histidine versus the single mutant
and the WT P450. Of more catalytic significance, this also indicates that the double mutant
is likely ligating an ʟ-his-NikP1 nitrogen, which may form a substrate-inhibitor complex.

Figure 4.6. Optical monitoring of I338G (A) and I338GI345G
(B) following the addition of 10 equivalents of free ʟ-histidine.
The ʟ-his-supplemented spectrum of the single mutant (A, dashed
pink spectrum) displays no shift in Soret maxima, significant change
in absorbance, or alteration of the β:α Q-band intensities. In contrast,
the addition of ʟ-his to the double mutant (B, dashed gold spectrum)
results in a 4 nm red-shift of the Soret, a decrease in Soret extinction,
and an increase in the β:α Q-band ratio confirming that this variant
has an enhanced affinity for this small molecule.
Quantitive comparison of ʟ-his binding in the WT, single mutant, and double
mutant NikQ variants necessitates ligand concentrations beyond the solubility of this amino
acid, due to the low affinities of NikQ-WT and I338G for this small molecule. To
circumvent the limited solubility of ʟ-his while still allowing the opportunity for binding
constant analysis, imidazole titrations were performed, as imidazole is structurally
analogous to the ʟ-his R-group but has significantly improved (~37-fold) solubility
compared to free histidine. Results of these equilibrium binding titrations for the substratefree WT, I338G, and I338GI345G NikQ variants are shown with representative spectra in
Figure 4.7 (binding data and fits in the insets). WT and I338G NikQ showed extremely low
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affinities for imidazole, with dissociation constants of 13.3 ± 0.6 mM and 5.3 ± 0.2 mM,
respectively. For context, CYPs with imidazole KD-values in the ~200 µM range are
considered to be low affinity.17, 52 The I338GI345G mutant exhibited a dramatic ~185-fold
increase in affinity relative to the WT protein, with a KD of 72 ± 1 µM. Attempts to meaure
a substrate-bound imidazole binding constant were made for the WT and I338G P450s.
Scattering from the NRPS substrate, however, becomes problematic at very high
concentrations of imidazole, and no saturation of the protein with the small molecule ligand
could be achieved. This was not carried out with substrate-bound I338GI345G, as the
substrate-bound form of this variant is optically indistinguishable from the imidazoleligated state.

Figure 4.7. Equilibrium binding analysis of the NikQ variants to imidazole. Substratefree NikQ-WT (A, dark blue), I338G (B, light blue), and I338GI345G (C, teal) were
titrated with pH 7.5 imidazole until spectral stability was reached following increasing
addition of the ligand. Imidazole-bound Soret peaks were at 424 nm for WT (red) and
I338G (pink), and 425 nm for I338G (gold). The changes in absorbance were graphed as a
function of imidazole concentration, and fit to a hyperbolic binding function to obtain
imidazole dissociation constants. Measured dissociation constants were 13.3 ± 0.6 mM,
5.3 ± 0.2 mM, and 72 ± 1µM for NikQ-WT, I338G, and I338GI345G, respectively.
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Figure 4.8. Equilibrium binding titration of aqueous sodium cyanide into each of the
substrate-free NikQ variants show low affinities for this ligand. Cyanide-binding
resulted in spectral shifts to 437 nm for WT (A) and I338G (B), and 439 nm for
I338GI345G (C). Changes in absorbance were graphed as a function of cyanide
concentration and fit to hyperbolic binding functions, as shown in the insets, to yield
dissociation constants of the substrate-free P450 for cyanide. The change in absorbance
was calculated from absolute value of the decrease in absorption at 437 nm.

The I338G and I338GI345G mutations proximal to the heme appear to modulate
ligand binding on the distal side of the cofactor with uncharged nitrogenous ligands
resembling the ʟ-his-NikP1 substrate. To further investigate the impact of removing the
sterics from the 338 and 345 positions, coordination of cyanide was analyzed. Cyanide
binding analyses allow for investigation of a small anionic ligand that is often used as a
mimic for O2 in P450s.53-55 Dioxygen only binds the ferrous enzyme to yield a typically
short-lived and unstable intermediate state with a Soret shift of 0-to-10 nm. In contrast,
cyanide ligates the ferric iron to form a stable complex with the cytochrome which
undergoes a large optical change (~ 20 nm) at the Soret.53-55 This spectral shift is distinct
from that of nitrogen-ligation, affording the option of binding analysis using the substratebound form of the NikQ mutants despite coordination of the substrate ʟ-histidine. Figure
4.8 shows the results of substrate-free cyanide binding titrations for NikQ-WT (A), I338G
(B), and I338GI345G (C). In agreement with other reported P450-cyano complexes,
cyanide-bound NikQ exhibits a Soret at ~437 nm (439 nm in the double mutant) with a
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decreased extinction coefficient and merged Q-bands at ~565 nm.53-55 All substrate-free
NikQ variants exhibit low affinities for cyanide, with KD values of 11 ± 3 mM, 11 ± 2 mM,
and 5 ± 1 mM for WT, the single mutant, and the double mutant.

Figure 4.9. Equilibrium binding analysis of cyanide to the ʟ-his-NikP1-bound NikQ
variants reveal differences between the WT enzyme and the mutants. The final
cyanide-ligated spectra for substrate-bound WT-NikQ (A, red), I338G (B, pink), and
I338GI345G (C, gold) share similar spectral characteristics between them, as well as with
the previously described cyanide-bound substrate-free states. However, the WT cyanide
affinity has increased ~5-fold, while the I338G value is largely unchanged, and the
I338GI345G binding constant is weakened by ~6-fold.

These titrations were also performed for the substrate-bound variants (Figure 4.9),
with NikQ-WT demonstrating an increased affinity for cyanide of 2 ± 1 mM. This orderof-magnitude higher affinity in the presence of substrate is not atypical of substrate-bound
P450s.54 The two mutants, however, both exhibited weakened affinities (14 ± 3 mM for
I338G and 32 ± 1 mM for I338GI345G) for the anionic small molecule when substratebound. This supports the observation that with each subsequent decrease in atypical
proximal sterics (via I-to-G substitution), the affinity for nitrogen-ligands increases,
resulting in partial ligation of the substrate in I338G and optical spectra indicative of full
ligation of the substrate by I338GI345G. In the mutants, this ligation of a high-affinity
substrate by the heme-iron essentially inhibits binding of cyanide to the metal until cyanide
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concentrations are excessive enough to drive the equilibrium toward displacement of the
ligated substrate nitrogen. This results in decreased cyanide affinities in the substratebound mutants, with KD values for cyanide that are inversely proportional to the those of a
variant for the substrate histidine. Due to the volatility of cyanide at neutral pH values,
titrations were performed using NaCN at a pH of ~11.5, which resulted in a pH-dependent
influence on the binding data which resembles a sigmoidal pH titration. This is not often
observed in P450-cyanide titrations, as most CYPs have a more favorable dissociation
constant for cyanide than the values reported here, and thus do not require such high
cyanide concentrations for complete binding. Accordingly, the influence of this sigmoidal
baseline becomes more pronounced with higher KD values, as the protein solution becomes
increasingly basic with the increased cyanide concentration required to acheive saturation
of the binding curve (as in Figure 4.9 B). For measurements resulting in lower K D values,
this effect is minimized and the binding curve is the expected hyperbolic shape (as in Figure
4.9 A).
In order to assess whether the ʟ-his-NikP1 substrate is able to displace a ligated
cyanide in the NikQ variants, and as an additional means of verifying the strength of
substrate-ligation relative to another ligand, 75 µM ʟ-his-NikP1 was incubated with ~5 µM
of NikQ-WT, I338G, and I338GI345G, each pre-bound to cyanide. Optical monitoring
revealed notable spectral differences following addition of the protein substrate, as shown
below in Figure 4.10. The wild-type enzyme (A) only undergoes a moderate blue shift from
the 437 nm cyanide-bound Soret to 435 nm after addition of 15 equivalents of substrate.
The I338 mutant exhibits a slightly larger blue shift upon substrate addition to 433 nm (data
not shown). The double mutant, shown in Figure 4.10 B, features Soret at 427 nm, just 2
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nm from the substrate-bound maximum for this variant, following addition of the same
amount of ʟ-his-NikP1. While the displacement of the anionic ligand by substrate due to
ligation was expected in the double mutant, and to a lesser degree in the single mutant, the
shift in absorbance maxima for wild-type is somewhat surprising. These results seem to
indicate that some degree of displacement cyanide-displacement is occurring in the wildtype enzyme, even though there are no optically distinguishable signs of ligation.

Figure 4.10. Attempted displacement of NikQ-bound cyanide
via addition of the ʟ-his-NikP1 substrate. 5 µM of cyanide-ligated
NikQ (purple WT spectrum in A and green I338GI345G spectrum
in B) was incubated with 75 µM substrate then analyzed using
absorbance spectroscopy. Each variant displayed some degree of
displacement, as determined by a blue-shifted Soret peak and
increased absorbance. WT experienced the most minimal change,
with final Soret maxima shifted to 435 nm (A, red) from an initial
437 nm. The I338GI345G mutant demonstrated the largest change
to 427 nm (B, gold) from 437 nm so that the final Soret peak was
within 2 nm of the substrate-bound form without cyanide.

4.3.3 Analysis of substrate and ligand-binding by electron paramagnetic resonance
Electron paramagnetic resonance (EPR) allows for sensitive investigation of
changes in ferric mononuclear iron ligation states, with signals arising from the non-integer
spins of the iron d-electrons. Following equilibrium binding analyses, EPR was performed
to gain better insight into the geometrical and electronic changes occurring at the heme
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across the three NikQ variants in the as-purified, substrate-bound, and small moleculeligated forms. Figure 4.11 shows the results of EPR studies using 100 µM NikQ-WT (A),
I338G (B), and I338G/I345G (C) in the substrate-free ferric resting state with aquo- sixth
ligand (top row of spectra). The next two rows down display spectra following incubation
with 500 µM ʟ-his-NikP1 substrate and in the presence of 5 equivalents of ʟ-histidine. The
bottom row features spectra of the imidazole-ligated form of each variant.

Figure 4.11. EPR spectra of 100 µM of the NikQ variants in the resting state, bound
to substrate, and with potential nitrogen ligands similar to the protein-tethered
substrate. NikQ WT (A), I338G (B), and I338GI345G (C) are shown in the substrate-free
ferric-aquo state (top row - dark blue, light blue, and teal), after addition of 500 µM ʟ-hisNikP1 substrate (second row down – red, pink, and gold), 5 equivalents of ʟ-histidine (third
row down – dark purple, navy blue, and dark green), or an excess of imidazole (bottom
row – violet, mauve, and light green).
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Table 4.2. EPR g-values and derived crystal field parameters for NikQ-WT, I338G,
and I338GI345G in the resting and substrate-bound states, and with various ligands.
NikQ
Variant

±
Substrate

Ligand
Added

-

N/A

g-values
gMax gMid gMin

Distortions Rhombicity, ΔRhombicity
|V/Δ|
(vs. Sub-Free)
|Δ/λ| |V/λ|

2.44 2.25 1.91 6.12 2.93
2.48 2.25 1.90 5.88 3.21
+
N/A
2.40 2.25 1.92 6.39 2.59
ʟ-His
2.44 2.25 1.91 6.12 2.93
WT
2.57 2.25 1.84 5.06 3.19
Imidazole 2.46 2.25 1.89 5.79 2.89
2.40 2.25 1.84 5.33 1.84
Cyanide 2.54 2.29 1.84 4.84 2.37
+
Cyanide 2.47 2.30 1.86 5.08 1.84
N/A
2.45 2.25 1.91 6.09 3.04
2.49 2.25 1.89 5.73 3.17
+
N/A
2.42 2.25 1.92 6.33 2.83
ʟ-His
2.45 2.25 1.91 6.09 3.04
I338G
2.60 2.25 1.84 5.05 3.34
Imidazole
2.47 2.25 1.89 5.77 2.98
Cyanide 2.56 2.29 1.84 4.81 2.51
2.56 2.30 1.84 4.76 2.37
+
Cyanide
2.49 2.30 1.85 4.95 1.94
N/A
2.46 2.25 1.90 5.93 3.01
2.57 2.25 1.84 5.06 3.19
+
N/A
2.48 2.25 1.89 5.75 3.08
2.60 2.25 1.84 5.05 3.34
ʟ-His
2.57 2.25 1.84 5.06 3.19
I338G/I345G
2.46 2.25 1.90 5.93 3.01
2.60 2.25 1.84 5.05 3.34
Imidazole
2.48 2.25 1.89 5.75 3.08
Cyanide 2.57 2.30 1.83 4.66 2.36
2.57 2.30 1.83 4.66 2.36
+
Cyanide
2.46 2.25 1.89 5.79 2.89
Bolded values represent the dominant set of g-values out of multiple species.
deviation from the axis of maximal distortion observed in data shown in black.

0.48
0.54
0.40
0.48
0.63
0.50
0.34
0.49
0.36
0.50
0.55
0.45
0.50
0.66
0.52
0.52
0.50
0.39
0.51
0.63
0.53
0.66
0.63
0.51
0.66
0.53
0.51
0.51
0.50
Values in blue

N/A
0.07
-0.07
0.00
0.15
0.02
-0.13
0.01
-0.12
N/A
0.05
-0.05
0.00
0.16
0.02
0.02
0.00
-0.11
N/A
0.12
0.03
0.15
0.12
0.00
0.15
0.03
0.00
0.00
-0.01
exhibited a

All spectra exhibit rhombic line shapes characteristic of ferric thiolate-ligated
heme-iron with hexacoordinate anisotropy.2, 53, 54, 56-61 The data from these experiments is
summarized in Table 4.2, with gmax corresponding to the highest magnitude g-value, gmin
to the lowest magnitude value, and gmid to the intermediate value.58 Table 4.2 also features
the derived values of tetragonal distortion (Δ/λ), orthorhombic distortion (V/λ), rhombicity
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(|V/Δ|), and the change-in-rhombicity (Δrhombicity) for each spectrum relative to the
resting state.58

Table 4.3. Assignment of NikQ EPR g-values to the correct z, x, and y
coordinates and the resulting eigenstates A, B, and C.
NikQ
Variant

±
ʟ-His-NikP1

Ligand
Added

-

N/A

+

N/A

-

ʟ-His

-

Imidazole

+
-

Cyanide
Cyanide
N/A

+

N/A

-

ʟ-His

-

Imidazole

-

Cyanide

+

Cyanide

-

N/A

+

N/A

-

ʟ-His

-

Imidazole

-

Cyanide

+

Cyanide

WT

I338G

I338G/I345G

gz

g-values
gy

gx

1.91
1.90
1.92
1.91
1.84
1.89
1.84
1.84
1.86
1.91
1.89
1.92
1.91
-2.60
1.89
1.84
1.84
1.85
1.90
1.84
1.89
-2.60
1.84
1.90
-2.60
1.89
1.83
1.83
1.89

2.25
2.25
2.25
2.25
2.25
2.25
2.25
2.29
2.30
2.25
2.25
2.25
2.25
-1.84
2.25
2.29
2.30
2.30
2.25
2.25
2.25
-1.84
2.25
2.25
-1.84
2.25
2.30
2.30
2.25

2.44
2.48
2.40
2.44
2.57
2.46
2.40
2.54
2.47
2.45
2.49
2.42
2.45
2.25
2.47
2.56
2.56
2.49
2.46
2.57
2.48
2.25
2.57
2.46
2.25
2.48
2.57
2.57
2.46

Eigenstates
A
B
C
0.13
0.14
0.12
0.13
0.17
0.14
0.14
0.17
0.15
0.13
0.14
0.13
0.13
0.81
0.14
0.17
0.17
0.16
0.14
0.17
0.14
0.81
0.17
0.14
0.81
0.14
0.17
0.17
0.14

0.99
0.99
1.00
0.99
0.99
0.99
0.98
0.99
0.99
0.99
0.99
1.00
0.99
0.08
0.99
0.99
0.99
0.99
0.99
0.99
0.99
0.08
0.99
0.99
0.08
0.99
0.99
0.99
0.99

-0.03
-0.03
-0.02
-0.03
-0.05
-0.03
-0.02
-0.04
-0.02
-0.03
-0.04
-0.03
-0.03
-0.59
-0.03
-0.04
-0.04
-0.03
-0.03
-0.05
-0.03
-0.59
-0.05
-0.03
-0.59
-0.03
-0.04
-0.04
-0.03

Table 4.3 shows additional calculated values and the assignments necessary to
compute the parameters shown in Table 4.2. Assignment of gMax, gMid, and gMin by default
as gz, gy, and gx can result in instances where rhombic distortion greatly exceeds axial
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distortion, resulting in inappropriately elevated rhombicity values that exceed the
theoretical upper limit of 2/3.58, 59 In such cases, correct assignment of gz, gy, and gx should
be based on the computed parameters from six different allowable coordinate assignments,
summarized in Table 4.4, that result in the lowest rhombicity value while yielding a
positive orthorhombic distortion.58 Each NikQ EPR spectrum possessed an axis of maximal
distortion deviating from that in which the assignment of the highest g-value as z and the
lowest as x is appropriate. This resulted in rhombicity values exceeding 0.67 and instead
ranging from 0.70 to 1.12. The correct assignment of the coordinates yielded crystal field
parameters within theoretical limits.

Table 4.4. Allowable assignments of gMax,
gMid, and gMin to the z, y, and x
coordinates.
Allowed
Assignment

gz

g-values
gy

I

-gMax

-gMin

gMid

II

gMin

gMid

gMax

III

-gMid

-gMin

gMax

IV

-gMax

gMid

-gMin

V

gMin

gMax

gMid

VI

-gMid

gMax

-gMin

gx

In the resting state with sixth aquo ligand, there appears to be only one species
present for each variant, with gMax at 2.44, 2.45, and 2.46 and gMin at 1.91, 1.91, and 1.90
for WT, I338G, and I338GI345G, respectively. All spectra shown in Figure 4.9 featured
gMid at ~2.25. The deviations in gMax and gMin values between the variants result in a
progressive increase of rhombic character with mutation, as |V/Δ| calculations indicate
values of 0.48 for WT, 0.50 for the single mutant, and 0.51 for the double mutant. This
trend of increasingly rhombic character with decreasing sterics at the proximal site due to
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mutation holds across the resting, substrate-bound, ʟ-his supplemented, and imidazoleligated states. Further, rhombicity increased with the likelihood of nitrogen-ligation
(generally, it is expected that a P450 would have a increased affinity for imidazole versus
ʟ-his, and ʟ-his versus a protein-tethered histidine).52 This likely signifies an alteration to
the geometry of the axial ligands and their bonds to the iron atom,59 which would have to
owe to changes near the thiolate ligand, as one mutated residue is adjacent to this cysteine
and the other is in close proximity. The tetragonal field is decreased in the single mutant,
and further so in the double mutant, which is consistent with diminished electron donation
to the iron from the axial ligands.59 It seems logical that this also derives from alterations
at the thiolate ligand side of the iron, due to the locations of the mutated amino acids and
the commonality of the ligands analyzed. This could implicate to an increasingly weakened
S-Fe bond corresponding to the removal of each targeted isoleucine side chain.
It may be relevant to note that the imidazole-bound geometries exhibiting
rhombicities of 0.66 for each of the mutants, along with one electronic species of ʟhistidine-coordinated double mutant with an equivalent value, showed a deviation from the
axis of maximal distortion used for the other species on Table 4.2. In fact, these three
display the highest rhombicity values from this series of EPR experiments, just below the
theoretical limit of 0.67. The tetragonality is also low for a P450 with such high rhombicity,
falling closer to the range of values expected of a low-spin hexacoordinate heme with axial
histidine and oxygen ligands than those of a low-spin thiolate-ligated heme.56, 59 This may
indicate a significant alteration to the geometry of the bonded axial ligands in this
conformer, and possibly even a change in ligand identity through the loss of the cysteinederived thiolate bond to the iron.
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Futher EPR analysis was performed on the cyanide complexes of NikQ-WT,
I338G, and I338G/I345G in both the substrate-free and ʟ-his-NikP1-bound forms.
Resulting spectra are shown in Figure 4.12 for WT (A), I338G (B), and I338GI345G (C),
with the substrate-free samples in shades of blue/teal and the NRPS-bound P450 in
red/pink/gold. The g-values obtained from this data are shown in Table 4.2. The cyanidebound, substrate-free variants feature g-values around 2.55, 2.30, and 1.84, which are
shifted versus the cyanide-free resting enzyme, but are within the range of EPR values
reported for some P450 cyanide complexes.54 Upon addition of substrate, the gMax- and
gMin-values of the WT enzyme exhibit (in red, A) increased intensity and peak-narrowing
relative to the substrate-free form. This is likely indicative of a more homogeneous cyanide
ligand geometry with fewer conforming species contributing to the averaged EPR signal.
The single mutant (pink spectra in B) undergoes a splitting of the gMax-value in the presence
of substrate, signifying two different populations of the cyanide-ligated CYP in the
presence of substrate, possibly owing to a perturbation of the coordinated ligand geometry
due to steric restrictions or hydration changes within the distal pocket. There also appear
to be two separate rhombic species in this spectrum (gold, C), indicated by the appearance
of a second, less intense gmid signal beneath the one at 2.30 corresponding to ligated
cyanide. This minor species, with g = 2.46, 2.25, and 1.89 may derive from ligation of the
substrate histidine, though the gmax more closely resembles the resting state of the enzyme.
It is surprising that this variant does not appear to be fully cyanide-bound despite the
extreme excess of cyanide in the sample, though this may owe to a difference in the
affinities of the P450, as well as the heme-iron, for the NikP1-tethered ʟ-histidine versus
cyanide.
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Figure 4.12. EPR of the cyanide-bound NikQ variants in the absence and presence of
substrate. 100 µM WT-NikQ (A), I338G (B), and I338GI345G (C) were incubated with
500 mM cyanide to yield the samples shown in dark blue, light blue, and teal, respectively.
The red, pink, and gold spectra resulted from samples in which 100 µM of each NikQ
variant was incubated with 500 µM ʟ-his-NikP1 prior to the addition of 500 mM cyanide.

With the negatively-charged cyanide ligand, the trend of increasingly rhombic
character that was observed for neutral nitrogen ligation is disrupted. In the cyanide
samples that do not contain NikP1, the I338G mutant displays the highest rhombicity,
followed by I338GI345G, then WT. Upon addition of substrate, the predominant
population of the double mutant undergoes minimal change, while the WT and one
geometry of the single mutant see decreases in |V/Δ|, with WT seemingly conforming to a
more homogeneous state. These observations may owe to the relatively large differences
in the affinities of each variant for cyanide presence of substrate, as determined from the
previously discussed equilibrium binding analyses.

4.3.4 Mutants Proximal to the NikQ Heme Alter Oxy-Complex Stability
Anaerobic stopped-flow spectroscopy was utilized to collect spectra detailing the
reaction of reduced NikQ I338G or I338GI345G with dioxygen, in both the absence and
presence of excess ʟ-his-NikP1. In the absence of substrate, initial spectra of both variants,
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shown in Figure 4.13 with I338G in A and I338GI345G in C, featured the red-shifted Soret
maxima and merged Q-bands (blue/teal spectra) consistent with a ferric-superoxide
species, at ~ 426 nm and ~557 nm respectively. Autoxidation was complete within 2
seconds for I338G and 1 second for I338GI345G, with both mutants returning to the waterligated ferric low-spin state with Soret at ~419 nm and α/β Q-bands at ~565/535 nm.
Formation of the oxy-complex was complete within the 1 ms deadtime of the instrument
for both variants, and thus could not be resolved under O2-saturating conditions, which is
consistent with what has observed for WT-NikQ under the same conditions.5 Difference
spectra revealed a maximal change in absorbance for autoxidation of 443 nm and
corresponding single-wavelength data (insets) was fit to a single exponential function. The
rate constants of autoxidation were found to be 3.7 ± 0.2 s-1 and 7.1 ± 0.1 s-1 for substratefree NikQ-I338G and I338GI345G. Though these rates are slightly accelerated, this
remains a rapid process on the same order of magnitude of the WT rate of 2.8 s-1,5 and thus
does not represent a significant kinetic deviation. In the substrate-free form, little has
changed between the WT enzyme and the mutants with respect to oxy-complex stability,
with all 3 variants being relatively unstable.
Intriguingly, autoxidation was considerably impaired in the substrate-bound I338G
mutant, requiring data collection over the course of 60 seconds. Figure 4.13 B shows initial
Soret maxima (navy blue spectrum) at ~414 nm with decreased extinction and merged Qbands centered at ~550 nm, likely a mix of ferrous-P450 and ferric-superoxide species. The
oxy-complex (light blue spectrum) of ʟ-his-NikP1-bound I388G displayed the same
spectral features described for the substrate-free form, and returned to the low-spin state
previously described (pink spectrum). Fitting of single wavelength data at 443 nm (inset)
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required a three-summed exponential function corresponding to a single oxy-intermediate
formation phase with increasing absorbance, and a biphasic autoxidation of decreasing
absorbance with respective rate constants of 44 ± 6 s-1, 0.8 ± 0.1 s-1 and 0.08 ± 0.01 s-1. The
increased kinetic complexity of superoxide release may owe to different species of the
substrate-bound P450 possessing varying degrees of oxy-complex stability due to
differences in substrate positioning above the iron. Data derived from optical and EPR
spectroscopies with this mutant reflect this possibility with a substrate-bound Soret
maxima of 422 nm in the former, possibly owing to partial deprotonation of the iron-ligated
water or a mixture of substrate ʟ-histidine-ligated and unligated species. EPR of ʟ-hisNikP1-bound NikQ shows a similar mixture of species with the same potential
assignments, providing little distinction between the two.

Figure 4.13. Autoxidation of substrate-free I338G (A), substrate-bound I338G (B),
and substrate-free I338GI345G (C). Stopped-flow transient kinetics analysis was
performed through rapid-mixing of 10 µM anaerobic, ferrous P450 (accompanied by 100
µM ʟ-his-NikP1 for the single mutant in panel B) with O2-saturated buffer at 4 °C.
Autoxidation of the oxy-complex (A and B, light blue; C, teal) at 426 nm to the low-spin
ferric resting state (pink in A and B, gold in C) was complete within 2 seconds for substratefree I338G and within 1 second for substrate-free I338GI345G. Formation of the dioxygen
adduct occurred within the deadtime of the instrument for the substrate-free mutants at
post-mix O2 concentrations above 0.4 mM. Initially, the substrate-bound mutant in B is
still partially in the ferrous form, in navy with Soret maxima at 414 nm, and data collection
for 60 seconds allowed for resolution of ferric-superoxide intermediate formation and biphasic autoxidation.
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The optical and EPR data agree that the double mutant likely ligates the heme-iron,
raising the possibility of inhibition of reduction and dioxygen ligation, which has been
observed in some P450s.52 Indeed, multiple reduction attempts were not successful in
generating the expected 410 nm Soret in the substrate-bound form of this variant so
subsequent O2-binding and autoxidation could not occur. In light of the inability to reduce
a substrate-ligated variant of the same protein, it seems likely that the substrate positioning
in NikQ-I338G has yielded two populations in the substrate-bound low-spin form, with
one altering the pKa of the aquo-ligand. These different populations within the active site
could have different stabilization effects on the dioxygen-adduct in the oxy-complex,
leading to the two autoxidation phases. The ability to reduce the single mutant to the ferrous
pentacoordinate P450 when substrate-bound seems to minimize the possibility of the
second autoxidation phase deriving from a substrate-ligated species, especially in
comparision with the double mutant.

Figure 4.14. Measured redox potentials of the substrate-free NikQ
mutants. The reduction potentials for the I338G (A) and I338GI345G (B)
mutants were measured in the absence of ʟ-his-NikP1 using methyl
viologen, with E° = -446 mV, as an indicator dye. The potential for the
single mutant was found to be -448 mV, with the double mutant potential
poised at -423 mV, demonstrating that neither variant deviates significantly
from the also unusually low -415 mV value measured for the WT enzyme.
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The reduction potentials of the substrate-free NikQ mutants were determined
through spectroelectrochemical titration using methyl viologen, with E° = -446 mV, as an
indicator dye, to probe whether the proximal mutants had impacted the 3+/2+ couple of the
heme-iron. Results are shown in Figure 4.14, with a measured E° of -448 mV for I338G
(A) and -423 mV for I338GI345G (B). Both of these values are similar to the measured
value for WT-NikQ of -415 mV, with neither mutant presenting a significant change from
this unusually low value.5

Figure 4.15. Attempts to reduce the I338GI345G imidazole complex (A) and
substrate-bound enzyme (B). Reduction of the imidazole (A, teal) or substratebound I338GI345G (B, teal) complex yields at least two species (green) for both
imidazole- and ʟ-his-NikP1-bound enzyme. One species features Soret at 423 nm,
and the other at 448 nm. Subsequent introduction of CO into the cuvette results in
formation of either the carbonmonoxyf-errous cytochrome with Soret at 449 nm, or
a species with increased extinction and Soret maxima at 422 nm typically indicative
of injury to the thiolate ligand.
Reduction of the ʟ-his-NikP1-bound I338GI345G mutant fails to yield the expected
pentacoordinate reduced complex with Soret at 410 nm and merged Q-bands. With the
majority of the data presented herein supporting inhibitory substrate-ligation by this
mutant, attempts to form the ferrous cytochrome in the imidazole-ligated form were
performed in parallel with the substrate-bound enzyme to explore the possibility of a
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nitrogen-ligated hexacoordinate ferrous enzyme. These results are presented in Figure 4.15
with the double mutant bound to imidazole (A) or substrate (B) initially in the ferric state
(teal). Chemical reduction yields the green spectra, which is comprised of a mixture of
states, including a minor species with Soret at 448 nm and merged Q-bands, consistent
with a ferrous hexacoordinate nitrogen-ligated complex62 which accumulates to a higher
degree in the presence of ʟ-his-NikP1 versus imidazole. The main peak at 423 nm in the
green spectra could be indicative of injury to the thiolate-ligand, unreduced ferric nitrogenligated enzyme, or an add-mix of the two. Following chemical reduction and data
collection, the sealed cuvette was bubbled with CO(g) to assess the integrity of the thiolate
ligand following reduction, and resulting spectra are presented in gold. In the instance of
thiolate-ligand injury, a high extinction (relative to the ferric P450) centered around 422
nm is expected, instead of the Soret at ~450 nm that validates thiolate integrity. The COadduct of the imidazole-bound I338GI345G mutant results in a small amount of the ~450
nm species with a majority of the enzyme cofactor absorbing strongly at 422 nm. This may
be indicative of a more labile Fe-S bond in this mutant, which would be consistent with the
loss of electron-donating ligand character observed in the EPR studies. Curiously, the
presence of substrate does appear to have a stabilizing effect on the thiolate compared to
the structurally similar imidazole, with a higher A450 nm/A422 nm ratio in the presence of ʟhis-NikP1. The majority of the enzyme, however, does appear to present predominantly
with damaged thiolate coordination regardless of whether the nitrogen bound to the iron at
the distal position derives from substrate or imidazole.
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4.4 CONCLUSIONS
In summary, we present evidence supporting ligation of the ʟ-his-NikP1 substrate
by variants of cytochrome P450 NikQ, in which two atypically bulky isoleucine residues
have been substituted by glycines to generate two mutants – I338G and I338GI345G. The
double mutant possesses a higher affinity for imidazole and free ʟ-his compared to the
other mutants, and exhibits optical properties consistent with nitrogen ligation upon
substrate binding. The single mutant also appears to ligate ʟ-his-NikP1, though to a lesser
degree. Both mutants demonstrate an increase in rhombicity with substrate or small
molecule-derived nitrogen coordination in EPR studies relative to the WT protein, as well
as a decrease in tetragonal distortion, supporting an alteration of ligand geometry and less
electron donation to the iron from an axial ligand. Ligand binding studies using cyanide
show an increase in KD for the mutants in the presence of substrate, implicating that cyanide
binding may be inhibited by the substrate. Attempts to produce the pentacoordinate ferrous
substrate-bound double mutant have proven unsuccessful, and thus the oxy-complex of this
variant cannot be analyzed. As a whole, this work demonstrates that removal of the sterics
imparted to the NikQ proximal site by these isoleucine residues exerts a significant
influence on interactions with the iron from the distal side of the heme cofactor, altering
substrate-binding properties and resulting in a substrate-inhibitor complex. These
unusually bulky proximal amino acids may serve the functional role of preventing
inhibitory ligation of the NikP1-appended substrate ʟ-histidine through modulation of
structural details regarding heme-distortion and iron-coordination.
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4.5 MATERIALS AND METHODS
4.5.1 Reagents and Chemicals
All microbiology reagents and media, as well as adenosine 5’-triphosphate,
kanamycin (kan), ampicillin (amp), and DTT, were purchased from Research Products
International. Glycerol, buffers, and chloramphenicol (CAM) were from VWR
International. Tetracycline, methyl viologen, ʟ-histidine, Tris-(2-carboxyethyl)-phosphine
hydrochloride (TCEP), and sodium hydrosulfite (dithionite) were from Sigma Aldrich.
Isopropyl-β-ᴅ-thiogalactopyranoside (IPTG) was from Gold Biotechnology. Hemin and δaminolevulinic acid were purchased from Carbosynth. The pChuA plasmid was a gift from
Alan Jasanoff (Addgene plasmid # 42539).63 The pG-Tf2 chaperone plasmid was from
Takara Bio Inc. The vector for co-expression of the Sfp phosphopantetheinyl transferase
out of Bacillus subtilis was generously provided by Professor Courtney Aldrich.
4.5.2 Molecular Biology, Heterologous Expression, and Protein Purification
NikQ-I338G and NikQ-I338G/I345G were generated by whole-plasmid
mutagenesis, using the following semi-overlapping 64 primers.
I338G-F: 5’-CACCTGGGCTTCGGCCAGGGCAACCACTACTGCATCGGCTCCTCGCTC-3’
I338G-R: 5’-CTGGCCGAAGCCCAGGTGGCGGTTGGGTTCGCGCTCGATGTCGAA-3’
I345G-F: 5’-CTACTGCGGCGGCTCCTCGCTCGCCAAGCTCGAACTCACGGTG-3’
I345G-R: 5’-GGAGCCGCCGCAGTAGTGGTTGCCCTGGATGAAGCCCAGGTG-3’
I338GI345G-F: 5’-CTACTGCGGCGGCTCCTCGCTCGCCAAGCTCGAACTCACGGTG-3’
I338GI345G-R: 5’-GGAGCCGCCGCAGTAGTGGTTGCCCTGGCCGAAGCCC-3

Mutagenic PCR reactions utilized the previously described NikQ-WT construct5 in
pET28b (KanR) as template for the NikQ-I338G and NikQ-I345G single mutants, then the
I338GI345G double mutant was amplified using the NikQ-I338G template. After
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successful mutagenesis was confirmed by Sanger sequencing, NikQ-WT and the I338G
variant were each expressed alongside the ChuA heme transporter protein

63, 65

in E. coli

BL21(DE3) cells. The NikQ-I338GI345G plasmid was co-transformed with the ChuA
plasmid (AmpR) into BL21(DE3) cells also containing the pG-Tf2 (CamR) chaperone
plasmid. Expression was carrier out in 2 L flasks containing 1 L of modified terrific broth
media, comprised of the following: 24 g∙L-1 yeast extract, 12 g∙L-1 tryptone, 2 g∙L-1 peptone,
2.31 g∙L-1 monobasic potassium phosphate, 12.54 g∙L-1 dibasic potassium phosphate, and
0.4% glycerol. Prior to inoculation with ~15 mL of saturated starter culture, media was
supplemented with 50 mg∙L-1 kanamycin, 100 mg∙L-1 ampicillin, 30 mg∙L-1
chloramphenicol (for I338GI345G growth containing the pG-Tf2 chaperone plasmid), 125
mg∙L-1 thiamine-HCl, and a trace metals solution (50 µM FeCl3, 20 µM CaCl2, 10 µM
MnCl2, 10 µM ZnCl2, 2 µM CuCl2, 2 µM CoCl2 and 2 µM NiSO4). Cultures were incubated
at 37 °C and 200 rpm until OD600 = ~1, when the temperature was decreased to 16 °C, and
expression of chaperones was induced with 10 µg∙L-1 tetracycline in the I338GI345G
cultures. At OD600 = ~1.8, 5 mg∙L-1 hemin was added and expression of the NikQ variants
and ChuA was induced by the addition of 60 µM IPTG. Cells were harvested via
centrifugation ~72 hours post-induction and stored at -70 °C until purification, which was
completed according to established methods 5. Expression and purification of holo-NikP1,
as well as preparation of ʟ-his-NikP1, were carried out using published protocols 5.
4.5.3 Equilibrium Binding Assessments
Spectroscopic shifts in NikQ upon substrate binding were investigated by the
addition of 10-equivalent addition of ʟ-His-NikP1 to NikQ with changes in absorbance
spectra being monitored by an Agilent 8453 spectrophotometer. Size-exclusion
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chromatography experiments were performed on NikQ mutants in accordance with the
protocols established for NikQ with the use of a 405 nm filter as opposed to a 280 nm filter,
thus eliminating the need for analysis of individual fractions using the spectrophotometer.5
Small ligand binding titrations of cyanide and imidazole to the heme-iron were conducted
via the incremental addition of ligand to a cuvette containing P450. For substrate bound
NikQ the cuvette was held at ~15:1 ʟ-His-NikP1:NikQ. Full UV-visible absorbance spectra
were collected on the spectrophotometer following an incubation period to ensure complete
equilibrium of the sample. Imidazole titrations were monitored for a Soret shift to 424 nm
and cyanide to 437 nm. The binding signal, data derived from the change in absorbance at
the wavelength of greatest change (ΔAbs) was graphed as a function of the ligand
concentration, [L], and fit to the equilibrium binding function shown below in Equation
4.1 to determine the dissociation constant, KD, where ΔAbsmax is the maximal change in
absorbance observed at that wavelength.
Equation 4.1: ∆Abs =

∆Absmax * [L]
KD + [L]

4.5.4 Electron Paramagnetic Resonance Spectroscopy
EPR Samples containing 100 µM NikQ-I338G/I345G alone in 25 mM HEPES pH 7.5
with 500 mM NaCl, or in this buffer supplemented with 500 µM ʟ-his-NikP1, 500 µM ʟhistidine, or 50 mM imidazole pH 7.5, were prepared in quartz EPR tubes at volumes of
225 µL before being frozen and stored in liquid nitrogen. EPR samples containing cyanide
were prepared in quartz EPR tubes at 225 µL volumes containing 100 µM NikQ-WT,
NikQ-I338G, or NikQ-I338G/I345G, each prepared in both the absence and presence of
500 µM ʟ-his-NikP1, in 25 mM HEPES pH 7.5 with 500 mM NaCl supplemented to a final
cyanide concentration of 500 mM. Cyanide was diluted from a 2.25 M stock with pH
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adjusted to ~8.0, as the high pH of initially prepared sodium cyanide without the addition
of acid caused enzyme precipitation. Samples were frozen and stored in liquid nitrogen.
Data collection was carried out on a Bruker X-Band EMXplus EPR spectrometer equipped
with an Oxford Instruments ESR900 X-Band Continuous Flow Liquid Helium Cryostat.
Analysis was performed at temperatures between 10 and 15 K at a modulation amplitude
of 10 Gauss and a microwave power of 2 mW. Resulting spectra were the average of ten
30 s scans from 340 to 6340 Gauss. Spectra were baselined using SpinCount software, then
processed further using OriginPro and Corel Designer. Assignments of g-values to z, y,
and x coordinates, calculation of eigenstates, and determination of tetragonal distortion,
orthorhombic distortion, and rhombicity were carried out in the method described by
Bohan.58
4.5.5 Stopped Flow Spectroscopy
Rapid-mix stopped-flow was performed on an Applied Photophysics SX-20
instrument equipped with an anaerobic accessory and a modified stop syringe allowing for
a 1 ms deadtime. A photodiode array detector was used to collect 1,000 spectra in
logarithmic time scales of 1 to 60 seconds, from ~265 to ~720 nm, at 4 °C. Instrument
anaerobicity and sample preparation were achieved as previously described.5 The buffer
used for all samples consisted of 25 mM HEPES with 500 mM NaCl, at pH 7.5. O2saturated buffer was rapidly mixed at a 1:1 ratio with 10 µM of ferrous NikQ-variant,
resulting in post-mix concentrations of ~1 mM O2 and 5 µM P450. Fitting was performed
using Pro-Data Viewer software from Applied Photophysics. Substrate-free traces at 443
nm were fit to a single exponential function shown below in Equation 4.2 according to
Scheme 4.1, where the sequence in parenthesis is not resolvable within the instrument

148

deadtime under O2-saturating conditions, At,

obs

is the observable absorbance, k is the

autoxidation rate constant (in s-1), a is the amplitude, A∞ is the final absorbance, and t is
the time (in s).
Equation 4.2: At,obs = A∞ + ae-tk
k

Scheme 4.1: (Fe2+ + O2 )→ Fe3+ -O⋅-2 → Fe3+ + O⋅-2
Data collected in the presence of excess ʟ-his-NikP1 substrate maintained the same
concentrations of O2 and NikQ-variant described for substrate-free experiments, but
featured 100 µM substrate in the P450-containing sample, resulting in a post-mix
concentration of 50 µM ʟ-his-NikP1. Substrate-bound data for NikQ-I338G was fit at 441
nm to a 3-summed exponential function (Equation 4.3) according to Scheme 4.2. The
single exponential formation phase of the oxy-intermediate with amplitude a1 and observed
dioxygen binding rate constant k1 (s-1). The more-complex double exponential decrease in
absorbance has amplitudes a2 and a3, with rate constants k2 and k3 (both in s-1)
corresponding to two different autoxidation processes. At, obs is the observable absorbance
and A∞ is the final absorbance.
Equation 4.3: 𝐴𝑡,𝑜𝑏𝑠 = 𝐴∞ + a1 e-tk1 + a2 e-tk2 + a3 e-tk3
k1

k2 , k3

Scheme 4.2: Fe2+ + O2 → Fe3+ -O⋅-2 →

Fe3+ + O⋅-2

Fitting was not performed for substrate-bound NikQ-I338G/I345G, as the reduced state of
the P450 was not achieved, and thus O2-binding could not occur.
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